10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2018

OR

o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission file number 001-34950

SABRA HEALTH CARE REIT, INC.

(Exact Name of Registrant as Specified in Its Charter)

Maryland	27-2560479
(State of Incorporation)	(I.R.S. Employer Identification No.)

18500 Von Karman Avenue, Suite 550

Irvine, CA 92612

(888) 393-8248

(Address, zip code and telephone number of Registrant)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  x    No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer	x	Accelerated filer	o
Non-accelerated filer	o  (Do not check if a smaller reporting company)	Smaller reporting company	o
		Emerging growth company	o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x

As of August 2, 2018, there were 178,283,590 shares of the registrant’s $0.01 par value Common Stock outstanding.

SABRA HEALTH CARE REIT, INC. AND SUBSIDIARIES

Index

		Page Numbers
PART I. FINANCIAL INFORMATION
Item 1.	Financial Statements:
	Condensed Consolidated Balance Sheets	4
	Condensed Consolidated Statements of Income	5
	Condensed Consolidated Statements of Comprehensive Income	6
	Condensed Consolidated Statements of Equity	7
	Condensed Consolidated Statements of Cash Flows	8
	Notes to Condensed Consolidated Financial Statements	9
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	41
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	56
Item 4.	Controls and Procedures	56
PART II. OTHER INFORMATION
Item 1.	Legal Proceedings	58
Item 1a.	Risk Factors	58
Item 6.	Exhibits	58
Signatures		59

1

References throughout this document to “Sabra,” “we,” “our,” “ours” and “us” refer to Sabra Health Care REIT, Inc. and its direct and indirect consolidated subsidiaries and not any other person.

STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

Certain statements in this Quarterly Report on Form 10-Q (this “10-Q”) contain “forward-looking” information as that term is defined by the Private Securities Litigation Reform Act of 1995. Any statements that do not relate to historical or current facts or matters are forward-looking statements. Examples of forward-looking statements include all statements regarding our expected future financial position, results of operations, cash flows, liquidity, financing plans, business strategy, tenants, the expected amounts and timing of dividends and other distributions, projected expenses and capital expenditures, competitive position, growth opportunities, potential investments, plans and objectives for future operations, and compliance with and changes in governmental regulations. You can identify some of the forward-looking statements by the use of forward-looking words such as “anticipate,” “believe,” “plan,” “estimate,” “expect,” “intend,” “should,” “may” and other similar expressions, although not all forward-looking statements contain these identifying words.

Our actual results may differ materially from those projected or contemplated by our forward-looking statements as a result of various factors, including, among others, the following:

• our dependence on the operating success of our tenants;

• operational risks with respect to our Senior Housing - Managed communities (as defined below);

• the effect of our tenants declaring bankruptcy or becoming insolvent;

• our ability to find replacement tenants and the impact of unforeseen costs in acquiring new properties;

• the impact of litigation and rising insurance costs on the business of our tenants;

• our ability to implement the previously announced rent repositioning program for certain of our tenants who were legacy tenants of Care Capital Properties, Inc. (“CCP”) on the timing or terms we have previously disclosed;

• our ability to dispose of facilities currently leased to Genesis Healthcare, Inc. (“Genesis”) on the timing or terms we have previously disclosed;

• the possibility that Sabra may not acquire the remaining majority interest in the Enlivant Joint Venture (as defined below);

• risks associated with our investments in joint ventures;

• changes in healthcare regulation and political or economic conditions;

• the impact of required regulatory approvals of transfers of healthcare properties;

• competitive conditions in our industry;

• our concentration in the healthcare property sector, particularly in skilled nursing/transitional care facilities and senior housing communities, which makes our profitability more vulnerable to a downturn in a specific sector than if we were investing in multiple industries;

• the significant amount of and our ability to service our indebtedness;

• covenants in our debt agreements that may restrict our ability to pay dividends, make investments, incur additional indebtedness and refinance indebtedness on favorable terms;

• increases in market interest rates;

• our ability to raise capital through equity and debt financings;

• changes in foreign currency exchange rates;

• the relatively illiquid nature of real estate investments;

• the loss of key management personnel or other employees;

• uninsured or underinsured losses affecting our properties and the possibility of environmental compliance costs and liabilities;

• the impact of a failure or security breach of information technology in our operations;

• our ability to maintain our status as a real estate investment trust (“REIT”);

• changes in tax laws and regulations affecting REITs (including the potential effects of the Tax Cuts and Jobs Act);

• compliance with REIT requirements and certain tax and tax regulatory matters related to our status as a REIT; and

• the ownership limits and anti-takeover defenses in our governing documents and under Maryland law, which may restrict change of control or business combination opportunities.

We urge you to carefully consider these risks and review the additional disclosures we make concerning risks and other factors that may materially affect the outcome of our forward-looking statements and our future business and operating results, including those made in Part I, Item 1A, “Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2017 (our “2017 Annual Report on Form 10-K”), as such risk factors may be amended, supplemented or superseded from time to time by other reports we file with the Securities and Exchange Commission (the “SEC”), including subsequent Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. We caution you that any forward-looking statements made in this

2

10-Q are not guarantees of future performance, events or results, and you should not place undue reliance on these forward-looking statements, which speak only as of the date of this report. We do not intend, and we undertake no obligation, to update any forward-looking information to reflect events or circumstances after the date of this 10-Q or to reflect the occurrence of unanticipated events, unless required by law to do so.

3

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(dollars in thousands, except per share data)

	June 30, 2018			December 31, 2017
	(unaudited)
Assets
Real estate investments, net of accumulated depreciation of $377,159 and $340,423 as of June 30, 2018 and December 31, 2017, respectively	$	5,993,682		$	5,994,432
Loans receivable and other investments, net	107,228			114,390
Investment in unconsolidated joint venture	348,950			—
Cash and cash equivalents	38,809			518,632
Restricted cash	186,845			68,817
Lease intangible assets, net	156,266			167,119
Accounts receivable, prepaid expenses and other assets, net	196,364			168,887
Total assets	$	7,028,144		$	7,032,277
Liabilities
Secured debt, net	$	253,567		$	256,430
Revolving credit facility	676,000			641,000
Term loans, net	1,187,398			1,190,774
Senior unsecured notes, net	1,306,842			1,306,286
Accounts payable and accrued liabilities	105,339			102,523
Lease intangible liabilities, net	91,073			98,015
Total liabilities	3,620,219			3,595,028
Commitments and contingencies (Note 13)
Equity
Preferred stock, $.01 par value; 10,000,000 shares authorized, 5,750,000 shares issued and outstanding as of December 31, 2017	—			58
Common stock, $.01 par value; 250,000,000 shares authorized, 178,283,590 and 178,255,843 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	1,783			1,783
Additional paid-in capital	3,502,954			3,636,913
Cumulative distributions in excess of net income	(125,606		)	(217,236		)
Accumulated other comprehensive income	24,412			11,289
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,403,543			3,432,807
Noncontrolling interests	4,382			4,442
Total equity	3,407,925			3,437,249
Total liabilities and equity	$	7,028,144		$	7,032,277

See accompanying notes to condensed consolidated financial statements.

4

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF INCOME

(dollars in thousands, except per share data)

(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Revenues:
Rental income	$	144,229		$	55,904		$	288,484		$	113,128
Interest and other income	4,553			2,027			8,891			3,972
Resident fees and services	17,530			6,805			35,023			10,286
Total revenues	166,312			64,736			332,398			127,386
Expenses:
Depreciation and amortization	46,828			17,220			94,833			36,357
Interest	36,757			15,862			72,575			31,650
Operating expenses	12,299			4,407			24,423			6,827
General and administrative	9,271			5,126			17,138			11,215
Merger and acquisition costs	112			5,887			442			6,451
(Recovery of) provision for doubtful accounts and loan losses	(674		)	535			539			2,305
Impairment of real estate	881			—			1,413			—
Total expenses	105,474			49,037			211,363			94,805
Other income:
Other income	—			941			2,820			3,070
Net gain on sales of real estate	142,903			4,032			142,431			4,032
Total other income	142,903			4,973			145,251			7,102
Income before loss from unconsolidated joint venture and income tax expense	203,741			20,672			266,286			39,683
Loss from unconsolidated joint venture	(2,347		)	—			(1,901		)	—
Income tax expense	(605		)	(136		)	(1,115		)	(356		)
Net income	200,789			20,536			263,270			39,327
Net (income) loss attributable to noncontrolling interests	(2		)	(16		)	(12		)	16
Net income attributable to Sabra Health Care REIT, Inc.	200,787			20,520			263,258			39,343
Preferred stock dividends	(7,207		)	(2,560		)	(9,768		)	(5,121		)
Net income attributable to common stockholders	$	193,580		$	17,960		$	253,490		$	34,222
Net income attributable to common stockholders, per:
Basic common share	$	1.09		$	0.27		$	1.42		$	0.52
Diluted common share	$	1.08		$	0.27		$	1.42		$	0.52
Weighted-average number of common shares outstanding, basic	178,314,750			65,438,739			178,304,733			65,396,146
Weighted-average number of common shares outstanding, diluted	178,684,024			65,670,853			178,600,789			65,694,019
Dividends declared per common share	$	0.45		$	0.43		$	0.90		$	0.85

See accompanying notes to condensed consolidated financial statements.

5

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME

(in thousands)

(unaudited)

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Net income	$	200,789		$	20,536		$	263,270		$	39,327
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	261			698			(113		)	140
Unrealized gain on cash flow hedges	3,338			97			13,236			825
Total other comprehensive income	3,599			795			13,123			965
Comprehensive income	204,388			21,331			276,393			40,292
Comprehensive (income) loss attributable to noncontrolling interest	(2		)	(16		)	(12		)	16
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	204,386		$	21,315		$	276,381		$	40,308

See accompanying notes to condensed consolidated financial statements.

6

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY

(dollars in thousands, except per share data)

(unaudited)

	Preferred Stock					Common Stock			Additional Paid-in Capital			Cumulative Distributions in Excess of Net Income			Accumulated Other Comprehensive Income (Loss)			Total Stockholders’ Equity			Noncontrolling Interests			Total Equity
	Shares		Amounts			Shares	Amounts
Balance, December 31, 2016	5,750,000		$	58		65,285,614	$	653	$	1,208,862		$	(192,201	)	$	(1,798	)	$	1,015,574		$	35		$	1,015,609
Net income (loss)	—		—			—	—		—			39,343			—			39,343			(16		)	39,327
Other comprehensive income	—		—			—	—		—			—			965			965			—			965
Amortization of stock-based compensation	—		—			—	—		4,848			—			—			4,848			—			4,848
Common stock issuance, net	—		—			139,820	1		(2,815		)	—			—			(2,814		)	—			(2,814		)
Preferred dividends	—		—			—	—		—			(5,121		)	—			(5,121		)	—			(5,121		)
Common dividends ($0.85 per share)	—		—			—	—		—			(56,099		)	—			(56,099		)	—			(56,099		)
Balance, June 30, 2017	5,750,000		$	58		65,425,434	$	654	$	1,210,895		$	(214,078	)	$	(833	)	$	996,696		$	19		$	996,715
	Preferred Stock					Common Stock			Additional Paid-in Capital			Cumulative Distributions in Excess of Net Income			Accumulated Other Comprehensive Income (Loss)			Total Stockholders’ Equity			Noncontrolling Interests			Total Equity
	Shares		Amount			Shares	Amounts
Balance, December 31, 2017	5,750,000		$	58		178,255,843	$	1,783	$	3,636,913		$	(217,236	)	$	11,289		$	3,432,807		$	4,442		$	3,437,249
Cumulative effect of ASU 2017-12 adoption	—		—			—	—		—			(795		)	795			—			—			—
Net income	—		—			—	—		—			263,258			—			263,258			12			263,270
Other comprehensive income	—		—			—	—		—			—			12,328			12,328			—			12,328
Distributions to noncontrolling interests	—		—			—	—		—			—			—			—			(72		)	(72		)
Amortization of stock-based compensation	—		—			—	—		4,434			—			—			4,434			—			4,434
Preferred stock redemption	(5,750,000	)	(58		)	—	—		(138,191		)	(5,501		)	—			(143,750		)	—			(143,750		)
Common stock issuance, net	—		—			27,747	—		(202		)	—			—			(202		)	—			(202		)
Preferred dividends	—		—			—	—		—			(4,267		)	—			(4,267		)	—			(4,267		)
Common dividends ($0.90 per share)	—		—			—	—		—			(161,065		)	—			(161,065		)	—			(161,065		)
Balance, June 30, 2018	—		$	—		178,283,590	$	1,783	$	3,502,954		$	(125,606	)	$	24,412		$	3,403,543		$	4,382		$	3,407,925

See accompanying notes to condensed consolidated financial statements.

7

SABRA HEALTH CARE REIT, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

	Six Months Ended June 30,
	2018			2017
Cash flows from operating activities:
Net income	$	263,270		$	39,327
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	94,833			36,357
Amortization of above and below market lease intangibles, net	(1,368		)	—
Non-cash interest income adjustments	(1,174		)	51
Non-cash interest expense	4,997			3,244
Stock-based compensation expense	3,839			4,319
Straight-line rental income adjustments	(23,752		)	(9,578		)
Provision for doubtful accounts and loan losses	539			2,305
Change in fair value of contingent consideration	—			(822		)
Net gain on sales of real estate	(142,431		)	(4,032		)
Impairment of real estate	1,413			—
Loss from unconsolidated joint venture	1,901			—
Distributions of earnings from unconsolidated joint venture	3,610			—
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net	(2,130		)	(15,575		)
Accounts payable and accrued liabilities	8,006			(1,314		)
Net cash provided by operating activities	211,553			54,282
Cash flows from investing activities:
Acquisition of real estate	(213,982		)	(14,456		)
Origination and fundings of loans receivable	(28,157		)	(927		)
Origination and fundings of preferred equity investments	(945		)	(76		)
Additions to real estate	(16,817		)	(1,294		)
Repayments of loans receivable	38,887			1,547
Repayments of preferred equity investments	375			2,766
Investment in unconsolidated joint venture	(354,461		)	—
Net proceeds from the sales of real estate	278,201			6,099
Net cash used in investing activities	(296,899		)	(6,341		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	35,000			6,000
Principal payments on secured debt	(2,128		)	(2,049		)
Payments of deferred financing costs	(12		)	(124		)
Distributions to noncontrolling interests	(72		)	—
Preferred stock redemption	(143,750		)	—
Issuance of common stock, net	(499		)	(3,224		)
Dividends paid on common and preferred stock	(164,736		)	(60,691		)
Net cash used in financing activities	(276,197		)	(60,088		)
Net decrease in cash, cash equivalents and restricted cash	(361,543		)	(12,147		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(252		)	130
Cash, cash equivalents and restricted cash, beginning of period	587,449			34,665
Cash, cash equivalents and restricted cash, end of period	$	225,654		$	22,648
Supplemental disclosure of cash flow information:
Interest paid	$	67,793		$	28,944

See accompanying notes to condensed consolidated financial statements.

8

SABRA HEALTH CARE REIT, INC.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

(unaudited)

1.     BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra's separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the United States and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and Sabra’s wholly owned subsidiaries are currently the only limited partners, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture.

On May 7, 2017, the Company, the Operating Partnership, PR Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub”), Care Capital Properties, Inc., a Delaware corporation (“CCP”), and Care Capital Properties, L.P. (“CCPLP”), a Delaware limited partnership and wholly owned subsidiary of CCP, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, on August 17, 2017, CCP merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation (the “CCP Merger”), following which Merger Sub merged with and into the Company, with the Company continuing as the surviving entity (the “Subsequent Merger”), and, simultaneous with the Subsequent Merger, CCPLP merged with and into the Operating Partnership, with the Operating Partnership continuing as the surviving entity.

Pursuant to the Merger Agreement, as of the effective time of the CCP Merger, each share of CCP common stock, par value $0.01 per share, issued and outstanding immediately prior to the effective time of the CCP Merger (other than shares of CCP common stock owned directly by CCP, the Company or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, par value $0.01 per share, plus cash in lieu of any fractional shares. See Note 3, “CCP Merger and Recent Real Estate Acquisitions” for additional information regarding the CCP Merger.

The acquisition of CCP has been reflected in the Company’s condensed consolidated financial statements since the effective date of the CCP Merger.

2.     SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of June 30, 2018 and December 31, 2017 and for the periods ended June 30, 2018 and 2017. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the Company’s consolidated financial statements and notes thereto for the

9

year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC.

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis.

As of June 30, 2018, the Company determined it was the primary beneficiary of two variable interest entities—one exchange accommodation titleholder variable interest entity and a joint venture variable interest entity owning one skilled nursing/transitional care facility—and has consolidated the operations of these entities in the accompanying condensed consolidated financial statements. As of June 30, 2018, the Company determined that operations of these entities were not material to the Company’s results of operations, financial condition or cash flows.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At June 30, 2018, none of the Company’s investments in loans are accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of June 30, 2018, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company’s consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations of prior periods. As a result, certain reclassifications were made to the condensed consolidated statements of income and condensed consolidated statements of cash flows.

10

Investment in Unconsolidated Joint Venture

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s condensed consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture.

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment.

On January 2, 2018, the Company completed its transaction with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, and contributed $352.7 million, before closing costs, to acquire a 49% equity interest in an entity that owns 172 senior housing communities managed by Enlivant (the “Enlivant Joint Venture”). At closing, the Enlivant Joint Venture had outstanding indebtedness of $791.3 million and net working capital of $22.9 million, and the Company’s investment in the Enlivant Joint Venture implied an aggregate portfolio value of $1.49 billion. The joint venture agreement includes an option for the Company to acquire the remainder of the outstanding equity interests in the Enlivant Joint Venture by January 2, 2021 and grants the Company the right of first offer if the Company’s partner in the Enlivant Joint Venture desires to transfer its equity interest (which it may do commencing on January 2, 2020). In addition, Sabra has the right to designate three directors on the seven member board of directors of the Enlivant Joint Venture and has other customary minority rights. As of June 30, 2018, the book value of the Company’s investment in the Enlivant Joint Venture was $349.0 million.

Net Investment in Direct Financing Lease

As of June 30, 2018, the Company had a $23.2 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying condensed consolidated balance sheets and represents the total undiscounted rental payments, plus the estimated unguaranteed residual value, less the unearned lease income. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Income from the Company’s net investment in direct financing lease was $0.6 million and $1.3 million for the three and six months ended June 30, 2018, respectively, and is reflected in interest and other income on the accompanying condensed consolidated statements of income. Future minimum lease payments contractually due under the direct financing lease at June 30, 2018, were as follows: $1.1 million for the remainder of 2018; $2.2 million for 2019; $2.3 million for 2020; and $2.1 million for 2021.

Recently Issued Accounting Standards Update

Adopted

Between May 2014 and February 2017, the FASB issued four Accounting Standards Updates (each, an “ASU”) changing the requirements for recognizing and reporting revenue (together, herein referred to as the “Revenue ASUs”): (i) ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”) and (iv) ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. The Revenue ASUs became effective for the Company on January 1, 2018 with the Company electing to use the modified retrospective approach for its adoption. Further, the Company elected to reassess only contracts that were not completed as of the adoption date. The adoption of these ASUs did not have a material impact to beginning retained earnings as of January 1, 2018.

11

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 provides specific guidance clarifying how certain cash receipts and payments should be classified. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-15 and ASU 2016-18 on January 1, 2018. The full retrospective approach of adoption is required for both ASUs and, accordingly, certain line items in the Company’s consolidated statements of cash flows have been reclassified to conform to the current period presentation. The following table illustrates changes in the Company’s cash flows as reported in the accompanying condensed consolidated statements of cash flows and as previously reported prior to the adoption (in thousands):

	Six Months Ended June 30, 2017
	As Reported		As Previously Reported
Net cash provided by operating activities	54,282		53,871
Net decrease in balance	(12,147	)	(12,558	)
Balance - beginning of the year	34,665		25,663
Balance - end of the year	22,648		13,235

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). ASU 2017-12 is intended to improve the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements and to simplify the application of the hedge accounting guidance in current GAAP. ASU 2017-12 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company adopted ASU 2017-12 effective beginning January 1, 2018. ASU 2017-12 requires a modified retrospective transition method in which the Company recognized the cumulative effect of the change on the opening balance of each affected component of equity in the condensed consolidated balance sheet as of the date of adoption, which resulted in a decrease to cumulative distributions in excess of net income and an increase to accumulated other comprehensive income of $0.8 million.

Issued but Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 supersedes guidance related to accounting for leases. ASU 2016-02 updates guidance around the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of ASU 2016-02 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. Under ASU 2016-02, entities currently are required to adopt the new lease requirements using a modified retrospective transition method whereby an entity initially applies the new lease requirements (subject to specific transition requirements and optional practical expedients) at the beginning of the earliest period presented in the financial statements. Upon adoption of ASU 2016-02, the Company will recognize its operating leases for which it is the lessee, mainly corporate office leases and ground leases, on its consolidated balance sheets. Further, as a result of adoption, the Company may be required to increase its revenue and expense for the amount of real estate taxes and insurance paid by its tenants under certain leasing arrangements with no net impact to net income.

In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”) that allows lessors to elect, as a practical expedient, not to separate lease and nonlease components (such as services rendered) in a contract for the purpose of revenue recognition and disclosure. The practical expedient can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. Further, ASU 2018-11 also provides for an additional (and optional) transition method to adopt the new lease requirements by allowing entities to initially apply the requirements by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company plans to elect this practical expedient and apply the optional transition method for its operating leases for which the Company is the lessee, using the cumulative-effect adjustment to the opening balance sheet as of January 1, 2019. The Company is still evaluating the full impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial statements.

12

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold in current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. ASU 2016-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in this update through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted.

3.     CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS

CCP Merger

On August 17, 2017, the Company completed the CCP Merger. Under the terms of the Merger Agreement, each share of CCP common stock issued and outstanding immediately prior to the effective time of the CCP Merger (other than any shares owned directly by CCP, the Company or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, resulting in the issuance of approximately 94.0 million shares of Company common stock at the effective time of the CCP Merger. As a result of the CCP Merger, the Company acquired 330 properties (consisting of 296 skilled nursing/transitional care facilities, 13 senior housing communities and 21 specialty hospitals and other facilities), one skilled nursing/transitional care facility leased to an operator under a direct financing lease (see Note 2, “Summary of Significant Accounting Policies—Net Investment in Direct Financing Lease”), 18 investments in loans receivable (see Note 6, “Loans Receivable and Other Investments”) and one specialty valuation firm that was subsequently sold in March 2018. Sabra also assumed certain outstanding equity awards and other debt and liabilities of CCP (see Note 7, “Debt”). Based on the closing price of Sabra’s common stock on August 16, 2017, the Company estimates the fair value of the consideration exchanged or assumed to be approximately $2.1 billion.

The following table summarizes the purchase price allocation for the CCP Merger based on the Company’s valuation, including estimates and assumptions of the acquisition date fair value of the tangible and intangible assets acquired and liabilities assumed on August 17, 2017 (in thousands):

Real estate investments	$	3,727,310
Loans receivable and other investments	58,244
Cash and cash equivalents	77,859
Restricted cash	779
Lease intangible assets, net	145,786
Accounts receivable, prepaid expenses and other assets, net	35,873
Secured debt, net	(98,500		)
Revolving credit facility	(362,000		)
Unsecured term loans	(674,000		)
Senior unsecured notes, net	(616,873		)
Accounts payable and accrued liabilities	(134,802		)
Lease intangible liabilities, net	(102,643		)
Noncontrolling interests	(4,455		)
Total consideration	$	2,052,578

The lease intangible assets and lease intangible liabilities acquired in connection with the CCP Merger have weighted-average amortization periods as of the closing date of the CCP Merger of 10 years.

13

Recent Real Estate Acquisitions

During the six months ended June 30, 2018, the Company acquired 11 Senior Housing - Managed communities, five senior housing communities and two skilled nursing/transitional care facilities. During the six months ended June 30, 2017, the Company acquired one senior housing community. The consideration was allocated based on certain valuations and analyses. Certain valuations and analyses related to acquisitions during the six months ended June 30, 2018 have yet to be finalized, and accordingly, the allocations are subject to adjustment once the analyses are completed. Allocation of the consideration is as follows (in thousands):

	Six Months Ended June 30,
	2018		2017
Land	$	24,356	$	1,034
Building and improvements	187,903		13,128
Tenant origination and absorption costs intangible assets	1,312		223
Tenant relationship intangible assets	412		71
Total consideration	$	213,983	$	14,456

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets acquired in connection with these acquisitions have weighted-average amortization periods as of the respective dates of acquisition of 13 years and 22 years, respectively, for acquisitions completed during the six months ended June 30, 2018, and 15 years and 25 years, respectively, for the acquisition completed during the six months ended June 30, 2017.

For the three and six months ended June 30, 2018, the Company recognized $10.7 million and $20.4 million of total revenues, respectively, and $1.6 million and $2.5 million of net income attributable to common stockholders, respectively, from the facilities acquired during the six months ended June 30, 2018. For both the three and six months ended June 30, 2017, the Company recognized $0.1 million of total revenues and net income attributable to common stockholders from the facility acquired during the six months ended June 30, 2017.

4.    REAL ESTATE PROPERTIES HELD FOR INVESTMENT

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of June 30, 2018

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	352	40,077	$	4,242,748	$	(223,777	)	$	4,018,971
Senior Housing - Leased	89	7,156	1,200,923		(113,020		)	1,087,903
Senior Housing - Managed	24	1,712	308,221		(15,961		)	292,260
Specialty Hospitals and Other	22	1,085	618,316		(24,109		)	594,207
	487	50,030	6,370,208		(376,867		)	5,993,341
Corporate Level			633		(292		)	341
			$	6,370,841	$	(377,159	)	$	5,993,682

14

As of December 31, 2017

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	384	43,223	$	4,364,387	$	(209,039	)	$	4,155,348
Senior Housing - Leased	88	8,137	1,166,687		(102,370		)	1,064,317
Senior Housing - Managed	13	1,113	189,120		(12,125		)	176,995
Specialty Hospitals and Other	22	1,085	614,068		(16,620		)	597,448
	507	53,558	6,334,262		(340,154		)	5,994,108
Corporate Level			593		(269		)	324
			$	6,334,855	$	(340,423	)	$	5,994,432

	June 30, 2018			December 31, 2017
Building and improvements	$	5,489,087		$	5,449,415
Furniture and equipment	236,838			232,889
Land improvements	1,971			3,456
Land	642,945			649,095
	6,370,841			6,334,855
Accumulated depreciation	(377,159		)	(340,423		)
	$	5,993,682		$	5,994,432

Operating Leases

As of June 30, 2018, the substantial majority of the Company’s real estate properties (excluding 24 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years. As of June 30, 2018, the leases had a weighted-average remaining term of nine years. The leases include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets and totaled $17.9 million and $20.3 million as of June 30, 2018 and December 31, 2017, respectively, and letters of credit deposited with the Company totaled approximately $90 million and $96 million as of June 30, 2018 and December 31, 2017, respectively. In addition, our tenants have deposited with the Company $28.0 million and $28.3 million as of June 30, 2018 and December 31, 2017, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to our properties and their operations.

As of June 30, 2018, the Company had a $1.1 million reserve for unpaid cash rental income and a $3.2 million reserve associated with accumulated straight-line rental income. As of December 31, 2017, the Company had a $3.2 million reserve for unpaid cash rental income and a $12.4 million reserve associated with accumulated straight-line rental income.

The Company has entered into memoranda of understanding with Genesis to market for sale up to all of its remaining Genesis facilities and to restructure its lease agreements with Genesis to increase the marketability of these facilities to potential buyers. Effective January 1, 2018, the annual base rent payable under the Genesis leases was reduced by $19.0 million pursuant to a lease restructuring agreement. During the six months ended June 30, 2018, the Company completed the sale of 27 facilities leased to Genesis and expects to complete the sale of 19 of its remaining 27 Genesis facilities during the remainder of 2018 and to retain eight facilities, although it cannot provide assurance that the sales will be completed in that timeframe, if at all.

The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. As formal credit ratings may not be available for most of the Company’s tenants, the primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio or the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest,

15

taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

For both the three and six months ended June 30, 2018, no tenant relationship represented 10% or more of the Company’s total revenues.

As of June 30, 2018, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows (in thousands):

July 1 through December 31, 2018	$	260,307
2019	529,844
2020	522,304
2021	520,553
2022	512,680
Thereafter	3,083,776
	$	5,429,464

5.    ASSET HELD FOR SALE AND DISPOSITIONS

Asset Held for Sale

As of June 30, 2018, the Company determined that one skilled nursing/transitional care facility, with a net book value of $6.0 million, met the criteria to be classified as held for sale. The net book value is included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. The facility was sold on July 2, 2018 for a gross sales price of $7.0 million.

2018 Dispositions

During the six months ended June 30, 2018, the Company completed the sale of 33 skilled nursing/transitional care facilities and four senior housing communities for aggregate consideration, net of closing costs, of $278.3 million. The net carrying value of the assets and liabilities of these facilities was $135.8 million, which resulted in an aggregate $142.5 million net gain on sale. The Company also recognized $0.1 million of additional selling expenses for sales completed in 2017.

During the six months ended June 30, 2018, the Company recognized a $1.4 million real estate impairment, of which $0.5 million related to one senior housing community sold during the period.

Excluding the net gain on sale and real estate impairment, the Company recognized $11.6 million and $15.4 million of net income during the six months ended June 30, 2018 and 2017, respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

2017 Disposition

During the six months ended June 30, 2017, the Company completed the sale of one skilled nursing/transitional care facility for consideration, net of closing costs, of $6.1 million. The net carrying value of the assets and liabilities of this facility was $2.1 million, which resulted in a $4.0 million net gain on sale.

Excluding the net gain on sale, the Company recognized $0.1 million of net income during the six months ended June 30, 2017 from this facility. The sale of this facility does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to this facility have remained in continuing operations.

16

6.    LOANS RECEIVABLE AND OTHER INVESTMENTS

As of June 30, 2018 and December 31, 2017, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

											June 30, 2018
Investment	Quantity as of June 30, 2018	Property Type	Principal Balance as of June 30, 2018 (1)		Book Value as of June 30, 2018			Book Value as of December 31, 2017			Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of June 30, 2018
Loans Receivable:
Mortgage	1	Specialty Hospital	$	15,332	$	15,332		$	12,351		10.0	%	10.0	%	01/31/27
Construction	2	Senior Housing	3,989		4,055			2,733			8.0	%	7.8	%	04/30/21- 09/30/22
Mezzanine	1	Skilled Nursing	25,000		2,301			10,239			10.0	%	41.9	%	05/25/20
Pre-development	1	Senior Housing	2,357		2,357			2,357			9.0	%	8.4	%	04/01/20
Other	17	Multiple	34,009		32,191			38,324			8.5	%	9.7	%	12/31/17- 04/30/27
	22		80,687		56,236			66,004			9.3	%	10.9	%
Loan loss reserve			—		(356		)	(97		)
			$	80,687	$	55,880		$	65,907
Other Investments:
Preferred Equity	13	Skilled Nursing / Senior Housing	50,856		51,348			48,483			12.6	%	12.6	%	N/A
Total	35		$	131,543	$	107,228		$	114,390		10.6	%	11.7	%

⁽¹⁾  Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

In connection with the CCP Merger, the Company acquired 18 loans receivable investments with a principal balance of $83.3 million and fair value of $58.2 million as of August 17, 2017.

Of the loans acquired in connection with the CCP Merger, eight loans receivable investments with a principal balance of $36.3 million were considered to have deteriorated credit quality, and based on the collateral or expected cash flows, the fair value was determined to be $11.3 million and the accretable yield was $3.5 million as of August 17, 2017. During the six months ended June 30, 2018, one loan with deteriorated credit quality was repaid in full. As of June 30, 2018 and December 31, 2017, the book value of these loans was $4.8 million and $10.0 million, respectively.

The following table presents changes in the accretable yield for the three and six months ended June 30, 2018 (in thousands):

	Three Months Ended			Six Months Ended
	June 30, 2018
Accretable yield, beginning of period	$	1,883		$	2,483
Accretion recognized in earnings	(1,529		)	(2,129		)
Net reclassification from nonaccretable difference	727			727
Accretable yield, end of period	$	1,081		$	1,081

During the three and six months ended June 30, 2018, the Company recorded no provision for specific loan losses and increased its portfolio-based loan loss reserve by $0.2 million and $0.3 million, respectively.

As of June 30, 2018, the Company had no specific loan loss reserve, and the portfolio-based loan loss reserve was $0.4 million. As of June 30, 2018, the Company did not consider any loans receivable investments to be impaired, and one loan receivable with a book value of $0 and three preferred equity investments totaling $14.5 million were on nonaccrual status. Additionally, as of June 30, 2018, the Company recognized interest income related to four loans receivable, with an aggregate book value of $10.6 million, that were more than 90 days past due.

17

As of December 31, 2017, the Company had no specific loan loss reserve, and the portfolio-based loan loss reserve was $0.1 million. As of December 31, 2017, the Company did not consider any loans receivable investments to be impaired, and one loan receivable with a book value of $0 was on nonaccrual status.

During the three and six months ended June 30, 2017, the Company recorded a provision for specific loan losses of $0.3 million and $1.8 million, respectively, related to five loans receivable investments, two of which were written-off during the three months ended June 30, 2017, and reduced its portfolio-based loan loss reserve by $0.1 million and $0.2 million, respectively.

7.    DEBT

Secured Indebtedness

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of June 30, 2018 (1)		Principal Balance as of December 31, 2017 (1)		Weighted Average Effective Interest Rate at June 30, 2018 (2)		Maturity Date
Fixed Rate	$	157,781	$	160,702	3.87	%	December 2021 -  August 2051
Variable Rate	98,500		98,500		3.89	%	July 2019
	$	256,281	$	259,202	3.88	%

⁽¹⁾   Principal balance does not include deferred financing costs, net of $2.7 million and $2.8 million as of June 30, 2018 and December 31, 2017, respectively.

⁽²⁾   Weighted average effective interest rate includes private mortgage insurance.

On August 17, 2017, in connection with the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”), the Company assumed a $98.5 million variable rate secured term loan that bears interest at LIBOR plus 1.80% and matures in July 2019.

Senior Unsecured Notes

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	June 30, 2018 (1)		December 31, 2017 (1)
5.5% senior unsecured notes due 2021 (“2021 Notes”)	February 1, 2021	$	500,000	$	500,000
5.375% senior unsecured notes due 2023 (“2023 Notes”)	June 1, 2023	200,000		200,000
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.38% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
		$	1,300,000	$	1,300,000

⁽¹⁾  Principal balance does not include premium, net of $15.2 million and deferred financing costs, net of $8.4 million as of June 30, 2018 and does not include premium, net of $15.9 million and deferred financing costs, net of $9.6 million as of December 31, 2017.

The 2021 Notes and the 2023 Notes were issued by the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the “Issuers”). The 2021 Notes accrue interest at a rate of 5.5% per annum payable semiannually on February 1 and August 1 of each year, and the 2023 Notes accrue interest at a rate of 5.375% per annum payable semiannually on June 1 and December 1 of each year.

The 2026 Notes and the 2027 Notes were assumed as a result of the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”) and accrue interest at a rate of 5.125% and 5.38%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.

The obligations under the 2021 Notes, 2023 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and certain subsidiaries of Sabra; provided, however, that such guarantees are subject to release under certain customary circumstances. The obligations under the 2026 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances. See Note 12, “Summarized Condensed Consolidating Information” for additional information

18

concerning the circumstances pursuant to which the guarantors will be automatically and unconditionally released from their obligations under the guarantees.

The indentures and agreements (the “Senior Notes Indentures”) governing the 2021 Notes, 2023 Notes, 2026 Notes and 2027 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of June 30, 2018, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.

Credit Facility

Effective on August 17, 2017, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fourth amended and restated unsecured credit facility (the “Credit Facility”). The Credit Facility amends and restates the prior credit facility entered into by the Borrowers in January 2016 (the “Prior Credit Facility”). The Company recognized a $0.6 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Facility.

The Credit Facility includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Facility also contains an accordion feature that can increase the total available borrowings to $2.5 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of August 17, 2021, and includes twosix-month extension options. $200.0 million of the U.S. dollar Term Loans has a maturity date of August 17, 2020, and the other Term Loans have a maturity date of August 17, 2022.

As of June 30, 2018, there was $676.0 million outstanding under the Revolving Credit Facility and $324.0 million available for borrowing.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). On August 17, 2017, Sabra’s ratings met the Investment Grade Ratings Criteria (as defined in the credit agreement), and Sabra elected to use the ratings-based applicable interest margin for borrowings which will vary based on the Debt Ratings, as defined in the credit agreement, and will range from 0.875% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. As of June 30, 2018, the interest rate on the Revolving Credit Facility was 3.34%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the credit agreement, and will range from 0.90% to 1.90% per annum for LIBOR based borrowings and 0.00% to 0.90% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that will range from 0.90% to 1.90% depending on the Debt Ratings.

On June 10, 2015, the Company entered into an interest rate swap agreement to fix the CDOR portion of the interest rate for CAD $90.0 million of its Canadian dollar Term Loan at 1.59%. In addition, CAD $90.0 million of the Canadian dollar Term Loan was designated as a net investment hedge. On August 10, 2016, the Company entered into two interest rate swap agreements to fix the LIBOR portion of the interest rate for $245.0 million of its U.S. dollar Term Loans at 0.90% and one interest rate swap agreement to fix the CDOR portion on CAD $35.0 million of its Canadian dollar Term Loan at 0.93%. See Note 8, “Derivative and Hedging Instruments” for further information.

As a result of the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”), the Company assumed eight interest rate swap agreements that fix the LIBOR portion of the interest rate for $600 million of the Company’s U.S. dollar Term Loans at a weighted average rate of 1.31%. See Note 8, “Derivative and Hedging Instruments” for further information.

The obligations of the Borrowers under the Credit Facility are guaranteed by Sabra and certain subsidiaries of Sabra.

The Credit Facility contains customary covenants that include restrictions or limitations on the ability to make acquisitions and other investments, pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Facility also requires Sabra, through the Operating Partnership, to comply with specified financial

19

covenants, which include a maximum leverage ratio, a minimum fixed charge coverage ratio and a minimum tangible net worth requirement. As of June 30, 2018, the Company was in compliance with all applicable financial covenants under the Credit Facility.

Interest Expense

During the three and six months ended June 30, 2018, the Company incurred interest expense of $36.8 million and $72.6 million, respectively, and $15.9 million and $31.7 million during the three and six months ended June 30, 2017, respectively. Interest expense includes non-cash interest expense of $2.5 million and $5.0 million for the three and six months ended June 30, 2018, respectively, and $1.7 million and $3.2 million for the three and six months ended June 30, 2017, respectively. As of June 30, 2018 and December 31, 2017, the Company had $24.5 million and $24.7 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets.

Maturities

The following is a schedule of maturities for the Company’s outstanding debt as of June 30, 2018 (in thousands): 

	Secured Indebtedness			Revolving Credit     Facility (1)		Term Loans			Senior Notes			Total
July 1 through December 31, 2018	$	2,156		$	—	$	—		$	—		$	2,156
2019	102,920			—		—			—			102,920
2020	4,568			—		200,000			—			204,568
2021	19,757			676,000		—			500,000			1,195,757
2022	4,285			—		995,163			—			999,448
Thereafter	122,595			—		—			800,000			922,595
Total Debt	256,281			676,000		1,195,163			1,300,000			3,427,444
Premium, net	—			—		—			15,216			15,216
Deferred financing costs, net	(2,714		)	—		(7,765		)	(8,374		)	(18,853		)
Total Debt, Net	$	253,567		$	676,000	$	1,187,398		$	1,306,842		$	3,423,807

⁽¹⁾  Revolving Credit Facility is subject to twosix-month extension options.

8.    DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.

Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

Cash Flow Hedges

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Approximately $6.6 million of gains, which are included in accumulated other comprehensive income, as of June 30, 2018, are expected to be reclassified into earnings in the next 12 months.

20

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

The following presents the notional amount of derivatives instruments as of the dates indicated (in thousands):

	June 30, 2018		December 31, 2017
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars	$	845,000	$	845,000
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	56,300	$	56,300
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at June 30, 2018 and December 31, 2017 (dollars in thousands):    

		Count as of June 30, 2018	Fair Value				Maturity Dates
Type	Designation		June 30, 2018		December 31, 2017			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	12	$	35,719	$	25,221	2020 - 2023	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	2,146		674		2025	Accounts receivable, prepaid expenses and other assets, net
			$	37,865	$	25,895
Liabilities:
CAD term loan	Net investment	1	95,163		99,588		2022	Term loans, net
			$	95,163	$	99,588

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three and six months ended June 30, 2018 and 2017 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income
	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017			Income Statement Location
Cash Flow Hedges:
Interest rate products	$	4,009	$	(136	)	$	13,132	$	125		Interest expense
Net Investment Hedges:
Foreign currency products	898		(242		)	1,505		(1,159		)	N/A
CAD term loan	1,750		(2,513		)	4,425		(3,288		)	N/A
	$	6,657	$	(2,891	)	$	19,062	$	(4,322	)

21

	Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017			Income Statement Location
Cash Flow Hedges:
Interest rate products	$	633	$	(399	)	$	583	$	(869	)	Interest expense
Net Investment Hedges:
Foreign currency products	—		—			—		—			N/A
CAD term loan	—		—			—		—			N/A
	$	633	$	(399	)	$	583	$	(869	)

The gain (loss) in the table above related to interest rate products, was reclassified from accumulated other comprehensive income into interest expense. Interest expense totaled $36.8 million and $72.6 million for the three and six months ended June 30, 2018, respectively, and $15.9 million and $31.7 million for the three and six months ended June 30, 2017, respectively.

During the three and six months ended June 30, 2018, no cash flow hedges were determined to be ineffective. During the three and six months ended June 30, 2017, the Company determined that a portion of a cash flow hedge was ineffective and recognized $14,000 and $0.1 million, respectively, of unrealized losses related to its interest rate swaps to other income in the condensed consolidated statements of income.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of June 30, 2018 and December 31, 2017 (in thousands):

	As of June 30, 2018
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	37,865	$	—	$	37,865	$	—	$	—	$	37,865
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

	As of December 31, 2017
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	25,895	$	—	$	25,895	$	—	$	—	$	25,895
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

Credit-risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender.

As of June 30, 2018, the Company had no derivatives with a fair value in a net liability position.

22

9.    FAIR VALUE DISCLOSURES

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Facility are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investment, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3.

23

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of June 30, 2018 and December 31, 2017 whose carrying amounts do not approximate their fair value (in thousands):

	June 30, 2018						December 31, 2017
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	80,687	$	55,880	$	58,656	$	91,280	$	65,907	$	65,892
Preferred equity investments	50,856		51,348		50,787		48,035		48,483		47,064
Financial liabilities:
Senior Notes	1,300,000		1,306,842		1,292,347		1,300,000		1,306,286		1,329,191
Secured indebtedness	256,281		253,567		236,862		259,202		256,430		246,461

⁽¹⁾  Face value represents amounts contractually due under the terms of the respective agreements.

⁽²⁾  Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

The Company determined the fair value of financial instruments as of June 30, 2018 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Financial assets:
Loans receivable	$	58,656	$	—	$	—	$	58,656
Preferred equity investments	50,787		—		—		50,787
Financial liabilities:
Senior Notes	1,292,347		—		1,292,347		—
Secured indebtedness	236,862		—		—		236,862

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Despite increased capital market and credit market activity, transaction volume for certain financial instruments remains relatively low. This has made the estimation of fair values difficult and, therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.

Items Measured at Fair Value on a Recurring Basis

During the six months ended June 30, 2018, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Recurring Basis:
Financial assets:
Interest rate swap	$	35,719	$	—	$	35,719	$	—
Cross currency swap	2,146		—		2,146		—

24

10.    EQUITY

Preferred Stock

On March 21, 2013, the Company completed an underwritten public offering of 5,750,000 shares of 7.125% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”) at a price of $25.00 per share, pursuant to an effective registration statement. The Company received net proceeds of $138.3 million from the offering, after deducting underwriting discounts and other offering expenses. The Company classified the par value as preferred equity on its condensed consolidated balance sheets with the balance of the liquidation preference, net of any issuance costs, recorded as an increase in paid-in capital.

The Company redeemed all 5,750,000 shares of its Series A Preferred Stock on June 1, 2018 (the “Redemption Date”) for $25.00 per share, plus accrued and unpaid dividends to, but not including, the Redemption Date, without interest, in the amount of $0.4453125 per share of Series A Preferred Stock, for a total redemption price per share of Series A Preferred Stock equal to $25.4453125. As a result of the redemption, the Company incurred a charge of $5.5 million related to the original issuance costs of the Series A Preferred Stock. The charge is presented as an additional preferred stock dividend in the Company’s condensed consolidated statements of income.

Common Stock

As a result of the CCP Merger completed on August 17, 2017, the Company issued approximately 94.0 million shares of its common stock in exchange for shares of CCP common stock and shares underlying share-based awards assumed by the Company outstanding as of the effective time of the CCP Merger.

On September 28, 2017, the Company completed an underwritten public offering of 16.0 million newly issued shares of its common stock pursuant to an effective registration statement. The underwriters exercised their option to purchase additional shares, and on October 2, 2017, the Company issued an additional 2.4 million newly issued shares of its common stock pursuant to an effective registration statement. The Company received net proceeds, before expenses, of $370.9 million from the offering, after giving effect to the issuance and sale of all 18.4 million shares of common stock, at a price of $21.00 per share. These proceeds were used to repay borrowings outstanding under the Revolving Credit Facility.

The following table lists the cash dividends on common stock declared and paid by the Company during the six months ended June 30, 2018:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 5, 2018	February 15, 2018	$	0.45	February 28, 2018
May 9, 2018	May 21, 2018	$	0.45	May 31, 2018

During the six months ended June 30, 2018, the Company issued 27,747 shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares as a result of restricted stock unit vestings, the related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the six months ended June 30, 2018 and 2017, the Company incurred $0.2 million and $2.6 million, respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants.

Accumulated Other Comprehensive Income

The following is a summary of the Company’s accumulated other comprehensive income (in thousands):

	June 30, 2018			December 31, 2017
Foreign currency translation loss	$	(3,026	)	$	(2,913	)
Unrealized gains on cash flow hedges	27,438			14,202
Total accumulated other comprehensive income	$	24,412		$	11,289

25

11.    EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share for the three and six months ended June 30, 2018 and 2017 (in thousands, except share and per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Numerator
Net income attributable to common stockholders	$	193,580	$	17,960	$	253,490	$	34,222
Denominator
Basic weighted average common shares and common equivalents	178,314,750		65,438,739		178,304,733		65,396,146
Dilutive restricted stock units	369,274		232,114		296,056		297,873
Diluted weighted average common shares	178,684,024		65,670,853		178,600,789		65,694,019
Net income attributable to common stockholders, per:
Basic common share	$	1.09	$	0.27	$	1.42	$	0.52
Diluted common share	$	1.08	$	0.27	$	1.42	$	0.52

During the three and six months ended June 30, 2018, approximately 35,300 and 46,000 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. During the three and six months ended June 30, 2017, approximately 15,900 and 19,300 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. No stock options were considered anti-dilutive during the three and six months ended June 30, 2018, and no stock options were outstanding during the three and six months ended June 30, 2017.

12.    SUMMARIZED CONDENSED CONSOLIDATING INFORMATION

In connection with the offerings of the 2021 Notes and the 2023 Notes by the Issuers, the Company and certain 100% owned subsidiaries of the Company (the “Guarantors”) have, jointly and severally, fully and unconditionally guaranteed the 2021 Notes and the 2023 Notes, subject to release under certain customary circumstances as described below. In connection with the assumption of the 2026 Notes as a result of the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”), the Company has fully and unconditionally guaranteed the 2026 Notes, subject to release under certain circumstances as described below. These guarantees are subordinated to all existing and future senior debt and senior guarantees of the Guarantors and are unsecured. The Company conducts all of its business through and derives virtually all of its income from its subsidiaries. Therefore, the Company’s ability to make required payments with respect to its indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of its subsidiaries and its ability to receive funds from its subsidiaries.

A Guarantor will be automatically and unconditionally released from its obligations under the guarantees with respect to the 2021 Notes and the 2023 Notes in the event of:

• Any sale of the subsidiary Guarantor or of all or substantially all of its assets;

• A merger or consolidation of a subsidiary Guarantor with an issuer of the 2021 Notes or the 2023 Notes or another Guarantor, provided that the surviving entity remains a Guarantor;

• A subsidiary Guarantor is declared “unrestricted” for covenant purposes under the indentures governing the 2021 Notes or the 2023 Notes;

• The requirements for legal defeasance or covenant defeasance or to discharge the indentures governing the 2021 Notes or the 2023 Notes have been satisfied;

• A liquidation or dissolution, to the extent permitted under the indentures governing the 2021 Notes or the 2023 Notes, of a subsidiary Guarantor; or

• The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty.

26

The Company will be automatically and unconditionally released from its obligations under the guarantees with respect to the 2026 Notes in the event of:

• A liquidation or dissolution, to the extent permitted under the indenture governing the 2026 Notes;

• A merger or consolidation, provided that the surviving entity remains a Guarantor; or

• The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2026 Notes have been satisfied.

Pursuant to Rule 3-10 of Regulation S-X, the following summarized condensed consolidating information is provided for the Company (the “Parent Company”), the Operating Partnership, Sabra Capital Corporation, the Guarantors, and the Company’s non-Guarantor subsidiaries with respect to the 2021 Notes and the 2023 Notes. This summarized financial information has been prepared from the books and records maintained by the Company, the Operating Partnership, Sabra Capital Corporation, the Guarantors and the non-Guarantor subsidiaries. The summarized financial information may not necessarily be indicative of the results of operations or financial position had the Operating Partnership, Sabra Capital Corporation, the Guarantors or non-Guarantor subsidiaries operated as independent entities. Sabra’s investments in its consolidated subsidiaries are presented based upon Sabra’s proportionate share of each subsidiary’s net assets. The Guarantor subsidiaries’ investments in the non-Guarantor subsidiaries and non-Guarantor subsidiaries’ investments in Guarantor subsidiaries are presented under the equity method of accounting. Intercompany activities between subsidiaries and the Parent Company are presented within operating activities on the condensed consolidating statement of cash flows.

Condensed consolidating financial statements for the Company and its subsidiaries, including the Parent Company only, the Operating Partnership only, Sabra Capital Corporation only, the combined Guarantor subsidiaries and the combined non-Guarantor subsidiaries, are as follows:

27

CONDENSED CONSOLIDATING BALANCE SHEET

June 30, 2018

(in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)		Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	341		$	—	$	—	$	1,666,116	$	4,327,225	$	—		$	5,993,682
Loans receivable and other investments, net	(356		)	—		—		52,315		55,269		—			107,228
Investment in unconsolidated joint venture	—			—		—		—		348,950		—			348,950
Cash and cash equivalents	31,269			—		—		1,405		6,135		—			38,809
Restricted cash	—			—		—		174,913		11,932		—			186,845
Lease intangible assets, net	—			—		—		16,815		139,451		—			156,266
Accounts receivable, prepaid expenses and other assets, net	(536		)	46,700		—		84,809		73,017		(7,626		)	196,364
Intercompany	2,186,044			2,727,032		—		—		—		(4,913,076		)	—
Investment in subsidiaries	1,209,953			1,538,155		—		15,830		—		(2,763,938		)	—
Total assets	$	3,426,715		$	4,311,887	$	—	$	2,012,203	$	4,961,979	$	(7,684,640	)	$	7,028,144
Liabilities
Secured debt, net	$	—		$	—	$	—	$	—	$	253,567	$	—		$	253,567
Revolving credit facility	—			676,000		—		—		—		—			676,000
Term loans, net	—			1,093,314		—		94,084		—		—			1,187,398
Senior unsecured notes, net	—			1,306,842		—		—		—		—			1,306,842
Accounts payable and accrued liabilities	23,172			25,778		—		3,576		60,439		(7,626		)	105,339
Lease intangible liabilities, net	—			—		—		—		91,073		—			91,073
Intercompany	—			—		—		636,037		4,277,039		(4,913,076		)	—
Total liabilities	23,172			3,101,934		—		733,697		4,682,118		(4,920,702		)	3,620,219
Total Sabra Health Care REIT, Inc. stockholders' equity	3,403,543			1,209,953		—		1,278,506		275,479		(2,763,938		)	3,403,543
Noncontrolling interests	—			—		—		—		4,382		—			4,382
Total equity	3,403,543			1,209,953		—		1,278,506		279,861		(2,763,938		)	3,407,925
Total liabilities and equity	$	3,426,715		$	4,311,887	$	—	$	2,012,203	$	4,961,979	$	(7,684,640	)	$	7,028,144

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

28

CONDENSED CONSOLIDATING BALANCE SHEET

December 31, 2017

(in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)		Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	324		$	—	$	—	$	1,756,933	$	4,237,175	$	—		$	5,994,432
Loans receivable and other investments, net	(97		)	—		—		55,297		59,190		—			114,390
Cash and cash equivalents	511,670			—		—		449		6,513		—			518,632
Restricted cash	—			—		—		36,910		31,907		—			68,817
Lease intangible assets, net	—			—		—		17,577		149,542		—			167,119
Accounts receivable, prepaid expenses and other assets, net	3,499			36,073		—		80,739		53,765		(5,189		)	168,887
Intercompany	2,043,402			2,721,979		—		—		—		(4,765,381		)	—
Investment in subsidiaries	890,462			1,198,305		—		14,661		—		(2,103,428		)	—
Total assets	$	3,449,260		$	3,956,357	$	—	$	1,962,566	$	4,538,092	$	(6,873,998	)	$	7,032,277
Liabilities
Secured debt, net	$	—		$	—	$	—	$	—	$	256,430	$	—		$	256,430
Revolving credit facility	—			641,000		—		—		—		—			641,000
Term loans, net	—			1,092,397		—		98,377		—		—			1,190,774
Senior unsecured notes, net	—			1,306,286		—		—		—		—			1,306,286
Accounts payable and accrued liabilities	16,453			26,212		—		3,560		61,487		(5,189		)	102,523
Lease intangible liabilities, net	—			—		—		—		98,015		—			98,015
Intercompany	—			—		—		785,120		3,980,261		(4,765,381		)	—
Total liabilities	16,453			3,065,895		—		887,057		4,396,193		(4,770,570		)	3,595,028
Total Sabra Health Care REIT, Inc. stockholders' equity	3,432,807			890,462		—		1,075,509		137,457		(2,103,428		)	3,432,807
Noncontrolling interests	—			—		—		—		4,442		—			4,442
Total equity	3,432,807			890,462		—		1,075,509		141,899		(2,103,428		)	3,437,249
Total liabilities and equity	$	3,449,260		$	3,956,357	$	—	$	1,962,566	$	4,538,092	$	(6,873,998	)	$	7,032,277

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

29

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Three Months EndedJune 30, 2018

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	44,560		$	103,989		$	(4,320	)	$	144,229
Interest and other income	40			96			—		1,198			3,315			(96		)	4,553
Resident fees and services	—			—			—		—			17,530			—			17,530
Total revenues	40			96			—		45,758			124,834			(4,416		)	166,312
Expenses:
Depreciation and amortization	222			—			—		14,146			32,460			—			46,828
Interest	—			33,415			—		810			2,628			(96		)	36,757
Operating expenses	—			—			—		—			16,619			(4,320		)	12,299
General and administrative	8,009			14			—		379			869			—			9,271
Merger and acquisition costs	112			—			—		—			—			—			112
Provision for (recovery of) doubtful accounts and loan losses	311			—			—		(985		)	—			—			(674		)
Impairment of real estate	—			—			—		881			—			—			881
Total expenses	8,654			33,429			—		15,231			52,576			(4,416		)	105,474
Other income:
Other income (expense)	—			32			—		(32		)	—			—			—
Net gain on sales of real estate	—			—			—		141,918			985			—			142,903
Total other income	—			32			—		141,886			985			—			142,903
Income in subsidiary	209,456			242,758			—		1,871			—			(454,085		)	—
Income before loss from unconsolidated joint venture and income tax expense	200,842			209,457			—		174,284			73,243			(454,085		)	203,741
Loss from unconsolidated joint venture	—			—			—		—			(2,347		)	—			(2,347		)
Income tax expense	(55		)	(1		)	—		(489		)	(60		)	—			(605		)
Net income	200,787			209,456			—		173,795			70,836			(454,085		)	200,789
Net income attributable to noncontrolling interests	—			—			—		—			(2		)	—			(2		)
Net income attributable to Sabra Health Care REIT, Inc.	200,787			209,456			—		173,795			70,834			(454,085		)	200,787
Preferred stock dividends	(7,207		)	—			—		—			—			—			(7,207		)
Net income attributable to common stockholders	$	193,580		$	209,456		$	—	$	173,795		$	70,834		$	(454,085	)	$	193,580
Net income attributable to common stockholders, per:
Basic common share																		$	1.09
Diluted common share																		$	1.08
Weighted-average number of common shares outstanding, basic																		178,314,750
Weighted-average number of common shares outstanding, diluted																		178,684,024

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

30

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Three Months EndedJune 30, 2017

(dollars in thousands, except per share amounts)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—	$	—	$	52,442		$	4,656		$	(1,194	)	$	55,904
Interest and other income	6			—		—		2,039			—			(18		)	2,027
Resident fees and services	—			—		—		—			6,805			—			6,805
Total revenues	6			—		—		54,481			11,461			(1,212		)	64,736
Expenses:
Depreciation and amortization	216			—		—		15,425			1,579			—			17,220
Interest	—			13,516		—		715			1,631			—			15,862
Operating expenses	—			—		—		—			5,619			(1,212		)	4,407
General and administrative	4,063			17		—		991			55			—			5,126
Merger and acquisition costs	5,883			—		—		4			—			—			5,887
Provision for doubtful accounts and loan losses	227			—		—		308			—			—			535
Total expenses	10,389			13,533		—		17,443			8,884			(1,212		)	49,037
Other income (expense):
Other income (expense)	916			703		—		(665		)	(13		)	—			941
Net gain on sales of real estate	—			—		—		4,026			6			—			4,032
Total other income (expense)	916			703		—		3,361			(7		)	—			4,973
Income in subsidiary	29,894			42,724		—		1,785			—			(74,403		)	—
Income before income tax benefit (expense)	20,427			29,894		—		42,184			2,570			(74,403		)	20,672
Income tax benefit (expense)	93			—		—		(227		)	(2		)	—			(136		)
Net income	20,520			29,894		—		41,957			2,568			(74,403		)	20,536
Net income attributable to noncontrolling interests	—			—		—		—			(16		)	—			(16		)
Net income attributable to Sabra Health Care REIT, Inc.	20,520			29,894		—		41,957			2,552			(74,403		)	20,520
Preferred stock dividends	(2,560		)	—		—		—			—			—			(2,560		)
Net income attributable to common stockholders	$	17,960		$	29,894	$	—	$	41,957		$	2,552		$	(74,403	)	$	17,960
Net income attributable to common stockholders, per:
Basic common share																	$	0.27
Diluted common share																	$	0.27
Weighted-average number of common shares outstanding, basic																	65,438,739
Weighted-average number of common shares outstanding, diluted																	65,670,853

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

31

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Six Months EndedJune 30, 2018

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	90,024		$	207,013		$	(8,553	)	$	288,484
Interest and other income	50			208			—		2,465			6,376			(208		)	8,891
Resident fees and services	—			—			—		—			35,023			—			35,023
Total revenues	50			208			—		92,489			248,412			(8,761		)	332,398
Expenses:
Depreciation and amortization	443			—			—		29,076			65,314			—			94,833
Interest	—			65,980			—		1,601			5,202			(208		)	72,575
Operating expenses	—			—			—		—			32,976			(8,553		)	24,423
General and administrative	13,831			29			—		810			2,468			—			17,138
Merger and acquisition costs	448			—			—		—			(6		)	—			442
Provision for (recovery of) doubtful accounts and loan losses	2,492			—			—		(1,956		)	3			—			539
Impairment of real estate	—			—			—		1,413			—			—			1,413
Total expenses	17,214			66,009			—		30,944			105,957			(8,761		)	211,363
Other income:
Other income	1,977			233			—		378			232			—			2,820
Net gain on sales of real estate	—			—			—		141,862			569			—			142,431
Total other income	1,977			233			—		142,240			801			—			145,251
Income in subsidiary	278,798			344,367			—		3,725			—			(626,890		)	—
Income before loss from unconsolidated joint venture and income tax expense	263,611			278,799			—		207,510			143,256			(626,890		)	266,286
Loss from unconsolidated joint venture	—			—			—		—			(1,901		)	—			(1,901		)
Income tax expense	(353		)	(1		)	—		(542		)	(219		)	—			(1,115		)
Net income	263,258			278,798			—		206,968			141,136			(626,890		)	263,270
Net income attributable to noncontrolling interests	—			—			—		—			(12		)	—			(12		)
Net income attributable to Sabra Health Care REIT, Inc.	263,258			278,798			—		206,968			141,124			(626,890		)	263,258
Preferred stock dividends	(9,768		)	—			—		—			—			—			(9,768		)
Net income attributable to common stockholders	$	253,490		$	278,798		$	—	$	206,968		$	141,124		$	(626,890	)	$	253,490
Net income attributable to common stockholders, per:
Basic common share																		$	1.42
Diluted common share																		$	1.42
Weighted-average number of common shares outstanding, basic																		178,304,733
Weighted-average number of common shares outstanding, diluted																		178,600,789

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

32

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Six Months EndedJune 30, 2017

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	105,481		$	9,625		$	(1,978	)	$	113,128
Interest and other income	13			—			—		3,977			—			(18		)	3,972
Resident fees and services	—			—			—		—			10,286			—			10,286
Total revenues	13			—			—		109,458			19,911			(1,996		)	127,386
Expenses:
Depreciation and amortization	432			—			—		32,381			3,544			—			36,357
Interest	—			26,924			—		1,445			3,281			—			31,650
Operating expenses	—			—			—		—			8,823			(1,996		)	6,827
General and administrative	9,322			31			—		1,758			104			—			11,215
Merger and acquisition costs	6,417			—			—		34			—			—			6,451
Provision for doubtful accounts and loan losses	82			—			—		2,223			—			—			2,305
Total expenses	16,253			26,955			—		37,841			15,752			(1,996		)	94,805
Other income:
Other income	2,283			737			—		50			—			—			3,070
Net gain on sales of real estate	—			—			—		4,026			6			—			4,032
Total other income	2,283			737			—		4,076			6			—			7,102
Income in subsidiary	53,331			79,550			—		3,564			—			(136,445		)	—
Income before income tax expense	39,374			53,332			—		79,257			4,165			(136,445		)	39,683
Income tax expense	(31		)	(1		)	—		(227		)	(97		)	—			(356		)
Net income	39,343			53,331			—		79,030			4,068			(136,445		)	39,327
Net loss attributable to noncontrolling interests	—			—			—		—			16			—			16
Net income attributable to Sabra Health Care REIT, Inc.	39,343			53,331			—		79,030			4,084			(136,445		)	39,343
Preferred stock dividends	(5,121		)	—			—		—			—			—			(5,121		)
Net income attributable to common stockholders	$	34,222		$	53,331		$	—	$	79,030		$	4,084		$	(136,445	)	$	34,222
Net income attributable to common stockholders, per:
Basic common share																		$	0.52
Diluted common share																		$	0.52
Weighted-average number of common shares outstanding, basic																		65,396,146
Weighted-average number of common shares outstanding, diluted																		65,694,019

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

33

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months EndedJune 30, 2018

(dollars in thousands)

(unaudited)

					Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	200,787	$	209,456	$	—	$	173,795		$	70,836		$	(454,085	)	$	200,789
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		1,064		—		(608		)	(195		)	—			261
Unrealized gain on cash flow hedges	—		3,335		—		3			—			—			3,338
Total other comprehensive income (loss)	—		4,399		—		(605		)	(195		)	—			3,599
Comprehensive income	200,787		213,855		—		173,190			70,641			(454,085		)	204,388
Comprehensive income attributable to noncontrolling interest	—		—		—		—			(2		)	—			(2		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	200,787	$	213,855	$	—	$	173,190		$	70,639		$	(454,085	)	$	204,386

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

34

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months EndedJune 30, 2017

(dollars in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	20,520	$	29,894		$	—	$	41,957		$	2,568		$	(74,403	)	$	20,536
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(415		)	—		833			280			—			698
Unrealized gain (loss) on cash flow hedges	—		285			—		(188		)	—			—			97
Total other comprehensive (loss) income	—		(130		)	—		645			280			—			795
Comprehensive income	20,520		29,764			—		42,602			2,848			(74,403		)	21,331
Comprehensive income attributable to noncontrolling interest	—		—			—		—			(16		)	—			(16		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	20,520	$	29,764		$	—	$	42,602		$	2,832		$	(74,403	)	$	21,315

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

35

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Six Months EndedJune 30, 2018

(dollars in thousands)

(unaudited)

					Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	263,258	$	278,798	$	—	$	206,968		$	141,136		$	(626,890	)	$	263,270
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		1,905		—		(1,536		)	(482		)	—			(113		)
Unrealized gain (loss) on cash flow hedges	—		13,238		—		(2		)	—			—			13,236
Total other comprehensive income (loss)	—		15,143		—		(1,538		)	(482		)	—			13,123
Comprehensive income	263,258		293,941		—		205,430			140,654			(626,890		)	276,393
Comprehensive income attributable to noncontrolling interest	—		—		—		—			(12		)	—			(12		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	263,258	$	293,941	$	—	$	205,430		$	140,642		$	(626,890	)	$	276,381

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

36

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Six Months EndedJune 30, 2017

(dollars in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Net income	$	39,343	$	53,331		$	—	$	79,030		$	4,068	$	(136,445	)	$	39,327
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(1,367		)	—		1,131			376		—			140
Unrealized gain (loss) on cash flow hedges	—		1,013			—		(188		)	—		—			825
Total other comprehensive (loss) income	—		(354		)	—		943			376		—			965
Comprehensive income	39,343		52,977			—		79,973			4,444		(136,445		)	40,292
Comprehensive loss attributable to noncontrolling interest	—		—			—		—			16		—			16
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	39,343	$	52,977		$	—	$	79,973		$	4,460	$	(136,445	)	$	40,308

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

37

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2018

(in thousands)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net cash provided by operating activities	$	204,440		$	—		$	—	$	1,041		$	6,072		$	—		$	211,553
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(29,711		)	(184,271		)	—			(213,982		)
Origination and fundings of loans receivable	—			—			—		(1,973		)	(26,184		)	—			(28,157		)
Origination and fundings of preferred equity investments	—			—			—		(945		)	—			—			(945		)
Additions to real estate	(40		)	—			—		(4,660		)	(12,117		)	—			(16,817		)
Repayments of loans receivable	—			—			—		6,577			32,310			—			38,887
Repayments of preferred equity investments	—			—			—		375			—			—			375
Investment in unconsolidated JV	—			—			—		—			(354,461		)	—			(354,461		)
Net proceeds from the sales of real estate	—			—			—		232,059			46,142			—			278,201
Distribution from subsidiaries	2,669			2,669			—		—			—			(5,338		)	—
Intercompany financing	(378,485		)	(413,473		)	—		—			—			791,958			—
Net cash (used in) provided by investing activities	(375,856		)	(410,804		)	—		201,722			(498,581		)	786,620			(296,899		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			35,000			—		—			—			—			35,000
Principal payments on secured debt	—			—			—		—			(2,128		)	—			(2,128		)
Payments of deferred financing costs	—			(12		)	—		—			—			—			(12		)
Distributions to noncontrolling interest	—			—			—		—			(72		)	—			(72		)
Preferred stock redemption	(143,750		)	—			—		—			—			—			(143,750		)
Issuance of common stock, net	(499		)	—			—		—			—			—			(499		)
Dividends paid on common and preferred stock	(164,736		)	—			—		—			—			—			(164,736		)
Distribution to parent	—			(2,669		)	—		—			(2,669		)	5,338			—
Intercompany financing	—			378,485			—		(63,658		)	477,131			(791,958		)	—
Net cash (used in) provided by financing activities	(308,985		)	410,804			—		(63,658		)	472,262			(786,620		)	(276,197		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(480,401		)	—			—		139,105			(20,247		)	—			(361,543		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		(146		)	(106		)	—			(252		)
Cash, cash equivalents and restricted cash, beginning of period	511,670			—			—		37,359			38,420			—			587,449
Cash, cash equivalents and restricted cash, end of period	$	31,269		$	—		$	—	$	176,318		$	18,067		$	—		$	225,654

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

38

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2017

(in thousands)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net cash provided by (used in) operating activities	$	49,670		$	—		$	—	$	(1,693	)	$	6,305		$	—		$	54,282
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(14,456		)	—			—			(14,456		)
Origination and fundings of loans receivable	—			—			—		(927		)	—			—			(927		)
Origination and fundings of preferred equity investments	—			—			—		(76		)	—			—			(76		)
Additions to real estate	(12		)	—			—		(1,106		)	(176		)	—			(1,294		)
Repayments of loans receivable	—			—			—		1,547			—			—			1,547
Repayments of preferred equity investments	—			—			—		2,766			—			—			2,766
Net proceeds from the sale of real estate	—			—			—		6,099			—			—			6,099
Distribution from subsidiaries	2,474			2,474			—		—			—			(4,948		)	—
Intercompany financing	(1,667		)	(7,543		)	—		—			—			9,210			—
Net cash provided by (used in) investing activities	795			(5,069		)	—		(6,153		)	(176		)	4,262			(6,341		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			6,000			—		—			—			—			6,000
Principal payments on secured debt	—			—			—		—			(2,049		)	—			(2,049		)
Payments of deferred financing costs	—			(124		)	—		—			—			—			(124		)
Issuance of common stock, net	(3,224		)	—			—		—			—			—			(3,224		)
Dividends paid on common and preferred stock	(60,691		)	—			—		—			—			—			(60,691		)
Distribution to parent	—			(2,474		)	—		—			(2,474		)	4,948			—
Intercompany financing	—			1,667			—		7,543			—			(9,210		)	—
Net cash (used in) provided by financing activities	(63,915		)	5,069			—		7,543			(4,523		)	(4,262		)	(60,088		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(13,450		)	—			—		(303		)	1,606			—			(12,147		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		69			61			—			130
Cash, cash equivalents and restricted cash, beginning of period	18,168			—			—		2,732			13,765			—			34,665
Cash, cash equivalents and restricted cash, end of period	$	4,718		$	—		$	—	$	2,498		$	15,432		$	—		$	22,648

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

39

13.    COMMITMENTS AND CONTINGENCIES

Environmental

As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of June 30, 2018, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.

Legal Matters

From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

14.    SUBSEQUENT EVENTS

The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.

Dividend Declaration

On August 8, 2018, the Company announced that its board of directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on August 31, 2018 to common stockholders of record as of the close of business on August 18, 2018.

40

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS.

The discussion below contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those which are discussed in the “Risk Factors” section in Part I, Item 1A of our 2017 Annual Report on Form 10-K. Also see “Statement Regarding Forward-Looking Statements” preceding Part I.

The following discussion and analysis should be read in conjunction with our accompanying condensed consolidated financial statements and the notes thereto.

Our Management’s Discussion and Analysis of Financial Condition and Results of Operations is organized as follows:

• Overview

• Critical Accounting Policies

• Recently Issued Accounting Standards Update

• Results of Operations

• Liquidity and Capital Resources

• Concentration of Credit Risk

• Skilled Nursing Facility Reimbursement Rates

• Obligations and Commitments

• Off-Balance Sheet Arrangements

Overview

We operate as a self-administered, self-managed REIT that, through our subsidiaries, owns and invests in real estate serving the healthcare industry.

Our primary business consists of acquiring, financing and owning real estate property to be leased to third party tenants in the healthcare sector using triple-net operating leases. We primarily generate revenues by leasing properties to tenants and owning properties operated by third-party property managers throughout the United States (“U.S.”) and Canada.

Our investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments and an investment in an unconsolidated joint venture.

In 2017 and the first half of 2018, we completed a series of transactions—including the CCP Merger (as defined below), sales of facilities leased to Genesis, investment in the Enlivant Joint Venture (as defined below) and entry into our new Credit Facility (as defined below), each of which are discussed below—that have significantly enhanced our scale and increased our diversification. Following these transactions, we expect to continue to grow our investment portfolio while diversifying our portfolio by tenant, facility type and geography within the healthcare sector. We plan to achieve these objectives primarily through making investments directly or indirectly in healthcare real estate, including the development of purpose built healthcare facilities with select developers. We also intend to achieve our objective of diversifying our portfolio by tenant and facility type through select asset sales and other arrangements with Genesis and other tenants. During the six months ended June 30, 2018, we completed the sale of 37 facilities, including 27 facilities leased to Genesis, and expect to complete the sales of 19 of our remaining 27 Genesis facilities during the remainder of 2018 and to retain eight facilities, although we cannot provide assurance that the sales will be completed in that timeframe, if at all.

We expect to continue to grow our portfolio primarily through the acquisition of assisted living, independent living and memory care communities in the U.S. and Canada and through the acquisition of skilled nursing/transitional care and behavioral health facilities in the U.S. We have and expect to continue to opportunistically acquire other types of healthcare real estate, originate financing secured directly or indirectly by healthcare facilities and invest in the development of senior housing communities and skilled nursing/transitional care facilities. We also expect to expand our portfolio through the development of purpose-built healthcare facilities through pipeline agreements and other arrangements with select developers. We further expect to work with existing operators to identify strategic development opportunities. These opportunities may involve replacing, renovating or expanding facilities in our portfolio that may have become less competitive and new development opportunities that present attractive risk-adjusted returns. In addition to pursuing acquisitions with triple-net leases, we expect to continue to pursue other forms of investment, including investments in Senior Housing - Managed communities, mezzanine and secured debt investments, and joint ventures for senior housing communities and skilled nursing/transitional care facilities.

41

We also expect to continue to enhance the strength of our investment portfolio by selectively disposing of underperforming facilities or working with new or existing operators to transfer underperforming but promising properties to new operators.

With respect to our debt and preferred equity investments, in general, we originate loans and make preferred equity investments when an attractive investment opportunity is presented and (a) the property is in or near the development phase, (b) the development of the property is completed but the operations of the facility are not yet stabilized or (c) the loan investment will provide capital to existing relationships. A key component of our development strategy related to loan originations and preferred equity investments is having the option to purchase the underlying real estate that is owned by our borrowers (and that directly or indirectly secures our loan investments) or by the entity in which we have an investment. These options become exercisable upon the occurrence of various criteria, such as the passage of time or the achievement of certain operating goals, and the method to determine the purchase price upon exercise of the option is set in advance based on the same valuation methods we use to value our investments in healthcare real estate. This proprietary development pipeline strategy allows us to diversify our revenue streams and build relationships with operators and developers, and provides us with the option to add new properties to our existing real estate portfolio if we determine that those properties enhance our investment portfolio and stockholder value at the time the options are exercisable.

We employ a disciplined, opportunistic approach in our healthcare real estate investment strategy by investing in assets that provide attractive opportunities for dividend growth and appreciation of asset values, while maintaining balance sheet strength and liquidity, thereby creating long-term stockholder value.

We elected to be treated as a REIT with the filing of our U.S. federal income tax return for the taxable year beginning January 1, 2011. We believe that we have been organized and have operated, and we intend to continue to operate, in a manner to qualify as a REIT. We operate through an umbrella partnership, commonly referred to as an UPREIT structure, in which substantially all of our properties and assets are held by Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which we are the sole general partner and our wholly owned subsidiaries are currently the only limited partners, or by subsidiaries of the Operating Partnership.

Care Capital Properties, Inc. Merger

On May 7, 2017, Sabra, the Operating Partnership, PR Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of Sabra (“Merger Sub”), Care Capital Properties, Inc., a Delaware corporation (“CCP”), and Care Capital Properties, L.P. (“CCPLP”), a Delaware limited partnership and wholly owned subsidiary of CCP, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, on August 17, 2017, CCP merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation (the “CCP Merger”), following which Merger Sub merged with and into Sabra, with Sabra continuing as the surviving entity (the “Subsequent Merger”), and, simultaneous with the Subsequent Merger, CCPLP merged with and into the Operating Partnership, with the Operating Partnership continuing as the surviving entity.

Pursuant to the Merger Agreement, as of the effective time of the CCP Merger, each share of CCP common stock, par value $0.01 per share, issued and outstanding immediately prior to the effective time of the CCP Merger (other than shares of CCP common stock owned directly by CCP, Sabra or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, par value $0.01 per share, plus cash in lieu of any fractional shares.

The acquisition of CCP has been reflected in our consolidated financial statements since the effective date of the CCP

Merger.

On September 7, 2017, Sabra announced its strategy to reposition the CCP portfolio, which includes a combination of lease modifications (including between $28.2 million and $31.2 million of reduction in rents), working capital advances, transitioning facilities to other Sabra tenants and strategic sales or closures of underperforming facilities.

As a result of the CCP Merger, we have increased our tenant diversification by operator and geography, including decreasing concentration from our top five relationships. In addition, shortly following the closing of the CCP Merger, we received investment grade ratings from Standard & Poor’s and Fitch and a two notch upgrade from Moody’s, which provided an immediate improvement in our cost of debt under our Credit Facility.

See Note 3, “CCP Merger and Recent Real Estate Acquisitions” in the Notes to Condensed Consolidated Financial Statements for additional information regarding the CCP Merger.

42

Acquisitions

During the six months ended June 30, 2018, we acquired 11 Senior Housing - Managed communities managed by Enlivant, five senior housing communities and two skilled nursing/transitional care facilities for an aggregate $214.0 million. See Note 3, “CCP Merger and Recent Real Estate Acquisitions” in the Notes to Condensed Consolidated Financial Statements for additional information regarding these acquisitions.

Dispositions

During the six months ended June 30, 2018, we completed the sale of 33 skilled nursing/transitional care facilities and four senior housing communities for aggregate consideration, net of closing costs, of $278.3 million. The net carrying value of the assets and liabilities of these facilities was $135.8 million, which resulted in an aggregate $142.5 million net gain on sale.

Enlivant Joint Venture

In addition to the acquisition of 11 Senior Housing - Managed communities managed by Enlivant, on January 2, 2018, we completed our transaction with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, and contributed $352.7 million, before closing costs, to acquire a 49% equity interest in an entity that owns 172 senior housing communities managed by Enlivant (the “Enlivant Joint Venture”). At closing, the Enlivant Joint Venture had outstanding indebtedness of $791.3 million and net working capital of $22.9 million, and our investment in the Enlivant Joint Venture implied an aggregate portfolio value of $1.49 billion. We financed this investment with proceeds from our Revolving Credit Facility. The joint venture agreement includes an option for us to acquire the remainder of the outstanding equity interests in the Enlivant Joint Venture by January 2, 2021 and grants us the right of first offer if our partner in the Enlivant Joint Venture desires to transfer its equity interest (which it may do commencing on January 2, 2020). In addition, Sabra has the right to designate three directors on the seven member board of directors of the Enlivant Joint Venture and has other customary minority rights.

Preferred Stock Redemption

On June 1, 2018 (the “Redemption Date”), we redeemed all 5,750,000 outstanding shares of our Series A Preferred Stock. The shares of Series A Preferred Stock were redeemed at a redemption price of $25.00 per share, plus accrued and unpaid dividends to, but not including, the Redemption Date, without interest, in the amount of $0.4453125 per share of Series A Preferred Stock, for a total redemption price per share of Series A Preferred Stock equal to $25.4453125.

Critical Accounting Policies

Our condensed consolidated interim financial statements have been prepared in accordance with GAAP and in conjunction with the rules and regulations of the SEC. The preparation of our financial statements requires significant management judgments, assumptions and estimates about matters that are inherently uncertain. These judgments affect the reported amounts of assets and liabilities and our disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expenses during the reporting periods. With different estimates or assumptions, materially different amounts could be reported in our financial statements. Additionally, other companies may utilize different estimates that may impact the comparability of our results of operations to those of companies in similar businesses. A discussion of the accounting policies that management considers critical in that they involve significant management judgments and assumptions, require estimates about matters that are inherently uncertain and because they are important for understanding and evaluating our reported financial results is included in Part II, Item 7 of our 2017 Annual Report on Form 10-K filed with the SEC. There have been no significant changes to our critical accounting policies during the six months ended June 30, 2018.

Recently Issued Accounting Standards Update

See Note 2, “Summary of Significant Accounting Policies,” in the Notes to Condensed Consolidated Financial Statements for information concerning recently issued accounting standards updates.

Results of Operations

As of June 30, 2018, our investment portfolio included 487 real estate properties held for investment, one asset held for sale, one investment in a direct financing lease, 22 investments in loans receivable, 13 preferred equity investments and one investment in an unconsolidated joint venture. As of June 30, 2017, our investment portfolio included 183 real estate properties held for investment, eight investments in loans receivable and 12 preferred equity investments. In general, we expect that our income and expenses related to our portfolio will increase in future periods in comparison to the corresponding prior periods as a result of owning acquired investments for an entire period, the anticipated future acquisition of additional investments and

43

completion of the CCP Merger. The results of operations presented are not directly comparable due to ongoing acquisition activity.

Comparison of results of operations for the three months ended June 30, 2018 versus the three months ended June 30, 2017 (dollars in thousands):

	Three Months Ended June 30,						Increase / (Decrease)			Percentage Difference		Variance due to the CCP Merger, Acquisitions, Originations and Dispositions (1)			Remaining Variance (2)
	2018			2017
Revenues:
Rental income	$	144,229		$	55,904		$	88,325		158	%	$	93,752		$	(5,427	)
Interest and other income	4,553			2,027			2,526			125	%	2,686			(160		)
Resident fees and services	17,530			6,805			10,725			158	%	10,089			636
Expenses:
Depreciation and amortization	46,828			17,220			29,608			172	%	29,636			(28		)
Interest	36,757			15,862			20,895			132	%	16,948			3,947
Operating expenses	12,299			4,407			7,892			179	%	7,458			434
General and administrative	9,271			5,126			4,145			81	%	302			3,843
Merger and acquisition costs	112			5,887			(5,775		)	(98	)%	(5,775		)	—
(Recovery of) provision for doubtful accounts and loan losses	(674		)	535			(1,209		)	(226	)%	—			(1,209		)
Impairment of real estate	881			—			881			NM		—			881
Other income:
Other income	—			941			(941		)	(100	)%	—			(941		)
Net gain on sales of real estate	142,903			4,032			138,871			3,444	%	138,871			—
Loss from unconsolidated joint venture	(2,347		)	—			(2,347		)	NM		(2,347		)	—
Income tax expense	(605		)	(136		)	(469		)	345	%	—			(469		)

⁽¹⁾  Represents the dollar amount increase (decrease) for the three months ended June 30, 2018 compared to the three months ended June 30, 2017 as a result of the CCP Merger and investments/dispositions made after April 1, 2017.

⁽²⁾  Represents the dollar amount increase (decrease) for the three months ended June 30, 2018 compared to the three months ended June 30, 2017 that is not a direct result of the CCP Merger and investments/dispositions made after April 1, 2017.

Rental Income

During the three months ended June 30, 2018, we recognized $144.2 million of rental income compared to $55.9 million for the three months ended June 30, 2017. The $88.3 million increase in rental income is primarily due to an increase of $86.4 million from properties acquired in the CCP Merger and an increase of $11.2 million from other properties acquired after April 1, 2017, partially offset by a decrease of $3.9 million from properties disposed of after April 1, 2017, a $4.8 million decrease due to the Genesis lease restructuring agreement which reduced the annual base rent payable under the Genesis leases by $19.0 million and a $1.5 million decrease due to five skilled nursing/transitional care facilities transitioned to a new operator. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the three months ended June 30, 2018 and 2017.

Interest and Other Income

Interest and other income primarily consists of income earned on our loans receivable investments, preferred returns earned on our preferred equity investments and income on the direct financing lease. During the three months ended June 30, 2018, we recognized $4.6 million of interest and other income compared to $2.0 million for the three months ended June 30, 2017. The increase of $2.5 million is primarily due to an increase of $2.5 million primarily related to interest income from loans receivable investments and income from a direct financing lease, partially offset by a $0.7 million decrease from investments that were disposed after April 1, 2017. Included in interest income is $0.9 million from a legacy CCP loan receivable that was fully repaid in June 2018, which represents the difference between the outstanding principal balance repaid and its discounted book value.

44

Resident Fees and Services

During the three months ended June 30, 2018, we recognized $17.5 million of resident fees and services compared to $6.8 million for the three months ended June 30, 2017. The $10.7 million increase is primarily due to a $10.1 million increase related to 13 properties acquired after April 1, 2017 and a $0.2 million increase due to one senior housing community that was transitioned to Senior Housing - Managed communities in May 2017.

Depreciation and Amortization

During the three months ended June 30, 2018, we incurred $46.8 million of depreciation and amortization expense compared to $17.2 million for the three months ended June 30, 2017. The $29.6 million net increase in depreciation and amortization expense is primarily due to an increase of $26.4 million related to the properties acquired in the CCP Merger and an increase of $4.6 million from other properties acquired after April 1, 2017, partially offset by a decrease of $1.4 million from properties disposed of after April 1, 2017.

Interest Expense

We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the three months ended June 30, 2018, we incurred $36.8 million of interest expense compared to $15.9 million for the three months ended June 30, 2017. The $20.9 million net increase is primarily related to (i) a $7.4 million increase in interest expense related to two senior notes assumed in the CCP Merger (see Note 7, “Debt” in the Notes to Condensed Consolidated Financial Statements for additional information), (ii) a $6.4 million increase in interest expense related to our U.S. dollar term loans as a result of increasing U.S. dollar term loan borrowings from $245.0 million to $1.1 billion in connection with the CCP Merger, (iii) a $5.6 million increase in interest expense related to the borrowings outstanding on the Revolving Credit Facility, (iv) a $0.9 million increase primarily related to the $98.5 million secured term loan assumed in the CCP Merger and (v) a $0.6 million increase of non-cash interest expense related to our interest rate hedges.

Operating Expenses

During the three months ended June 30, 2018, we recognized $12.3 million of operating expenses compared to $4.4 million for the three months ended June 30, 2017. The $7.9 million increase is primarily due to a $7.5 million increase related to 13 properties acquired after April 1, 2017 and a $0.1 million increase due to one senior housing community that was transitioned to Senior Housing - Managed communities in May 2017.

General and Administrative Expenses

General and administrative expenses include compensation-related expenses as well as professional services, office costs, and other costs associated with asset management. During the three months ended June 30, 2018, general and administrative expenses were $9.3 million compared to $5.1 million during the three months ended June 30, 2017. The $4.1 million increase is primarily related to (i) a $1.0 million increase in stock-based compensation expense, (ii) a $0.7 million increase in payroll expenses related to the increased number of employees, (iii) $0.6 million of expenses related to the previously anticipated refinancing of the Senior Notes (as defined below), (iv) a $0.5 million increase in legal, professional and insurance fees primarily due to the management of the increased number of investments, (v) $0.3 million in legal fees related to the recovery of previously reserved cash rental income and (vi) $0.3 million of transition expenses for the CCP Merger primarily consisting of salaries, severance benefits and office expenses. The increase in stock-based compensation expense, from $1.7 million during the three months ended June 30, 2017 to $2.7 million during the three months ended June 30, 2018, is primarily due to the increased number of employees and the change in our stock price during the three months ended June 30, 2018 (an increase of $4.08 per share) compared to the three months ended June 30, 2017 (a decrease of $3.83 per share). We issue stock to employees who elected to receive annual bonuses in stock rather than in cash and therefore changes in our stock price will result in changes to our bonus expense.

Merger and Acquisition Costs

During the three months ended June 30, 2018, we incurred $0.1 million of merger and acquisition costs compared to $5.9 million for the three months ended June 30, 2017. The costs incurred in both periods were primarily related to the CCP Merger.

(Recovery of) Provision for Doubtful Accounts and Loan Losses

During the three months ended June 30, 2018, we recognized a $0.7 million net recovery of doubtful accounts and loan losses, which is comprised of a $1.0 million recovery of previously reserved cash rental income, offset by a $0.1 million increase in reserves on straight-line rental income and a $0.2 million increase in loan loss reserves. During the three months

45

ended June 30, 2017, we recognized a $0.5 million provision for doubtful accounts and loan losses, which is primarily comprised of a $0.3 million increase in reserves on straight-line rental income and a $0.2 million increase in loan loss reserves.

Impairment of Real Estate

During the three months ended June 30, 2018, we recognized $0.9 million of impairment of real estate related to one skilled nursing/transitional care facility. No impairment of real estate was recognized during the three months ended June 30, 2017.

Other Income

During the three months ended June 30, 2018, we did not recognize any other income. During the three months ended June 30, 2017, we recognized $0.9 million of other income, which was primarily due to the amortization of lease termination payments related to a memorandum of understanding with Genesis.

Net Gain on Sales of Real Estate

During the three months ended June 30, 2018, we recognized an aggregate net gain on the sales of real estate of $142.9 million primarily related to the disposition of 32 skilled nursing/transitional care facilities and four senior housing communities. During the three months ended June 30, 2017, we recognized a net gain on the sale of real estate of $4.0 million related to the disposition of one skilled nursing/transitional care facility. See Note 5, “Asset Held for Sale and Dispositions” in the Notes to Condensed Consolidated Financial Statements for additional information.

Loss from Unconsolidated Joint Venture

During the three months ended June 30, 2018, we recognized $2.3 million of loss from the Enlivant Joint Venture. Included in the loss is $0.6 million of deferred tax expense.

Income Tax Expense

During the three months ended June 30, 2018, we recognized $0.6 million of income tax expense compared to $0.1 million for the three months ended June 30, 2017. The increase is primarily due to the increase in Senior Housing - Managed communities and higher state taxes as a result of the increased number of investments.

46

Comparison of results of operations for the six months ended June 30, 2018 versus the six months ended June 30, 2017 (dollars in thousands):

	Six Months Ended June 30,						Increase / (Decrease)			Percentage Difference		Variance due to the CCP Merger, Acquisitions, Originations and Dispositions (1)			Remaining Variance (2)
	2018			2017
Revenues:
Rental income	$	288,484		$	113,128		$	175,356		155	%	$	188,081		$	(12,725	)
Interest and other income	8,891			3,972			4,919			124	%	5,399			(480		)
Resident fees and services	35,023			10,286			24,737			240	%	19,916			4,821
Expenses:
Depreciation and amortization	94,833			36,357			58,476			161	%	59,215			(739		)
Interest	72,575			31,650			40,925			129	%	33,380			7,545
Operating expenses	24,423			6,827			17,596			258	%	14,803			2,793
General and administrative	17,138			11,215			5,923			53	%	1,703			4,220
Merger and acquisition costs	442			6,451			(6,009		)	(93	)%	(6,009		)	—
Provision for doubtful accounts and loan losses	539			2,305			(1,766		)	(77	)%	—			(1,766		)
Impairment of real estate	1,413			—			1,413			NM		532			881
Other income:
Other income	2,820			3,070			(250		)	(8	)%	—			(250		)
Net gain on sales of real estate	142,431			4,032			138,399			3,433	%	138,399			—
Loss from unconsolidated joint venture	(1,901		)	—			(1,901		)	NM		(1,901		)	—
Income tax expense	(1,115		)	(356		)	(759		)	213	%	—			(759		)

⁽¹⁾  Represents the dollar amount increase (decrease) for the six months ended June 30, 2018 compared to the six months ended June 30, 2017 as a result of the CCP Merger and investments/dispositions made after January 1, 2017.

⁽²⁾  Represents the dollar amount increase (decrease) for the six months ended June 30, 2018 compared to the six months ended June 30, 2017 that is not a direct result of the CCP Merger and investments/dispositions made after January 1, 2017.

Rental Income

During the six months ended June 30, 2018, we recognized $288.5 million of rental income compared to $113.1 million for the six months ended June 30, 2017. The $175.4 million increase in rental income is primarily due to an increase of $172.4 million from properties acquired in the CCP Merger and an increase of $21.8 million from other properties acquired after January 1, 2017, partially offset by a decrease of $6.1 million from properties disposed of after January 1, 2017, a $9.5 million decrease due to the Genesis lease restructuring agreement which reduced the annual base rent payable under the Genesis leases by $19.0 million, a $2.8 million decrease due to five skilled nursing/transitional care facilities transitioned to a new operator and a $1.4 million decrease due to the nine senior housing communities that were transitioned to Senior Housing - Managed communities in March and May 2017. Amounts due under the terms of all of our lease agreements are subject to contractual increases, and contingent rental income may be derived from certain lease agreements. No material contingent rental income was derived during the six months ended June 30, 2018 and 2017.

Interest and Other Income

Interest and other income primarily consists of income earned on our loans receivable investments, preferred returns earned on our preferred equity investments and income on the direct financing lease. During the six months ended June 30, 2018, we recognized $8.9 million of interest and other income compared to $4.0 million for the six months ended June 30, 2017. The increase of $4.9 million is primarily due to an increase of $5.5 million primarily related to interest income from loans receivable investments, income from a direct financing lease and income from the specialty valuation firm acquired in the CCP Merger that we subsequently sold in March 2018, partially offset by a $1.0 million decrease from investments that were disposed after January 1, 2017. Included in interest income is $0.9 million from a legacy CCP loan receivable that was fully repaid in June 2018, which represents the difference between the outstanding principal balance repaid and its discounted book value.

47

Resident Fees and Services

During the six months ended June 30, 2018, we recognized $35.0 million of resident fees and services compared to $10.3 million for the six months ended June 30, 2017. The $24.7 million increase is primarily due to a $19.9 million increase related to 13 properties acquired after January 1, 2017 and a $4.5 million increase due to nine senior housing communities that were transitioned to Senior Housing - Managed communities in March and May 2017.

Depreciation and Amortization

During the six months ended June 30, 2018, we incurred $94.8 million of depreciation and amortization expense compared to $36.4 million for the six months ended June 30, 2017. The $58.5 million net increase in depreciation and amortization expense is primarily due to an increase of $53.1 million related to the properties acquired in the CCP Merger and an increase of $8.5 million from other properties acquired after January 1, 2017, partially offset by a decrease of $2.4 million from properties disposed of after January 1, 2017; the remaining $0.7 million decrease is primarily due to the acceleration of lease intangible amortization related to the nine senior housing communities transitioned to Senior Housing - Managed communities in March and May 2017.

Interest Expense

We incur interest expense comprised of costs of borrowings plus the amortization of deferred financing costs related to our indebtedness. During the six months ended June 30, 2018, we incurred $72.6 million of interest expense compared to $31.7 million for the six months ended June 30, 2017. The $40.9 million net increase is primarily related to (i) a $14.7 million increase in interest expense related to two senior notes assumed in the CCP Merger (see Note 7, “Debt” in the Notes to Condensed Consolidated Financial Statements for additional information), (ii) a $12.5 million increase in interest expense related to our U.S. dollar term loans as a result of increasing U.S. dollar term loan borrowings from $245.0 million to $1.1 billion in connection with the CCP Merger, (iii) a $10.7 million increase in interest expense related to the borrowings outstanding on the Revolving Credit Facility, (iv) a $1.7 million increase primarily related to the $98.5 million secured term loan assumed in the CCP Merger and (v) a $1.3 million increase of non-cash interest expense related to our interest rate hedges.

Operating Expenses

During the six months ended June 30, 2018, we recognized $24.4 million of operating expenses compared to $6.8 million for the six months ended June 30, 2017. The $17.6 million increase is primarily due to a $14.8 million increase related to 13 properties acquired after January 1, 2017 and a $2.6 million increase due to nine senior housing communities that were transitioned to Senior Housing - Managed communities in March and May 2017.

General and Administrative Expenses

General and administrative expenses include compensation-related expenses as well as professional services, office costs, and other costs associated with asset management. During the six months ended June 30, 2018, general and administrative expenses were $17.1 million compared to $11.2 million during the six months ended June 30, 2017. The $5.9 million increase is primarily related to (i) a $1.4 million increase in payroll expenses related to the increased number of employees, (ii) a $1.0 million increase in legal, professional and insurance fees primarily due to the management of the increased number of investments, (iii) $1.0 million of transition expenses for the CCP Merger primarily consisting of salaries, severance benefits and office expenses, (iv) $0.8 million in expenses incurred by our specialty valuation firm that we sold in March 2018, (v) $0.6 million in legal fees related to the recovery of previously reserved cash rental income and (vi) $0.6 million of expenses related to the previously anticipated refinancing of the Senior Notes. The increases are partially offset by a $0.5 million decrease in stock-based compensation. The decrease in stock-based compensation expense, from $4.3 million during the six months ended June 30, 2017 to $3.8 million during the six months ended June 30, 2018, is primarily due to a change in performance-based vesting assumptions on management’s equity compensation.

Merger and Acquisition Costs

During the six months ended June 30, 2018, we incurred $0.4 million of merger and acquisition costs compared to $6.5 million for the six months ended June 30, 2017. The costs incurred in both periods were primarily related to the CCP Merger.

Provision for Doubtful Accounts and Loan Losses

During the six months ended June 30, 2018, we recognized a $0.5 million provision for doubtful accounts and loan losses, which is comprised of a $2.2 million increase in reserves on straight-line rental income and a $0.3 million increase in loan loss reserves, partially offset by a $2.0 million recovery of previously reserved cash rental income. During the six months ended June 30, 2017, we recognized a $2.3 million provision for doubtful accounts and loan losses, which is primarily

48

comprised of a $1.9 million increase in loan loss reserves, a $0.3 million increase in reserves on straight-line rental income and a $0.1 million increase in reserves on cash rental income.

Impairment of Real Estate

During the six months ended June 30, 2018, we recognized $1.4 million of impairment of real estate related to one senior housing community and one skilled nursing/transitional care facility. The senior housing community was sold during the six months ended June 30, 2018. See Note 5, “Asset Held for Sale and Dispositions” in the Notes to Condensed Consolidated Financial Statements for additional information. No impairment of real estate was recognized during the six months ended June 30, 2017.

Other Income

During the six months ended June 30, 2018, we recognized $2.8 million of other income. The $2.8 million of other income is comprised of a $2.0 million contingency fee earned in the current period related to a legacy CCP investment, $0.6 million related to cash payments received from two facilities not subject to a lease and $0.2 million related to the sale of our specialty valuation firm. During the six months ended June 30, 2017, we recognized $3.1 million of other income, of which $2.3 million was due to the amortization of lease termination payments related to a memorandum of understanding with Genesis and $0.8 million related to other income as a result of adjusting the fair value of our contingent consideration liability related to the acquisition of a real estate property, partially offset by $0.1 million of ineffectiveness loss related to our LIBOR interest rate swaps.

Net Gain on Sales of Real Estate

During the six months ended June 30, 2018, we recognized an aggregate net gain on the sales of real estate of $142.4 million primarily related to the disposition of 33 skilled nursing/transitional care facilities and four senior housing communities. During the six months ended June 30, 2017, we recognized a net gain on the sale of real estate of $4.0 million related to the disposition of one skilled nursing/transitional care facility. See Note 5, “Asset Held for Sale and Dispositions” in the Notes to Condensed Consolidated Financial Statements for additional information.

Loss from Unconsolidated Joint Venture

During the six months ended June 30, 2018, we recognized $1.9 million of loss from the Enlivant Joint Venture. Included in the loss is $1.1 million of deferred tax expense.

Income Tax Expense

During the six months ended June 30, 2018, we recognized $1.1 million of income tax expense compared to $0.4 million for the six months ended June 30, 2017. The increase is primarily due to the increase in Senior Housing - Managed communities and higher state taxes as a result of the increased number of investments.

Funds from Operations and Adjusted Funds from Operations

We believe that net income attributable to common stockholders as defined by GAAP is the most appropriate earnings measure. We also believe that funds from operations attributable to common stockholders (“FFO”), as defined in accordance with the definition used by the National Association of Real Estate Investment Trusts (“NAREIT”), and adjusted funds from operations attributable to common stockholders (“AFFO”) (and related per share amounts) are important non-GAAP supplemental measures of our operating performance. Because the historical cost accounting convention used for real estate assets requires straight-line depreciation (except on land), such accounting presentation implies that the value of real estate assets diminishes predictably over time. However, since real estate values have historically risen or fallen with market and other conditions, presentations of operating results for a REIT that uses historical cost accounting for depreciation could be less informative. Thus, NAREIT created FFO as a supplemental measure of operating performance for REITs that excludes historical cost depreciation and amortization, among other items, from net income attributable to common stockholders, as defined by GAAP. FFO is defined as net income attributable to common stockholders, computed in accordance with GAAP, excluding gains or losses from real estate dispositions, plus real estate depreciation and amortization, net of amounts related to noncontrolling interests, plus our share of depreciation and amortization related to our unconsolidated joint venture, and real estate impairment charges. AFFO is defined as FFO excluding merger and acquisition costs, stock-based compensation expense, straight-line rental income adjustments, amortization of above and below market lease intangibles, non-cash interest income adjustments, non-cash interest expense, change in fair value of contingent consideration, non-cash portion of loss on extinguishment of debt, provision for doubtful straight-line rental income, loan losses and other reserves and deferred income taxes, as well as other non-cash revenue and expense items (including ineffectiveness gain/loss on derivative instruments, and non-cash revenue and expense amounts related to noncontrolling interests) and our share of non-cash adjustments related to our

49

unconsolidated joint venture. We believe that the use of FFO and AFFO (and the related per share amounts), combined with the required GAAP presentations, improves the understanding of our operating results among investors and makes comparisons of operating results among REITs more meaningful. We consider FFO and AFFO to be useful measures for reviewing comparative operating and financial performance because, by excluding the applicable items listed above, FFO and AFFO can help investors compare our operating performance between periods or as compared to other companies. While FFO and AFFO are relevant and widely used measures of operating performance of REITs, they do not represent cash flows from operations or net income attributable to common stockholders as defined by GAAP and should not be considered an alternative to those measures in evaluating our liquidity or operating performance. FFO and AFFO also do not consider the costs associated with capital expenditures related to our real estate assets nor do they purport to be indicative of cash available to fund our future cash requirements. Further, our computation of FFO and AFFO may not be comparable to FFO and AFFO reported by other REITs that do not define FFO in accordance with the current NAREIT definition or that interpret the current NAREIT definition or define AFFO differently than we do.

The following table reconciles our calculations of FFO and AFFO for the three and six months ended June 30, 2018 and 2017, to net income attributable to common stockholders, the most directly comparable GAAP financial measure, for the same periods (in thousands, except share and per share amounts):

	Three Months Ended June 30,						Six Months Ended June 30,
	2018			2017			2018			2017
Net income attributable to common stockholders	$	193,580		$	17,960		$	253,490		$	34,222
Depreciation and amortization of real estate assets	46,828			17,220			94,833			36,357
Depreciation and amortization of real estate asset related to noncontrolling interests	(40		)	—			(80		)	—
Depreciation and amortization of real estate assets related to unconsolidated joint venture	6,163			—			10,715			—
Net gain on sales of real estate	(142,903		)	(4,032		)	(142,431		)	(4,032		)
Impairment of real estate	881			—			1,413			—
FFO attributable to common stockholders	104,509			31,148			217,940			66,547
Merger and acquisition costs (1)	112			5,888			442			6,451
Stock-based compensation expense	2,704			1,731			3,839			4,319
Straight-line rental income adjustments	(12,189		)	(4,971		)	(23,752		)	(9,578		)
Amortization of above and below market lease intangibles, net	(684		)	—			(1,368		)	—
Non-cash interest income adjustments	(604		)	25			(1,174		)	51
Non-cash interest expense	2,516			1,653			4,997			3,244
Change in fair value of contingent consideration	—			—			—			(822		)
Provision for doubtful straight-line rental income, loan losses and other reserves	311			534			2,492			1,924
Other non-cash adjustments related to unconsolidated joint venture	1,350			—			1,014			—
Other non-cash adjustments	15			126			30			185
AFFO attributable to common stockholders	$	98,040		$	36,134		$	204,460		$	72,321
FFOattributable to common stockholders per diluted common share	$	0.58		$	0.47		$	1.22		$	1.01
AFFO attributable to common stockholders per diluted common share	$	0.55		$	0.55		$	1.14		$	1.10
Weighted average number of common shares outstanding, diluted:
FFO attributable to common stockholders	178,684,024			65,670,853			178,600,789			65,694,019
AFFO attributable to common stockholders	179,226,155			65,985,940			179,215,960			66,009,102

⁽¹⁾  Merger and acquisition costs primarily relate to the CCP Merger.

50

The following table sets forth additional information related to certain other items included in net income attributable to common stockholders above, and the portions of each that are included in FFO and AFFO attributable to common stockholders, which may be helpful in assessing our operating results. Please refer to “—Results of Operations” above for additional information regarding these items (in millions):

	Three Months Ended June 30,															Six Months Ended June 30,
	2018			2017		2018			2017		2018			2017		2018		2017		2018		2017		2018			2017
	Net Income					FFO					AFFO					Net Income				FFO				AFFO
Income on repayment of loan (1)	$	0.9		$	—	$	0.9		$	—	$	0.9		$	—	$	0.9	$	—	$	0.9	$	—	$	0.9		$	—
Previously anticipated Senior Notes refinancing expenses (2)	0.6			—		0.6			—		0.6			—		0.6		—		0.6		—		0.6			—
CCP transition expenses (2)	0.3			—		0.3			—		0.3			—		0.9		—		0.9		—		0.9			—
Legal fees related to the recovery of previously reserved cash rental income (2)	0.3			—		0.3			—		0.3			—		0.6		—		0.6		—		0.6			—
Merger and acquisition costs	0.1			5.9		0.1			5.9		—			—		0.4		6.5		0.4		6.5		—			—
(Recovery of) provision for doubtful accounts	(0.7		)	0.5		(0.7		)	0.5		(1.0		)	—		0.5		2.3		0.5		2.3		(2.0		)	0.4
Other income	—			0.9		—			0.9		—			1.1		2.8		3.1		2.8		3.1		2.8			2.4
Deferred income tax expense (3)	0.6			—		0.6			—		—			—		1.1		—		1.1		—		—			—
Preferred stock redemption charge (4)	5.5			—		5.5			—		5.5			—		5.5		—		5.5		—		5.5			—

⁽¹⁾  Reflected in interest and other income on the accompanying condensed consolidated statements of income.

⁽²⁾  Reflected in general and administrative expenses on the accompanying condensed consolidated statements of income.

⁽³⁾  Reflected in loss from unconsolidated joint venture on the accompanying condensed consolidated statements of income.

⁽⁴⁾  Reflected in preferred stock dividends on the accompanying condensed consolidated statements of income.

Liquidity and Capital Resources

As of June 30, 2018, we had approximately $362.6 million in liquidity, consisting of unrestricted cash and cash equivalents of $38.6 million (excluding joint venture cash and cash equivalents), and available borrowings under our Revolving Credit Facility of $324.0 million. The Credit Facility also contains an accordion feature that can increase the total available borrowings to $2.5 billion (from U.S. $2.1 billion plus CAD $125.0 million), subject to terms and conditions. In addition, restricted cash as of June 30, 2018 includes $174.4 million held by exchange accommodation titleholders, which may be used to fund future real estate acquisitions.

We have filed a shelf registration statement with the SEC that expires in January 2020, which allows us to offer and sell shares of common stock, preferred stock, warrants, rights, units, and certain of our subsidiaries to offer and sell debt securities, through underwriters, dealers or agents or directly to purchasers, on a continuous or delayed basis, in amounts, at prices and on terms we determine at the time of the offering, subject to market conditions.

We believe that our available cash, operating cash flows and borrowings available to us under our Revolving Credit Facility provide sufficient funds for our operations, scheduled debt service payments and dividend requirements for the next twelve months. In addition, we do not believe that the restrictions under our Senior Notes Indentures (as defined below) significantly limit our ability to use our available liquidity for these purposes.

We intend to invest in additional healthcare properties as suitable opportunities arise and adequate sources of financing are available. We expect that future investments in properties, including any improvements or renovations of current or newly-acquired properties, will depend on and will be financed, in whole or in part, by our existing cash, borrowings available to us under our Revolving Credit Facility, future borrowings or the proceeds from issuances of common stock, preferred stock, debt or other securities. In addition, we may seek financing from U.S. government agencies, including through Fannie Mae and HUD, in appropriate circumstances in connection with acquisitions.

51

Cash Flows from Operating Activities

Net cash provided by operating activities was $211.6 million for the six months ended June 30, 2018. Operating cash inflows were derived primarily from the rental payments received under our lease agreements, resident fees and services net of the corresponding operating expenses and interest payments from borrowers under our loan investments. Operating cash outflows consisted primarily of interest payments on borrowings and payment of general and administrative expenses, including corporate overhead. We expect our annualized cash flows provided by operating activities to increase as a result of the CCP Merger and other completed and anticipated future real estate investments.

Cash Flows from Investing Activities

During the six months ended June 30, 2018, net cash used in investing activities was $296.9 million and consisted of $354.5 million used for our investment in the Enlivant Joint Venture, $214.0 million used in the acquisition of 11 Senior Housing - Managed communities, five senior housing communities and two skilled nursing/transitional care facilities, $28.2 million used to provide additional funding for existing loans receivable, $16.8 million used for tenant improvements and $0.9 million used to fund preferred equity investments, partially offset by $278.2 million in sales proceeds related to the disposition of 37 real estate facilities, $38.9 million in repayments of loans receivable and $0.4 million in repayments of preferred equity investments.

We expect to continue using available liquidity in connection with anticipated future real estate investments, loan originations and preferred equity investments.

Cash Flows from Financing Activities

During the six months ended June 30, 2018, net cash used in financing activities was $276.2 million and included $164.7 million of dividends paid to stockholders, $143.8 million for the preferred stock redemption payment, $2.1 million of principal repayments of secured debt and $0.5 million in payroll tax payments related to the issuance of common stock pursuant to equity compensation arrangements. In addition, during the six months ended June 30, 2018, we borrowed a net amount of $35.0 million on our Revolving Credit Facility.

Please see the accompanying condensed consolidated statements of cash flows for details of our operating, investing and financing cash activities.

Loan Agreements

2021 Notes. On January 23, 2014, the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of Sabra (the “Issuers”), issued $350.0 million aggregate principal amount of 5.5% senior unsecured notes due 2021 (the “Original 2021 Notes”), providing net proceeds of approximately $340.8 million after deducting underwriting discounts and other offering expenses. On October 10, 2014, the Issuers issued an additional $150.0 million aggregate principal amount of 5.5% senior unsecured notes due 2021 (together with the Original 2021 Notes, the “2021 Notes”), providing net proceeds of approximately $145.6 million (not including pre-issuance accrued interest), after deducting underwriting discounts and other offering expenses and a yield-to-maturity of 5.593%.

2023 Notes. On May 23, 2013, the Issuers issued $200.0 million aggregate principal amount of 5.375% senior notes due 2023 (the “2023 Notes”), providing net proceeds of approximately $194.6 million after deducting underwriting discounts and other offering expenses.

2026 and 2027 Notes. In connection with the CCP Merger, on August 17, 2017, Sabra assumed $500 million aggregate principal amount of 5.125% senior notes due 2026 (the “2026 Notes”) and $100 million aggregate principal amount of 5.38% senior notes due 2027 (the “2027 Notes” and, together with the 2021 Notes, the 2023 Notes and the 2026 Notes, the “Senior Notes”).

See Note 7, “Debt,” in the Notes to Condensed Consolidated Financial Statements for additional information concerning the Senior Notes, including information regarding the indentures and agreements governing the Senior Notes (the “Senior Notes Indentures”). As of June 30, 2018, we were in compliance with all applicable covenants under the Senior Notes Indentures.

Credit Facility. Effective on August 17, 2017, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fourth amended and restated unsecured credit facility (the “Credit Facility”).

The Credit Facility includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0

52

million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Facility also contains an accordion feature that can increase the total available borrowings to $2.5 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of August 17, 2021, and includes twosix-month extension options. $200.0 million of the U.S. dollar Term Loans has a maturity date of August 17, 2020, and the other Term Loans have a maturity date of August 17, 2022.

The obligations of the Borrowers under the Credit Facility are guaranteed by us and certain of our subsidiaries.

See Note 7, “Debt,” in the Notes to Condensed Consolidated Financial Statements for additional information concerning the Credit Facility, including information regarding covenants contained in the Credit Facility. As of June 30, 2018, we were in compliance with all applicable covenants under the Credit Facility.

Secured Indebtedness

Of our 487 properties held for investment, 30 are subject to secured indebtedness to third parties that, as of June 30, 2018, totaled approximately $256.3 million. As of June 30, 2018 and December 31, 2017, our secured debt consisted of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of June 30, 2018 (1)		Principal Balance as of December 31, 2017 (1)		Weighted Average Effective Interest Rate at June 30, 2018 (2)		Maturity Date
Fixed Rate	$	157,781	$	160,702	3.87	%	December 2021 -  August 2051
Variable Rate	98,500		98,500		3.89	%	July 2019
	$	256,281	$	259,202	3.88	%

⁽¹⁾  Principal balance does not include deferred financing costs, net of $2.7 million and $2.8 million as of June 30, 2018 and December 31, 2017, respectively.

⁽²⁾  Weighted average effective interest rate includes private mortgage insurance.

Capital Expenditures

We had $16.8 million and $1.3 million of capital expenditures for the six months ended June 30, 2018 and 2017, respectively. The capital expenditures for the six months ended June 30, 2018 and 2017 include $40,000 and $12,000, respectively, of capital expenditures for corporate office needs. There are no present plans for the improvement or development of any unimproved or undeveloped property; however, from time to time we may agree to fund improvements our tenants make at our facilities. Accordingly, we anticipate that our aggregate capital expenditure requirements for the next 12 months will not exceed $59.0 million, and that such expenditures will principally be for improvements to our facilities and result in incremental rental income.

Dividends

We paid dividends of $164.7 million on our common and preferred stock during the six months ended June 30, 2018. As described above, on June 1, 2018, we redeemed all outstanding shares of our Series A Preferred Stock. On August 8, 2018, our board of directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on August 31, 2018 to common stockholders of record as of August 18, 2018.

Concentration of Credit Risk

Concentrations of credit risk arise when a number of operators, tenants or obligors related to our investments are engaged in similar business activities, or activities in the same geographic region, or have similar economic features that would cause their ability to meet contractual obligations, including those to us, to be similarly affected by changes in economic conditions. We regularly monitor our portfolio to assess potential concentrations of risks.

Management believes our current portfolio is reasonably diversified across healthcare related real estate and geographical location and does not contain any other significant concentration of credit risks. Our portfolio of 487 real estate properties held for investment as of June 30, 2018 is diversified by location across the United States and Canada.

For the three and six months ended June 30, 2018, no tenant relationships represented 10% or more of our total revenues.

Skilled Nursing Facility Reimbursement Rates

For the six months ended June 30, 2018, 63.9% of our revenues was derived directly or indirectly from skilled nursing/transitional care facilities. Medicare reimburses skilled nursing facilities for Medicare Part A services under the Prospective

53

Payment System (“PPS”), as implemented pursuant to the Balanced Budget Act of 1997 and modified pursuant to subsequent laws, most recently the Patient Protection and Affordable Care Act of 2010. PPS regulations predetermine a payment amount per patient, per day, based on a market basket index calculated for all covered costs. The amount to be paid is determined by classifying each patient into one of 66 Resource Utilization Group (“RUG”) categories that represent the level of services required to treat different conditions and levels of acuity.

The current system of 66 RUG categories, or Resource Utilization Group, Version IV (“RUG-IV”), became effective as of October 1, 2010. RUG-IV resulted from research performed by the Centers for Medicare & Medicaid Services (“CMS”) and was part of CMS’s continuing effort to increase the correlation of the cost of services to the condition of individual patients.

On July 31, 2018, CMS issued a final rule, CMS-1696-F, which includes changes to the case-mix classification system used under the PPS and fiscal year 2019 Medicare payment updates.

CMS-1696-F includes a new case-mix classification system called the skilled nursing facility Patient-Driven Payment Model (“PDPM”) that will become effective on October 1, 2019. PDPM reflects significant changes to the Resident Classification System, Version I (“RCS-I”) that was being considered to replace RUG-IV as outlined in an Advanced Notice of Proposed Rulemaking released by CMS in May 2017.

PDPM focuses on clinically relevant factors, rather than volume-based service, for determining Medicare payment. PDPM adjusts Medicare payments based on each aspect of a resident’s care, most notably for non-therapy ancillaries, which are items and services not related to the provision of therapy such as drugs and medical supplies, thereby more accurately addressing costs associated with medically complex patients. It further adjusts the skilled nursing facility per diem payments to reflect varying costs throughout the stay and incorporates safeguards against potential financial incentives to ensure that beneficiaries receive care consistent with their unique needs and goals.

Based on changes contained within CMS-1696-F, CMS estimates that the fiscal year 2019 aggregate impact will be an increase of $820 million in Medicare payments to skilled nursing facilities, resulting from the fiscal year 2019 market basket update required to be 2.4% by the Bipartisan Budget Act of 2018. Absent the application of this statutory requirement, the fiscal year 2019 market basket update factor would have been 2.0% (comprised of a market basket index of 2.8% less the productivity adjustment of 0.8%). This 2.0% update would have resulted in an estimated aggregate increase of $670 million in Medicare payments to skilled nursing facilities.

On July 31, 2017, CMS released final fiscal year 2018 Medicare rates for skilled nursing facilities providing an estimated net increase of 1.0% over fiscal year 2017 payments. The new payment rates became effective on October 1, 2017. In its final rule, CMS also revised and rebased the market basket index by updating the base year from fiscal year 2010 to fiscal year 2014.

On July 29, 2016, CMS released final fiscal year 2017 Medicare rates for skilled nursing facilities providing a net increase of 2.4% over fiscal year 2016 payments (comprised of a market basket increase of 2.7% less the productivity adjustment of 0.3%). The new payment rates became effective on October 1, 2016.

54

Obligations and Commitments

The following table summarizes our contractual obligations and commitments in future years, including our secured indebtedness to third parties on certain of our properties, our Revolving Credit Facility, our Term Loans, our Senior Notes and our operating leases. The following table is presented as of June 30, 2018 (in thousands):

			July 1 through December 31, 2018				Year Ending December 31,
	Total				2019		2020		2021		2022		After 2022
Secured indebtedness (1)	$	334,672	$	6,820	$	110,395	$	9,723	$	24,759	$	8,581	$	174,394
Revolving Credit Facility (2)	755,699		12,819		25,428		25,498		691,954		—		—
Term Loans (3)	1,336,171		17,393		34,502		233,208		33,799		1,017,269		—
Senior Notes (4)	1,702,482		34,627		69,255		69,255		555,505		41,755		932,085
Operating leases	3,645		326		440		426		445		467		1,541
Total	$	4,132,669	$	71,985	$	240,020	$	338,110	$	1,306,462	$	1,068,072	$	1,108,020

⁽¹⁾  Secured indebtedness includes principal payments and interest payments through the applicable maturity dates. Total interest on secured indebtedness, based on contractual rates, is $78.4 million, of which $4.1 million is attributable to variable rate debt.

⁽²⁾  Revolving Credit Facility includes payments related to the facility fee due to the lenders based on the amount of commitments under the Revolving Credit Facility and also includes interest payments through the maturity date (assuming no exercise of our twosix-month extension options). Total interest on the Revolving Credit Facility is $79.7 million.

⁽³⁾  Term Loans includes interest payments through the applicable maturity dates totaling $141.0 million.

⁽⁴⁾  Senior Notes includes interest payments through the applicable maturity dates totaling $402.5 million.

In addition to the above, as of June 30, 2018, we have committed to provide up to $12.6 million of future funding related to seven investments, including six loans receivable investments with maturity dates ranging from September 2018 to January 2027.

Off-Balance Sheet Arrangements

We have a 49% interest in an unconsolidated joint venture. See Note 2, “Summary of Significant Accounting Policies” in the Notes to Condensed Consolidated Financial Statements for additional information. We have no other off-balance sheet arrangements that we expect would materially affect our liquidity and capital resources.

55

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to various market risks, primarily related to adverse changes in interest rates and the exchange rate for Canadian dollars. We use derivative instruments in the normal course of business to mitigate interest rate and foreign currency risk. We do not use derivative financial instruments for speculative or trading purposes. See Note 8, “Derivative and Hedging Instruments,” in the Notes to Condensed Consolidated Financial Statements for further discussion on our derivative instruments.

Interest rate risk. As of June 30, 2018, our indebtedness included $1.3 billion aggregate principal amount of Senior Notes outstanding, $256.3 million of secured indebtedness to third parties on certain of the properties that our subsidiaries own, $1.2 billion in Term Loans and $676.0 million outstanding under the Revolving Credit Facility. As of June 30, 2018, we had $2.0 billion of outstanding variable rate indebtedness and $324.0 million available for borrowing under our Revolving Credit Facility. Additionally, as of June 30, 2018, our share of unconsolidated joint venture debt was $384.2 million, of which $382.1 million was variable rate indebtedness.

We expect to manage our exposure to interest rate risk by maintaining a mix of fixed and variable rates for our indebtedness. We also may manage, or hedge, interest rate risks related to our borrowings through interest rate swap agreements. As of June 30, 2018, we had 10 interest rate swaps that fix the LIBOR portion of the interest rate for $845.0 million of LIBOR-based borrowings under the U.S. dollar Term Loans at a weighted average rate of 1.19% and two interest rate swaps that fix the CDOR portion of the interest rate for CAD $90.0 million and CAD $35.0 million of CDOR-based borrowings at 1.59% and 0.93%, respectively. Additionally, as of June 30, 2018, our share of unconsolidated joint venture debt included $368.4 million of LIBOR-based borrowings subject to interest rate cap agreements that cap the LIBOR portion of the interest rate at a weighted average rate of 2.89%.

From time to time, we may borrow under the Revolving Credit Facility to finance future investments in properties, including any improvements or renovations of current or newly acquired properties, or for other purposes. Because borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at our option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0%, the interest rate we will be required to pay on any such borrowings will depend on then applicable rates and may vary. An increase in interest rates could make the financing of any investment by us more costly. Rising interest rates could also limit our ability to refinance our debt when it matures or cause us to pay higher interest rates upon refinancing and increase interest expense on refinanced indebtedness.

Assuming a 100 basis point increase or decrease in the interest rate related to our variable rate debt, including our share of unconsolidated joint venture debt, and after giving effect to the impact of interest rate derivative instruments, income would decrease by $13.4 million or increase by $14.1 million, respectively, for the twelve months following June 30, 2018.

Foreign currency risk. We are exposed to changes in foreign exchange rates as a result of our investments in Canadian real estate. Our foreign currency exposure is partially mitigated through the use of Canadian dollar denominated debt totaling CAD $147.3 million and cross currency swap instruments. Based on our operating results for the three months ended June 30, 2018, if the value of the Canadian dollar relative to the U.S. dollar were to increase or decrease by 10% compared to the average exchange rate during the three months ended June 30, 2018, our cash flows would have decreased or increased, as applicable, by $0.1 million.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Controls and Procedures

As of the end of the period covered by this report, management, including our chief executive officer and chief financial officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures. Based upon, and as of the date of, the evaluation, our chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective as of June 30, 2018 to ensure that information required to be disclosed in the reports we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive officer and our chief financial officer, as appropriate to allow timely decisions regarding required disclosure.

56

Changes in Internal Control Over Financial Reporting

There were no changes in our internal control over financial reporting during the quarter ended June 30, 2018 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

57

PART II. OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None of the Company or any of its subsidiaries is a party to, and none of their respective property is the subject of, any material legal proceeding, although we are from time to time party to legal proceedings that arise in the ordinary course of our business.

ITEM 1A. RISK FACTORS

There have been no material changes in our assessment of our risk factors from those set forth in Part I, Item 1A of our 2017 Annual Report on Form 10-K.

ITEM 6. EXHIBITS

Ex.	Description
2.1	Agreement and Plan of Merger, dated as of May 7, 2017, by and among Sabra Health Care REIT, Inc., PR Sub, LLC, Sabra Health Care Limited Partnership, Care Capital Properties, Inc. and Care Capital Properties, LP (incorporated by reference to Exhibit 2.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on May 8, 2017).†
3.1	Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated October 20, 2010, filed with the State Department of Assessments and Taxation of the State of Maryland on October 21, 2010 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on October 26, 2010).
3.1.1	Articles of Amendment to the Articles of Amendment and Restatement of Sabra Health Care REIT, Inc., dated as of July 31, 2017 (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on July 31, 2017).
3.2	Amended and Restated Bylaws of Sabra Health Care REIT, Inc. (incorporated by reference to Exhibit 3.1 of the Current Report on Form 8-K filed by Sabra Health Care REIT, Inc. on May 7, 2017).
12.1*	Statement Re: Computation of Ratios of Earnings to Combined Fixed Charges and Preferred Stock Dividends.
31.1*	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1**	Certification of Chief Executive Officer pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002.
32.2**	Certification of Chief Financial Officer pursuant to 18 U.S.C. 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS*	XBRL Instance Document.
101.SCH*	XBRL Taxonomy Extension Schema Document.
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document.

*	Filed herewith.
**	Furnished herewith.

58

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	SABRA HEALTH CARE REIT, INC.
Date: August 8, 2018	By:	/S/    RICHARD K. MATROS
		Richard K. Matros
		Chairman, President and
		Chief Executive Officer
		(Principal Executive Officer)
Date: August 8, 2018	By:	/S/    HAROLD W. ANDREWS, JR.
		Harold W. Andrews, Jr.
		Executive Vice President,
		Chief Financial Officer and Secretary
		(Principal Financial and Accounting Officer)

59

EX-12.1

Exhibit 12.1

SABRA HEALTH CARE REIT, INC. AND SUBSIDIARIES

COMPUTATION OF RATIOS OF EARNINGS TO COMBINED FIXED CHARGES

AND PREFERRED STOCK DIVIDENDS

(dollars in thousands)

		Three Months Ended June 30,						Six Months Ended June 30,
		2018			2017			2018			2017
Earnings
	Income before loss from unconsolidated joint venture and income tax expense	$	203,741		$	20,672		$	266,286		$	39,683
	Add:
	Fixed charges	36,811			15,878			72,683			31,682
	Noncontrolling interests	(2		)	(16		)	(12		)	16
Earnings, as adjusted		$	240,550		$	36,534		$	338,957		$	71,381
Fixed charges
	Interest expensed and capitalized	$	34,241		$	14,209		$	67,578		$	28,406
	Non-cash interest expense	2,516			1,653			4,997			3,244
	Estimate of interest within rental expense	54			16			108			32
Fixed charges, as adjusted		36,811			15,878			72,683			31,682
Preferred stock dividends (1)		1,706			2,560			4,267			5,121
Combined fixed charges and preferred stock dividends		$	38,517		$	18,438		$	76,950		$	36,803
Ratio of earnings to fixed charges		6.53		x	2.30		x	4.66		x	2.25		x
Ratio of earnings to combined fixed charges and preferred stock dividends		6.25		x	1.98		x	4.40		x	1.94		x

⁽¹⁾  The three and six months ended June 30, 2018 exclude $5.5 million of capitalized issuance costs related to the preferred stock issuance that were written off as a result of the June 1, 2018 preferred stock redemption and presented as an additional preferred stock dividend in the condensed consolidated statements of income of Sabra Health Care REIT, Inc.

EX-31.1

Exhibit 31.1

Certification of Chief Executive Officer pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Richard K. Matros, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2018

/S/    RICHARD K. MATROS

Richard K. Matros

Chairman, President and

Chief Executive Officer

EX-31.2

Exhibit 31.2

Certification of Chief Financial Officer pursuant to

Section 302 of the Sarbanes-Oxley Act of 2002

I, Harold W. Andrews, Jr., certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sabra Health Care REIT, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: 

a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

c)Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

d)Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 8, 2018

/S/    HAROLD W. ANDREWS, JR.

Harold W. Andrews, Jr.

Executive Vice President,

Chief Financial Officer and Secretary

EX-32.1

Exhibit 32.1

Certification pursuant to 18 U.S.C. Section 1350,

as Adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Sabra Health Care REIT, Inc. (the “Registrant”) for the three and six months ended June 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Richard K. Matros, as Chairman, President and Chief Executive Officer of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: August 8, 2018

/S/    RICHARD K. MATROS

Richard K. Matros

Chairman, President and

Chief Executive Officer

EX-32.2

Exhibit 32.2

Certification pursuant to 18 U.S.C. Section 1350,

as Adopted pursuant to Section 906 of the

Sarbanes-Oxley Act of 2002

In connection with the Quarterly Report on Form 10-Q of Sabra Health Care REIT, Inc. (the “Registrant”) for the three and six months ended June 30, 2018, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), Harold W. Andrews, Jr., the Executive Vice President, Chief Financial Officer and Secretary of the Registrant, hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge:

1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Registrant.

Date: August 8, 2018

/S/    HAROLD W. ANDREWS, JR.

Harold W. Andrews, Jr.

Executive Vice President,

Chief Financial Officer and Secretary

XML

DOCUMENT AND ENTITY INFORMATION - shares	6 Months Ended
	Jun. 30, 2018	Aug. 02, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Sabra Health Care REIT, Inc.
Entity Central Index Key	0001492298
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Jun. 30, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	Q2
Amendment Flag	false
Entity Common Stock, Shares Outstanding		178,283,590

XML

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets
Real estate investments, net of accumulated depreciation of $377,159 and $340,423 as of June 30, 2018 and December 31, 2017, respectively	$ 5,993,682	$ 5,994,432
Loans receivable and other investments, net	107,228	114,390
Investment in unconsolidated joint venture	348,950	0
Cash and cash equivalents	38,809	518,632
Restricted cash	186,845	68,817
Lease intangible assets, net	156,266	167,119
Accounts receivable, prepaid expenses and other assets, net	196,364	168,887
Total assets	7,028,144	7,032,277
Liabilities
Secured debt, net	253,567	256,430
Revolving credit facility	676,000	641,000
Term loans, net	1,187,398	1,190,774
Senior unsecured notes, net	1,306,842	1,306,286
Accounts payable and accrued liabilities	105,339	102,523
Lease intangible liabilities, net	91,073	98,015
Total liabilities	3,620,219	3,595,028
Commitments and contingencies (Note 13)
Equity
Preferred stock, $.01 par value; 10,000,000 shares authorized, 5,750,000 shares issued and outstanding as of December 31, 2017	0	58
Common stock, $.01 par value; 250,000,000 shares authorized, 178,283,590 and 178,255,843 shares issued and outstanding as of June 30, 2018 and December 31, 2017, respectively	1,783	1,783
Additional paid-in capital	3,502,954	3,636,913
Cumulative distributions in excess of net income	(125,606)	(217,236)
Accumulated other comprehensive income	24,412	11,289
Total Sabra Health Care REIT, Inc. stockholders’ equity	3,403,543	3,432,807
Noncontrolling interests	4,382	4,442
Total equity	3,407,925	3,437,249
Total liabilities and equity	$ 7,028,144	$ 7,032,277

XML

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Assets
Accumulated depreciation	$ 377,159	$ 340,423
Preferred stock
Par value (in dollars per share)	$ 0.01	$ 0.01
Shares authorized (in shares)	10,000,000	10,000,000
Shares issued (in shares)		5,750,000
Shares outstanding (in shares)		5,750,000
Common stock
Par value (in dollars per share)	$ 0.01	$ 0.01
Shares authorized (in shares)	250,000,000	250,000,000
Shares issued (in shares)	178,283,590	178,255,843
Shares outstanding (in shares)	178,283,590	178,255,843

XML

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) $ in Thousands			3 Months Ended		6 Months Ended
	May 09, 2018	Feb. 05, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Rental income			$ 144,229	$ 55,904	$ 288,484	$ 113,128
Interest and other income			4,553	2,027	8,891	3,972
Resident fees and services			17,530	6,805	35,023	10,286
Total revenues			166,312	64,736	332,398	127,386
Expenses:
Depreciation and amortization			46,828	17,220	94,833	36,357
Interest			36,757	15,862	72,575	31,650
Operating expenses			12,299	4,407	24,423	6,827
General and administrative			9,271	5,126	17,138	11,215
Merger and acquisition costs			112	5,887	442	6,451
(Recovery of) provision for doubtful accounts and loan losses			(674)	535	539	2,305
Impairment of real estate			881	0	1,413	0
Total expenses			105,474	49,037	211,363	94,805
Other income:
Other income			0	941	2,820	3,070
Net gain on sales of real estate			142,903	4,032	142,431	4,032
Total other income			142,903	4,973	145,251	7,102
Income before loss from unconsolidated joint venture and income tax expense			203,741	20,672	266,286	39,683
Loss from unconsolidated joint venture			(2,347)	0	(1,901)	0
Income tax expense			(605)	(136)	(1,115)	(356)
Net income			200,789	20,536	263,270	39,327
Net (income) loss attributable to noncontrolling interests			(2)	(16)	(12)	16
Net income attributable to Sabra Health Care REIT, Inc.			200,787	20,520	263,258	39,343
Preferred stock dividends			(7,207)	(2,560)	(9,768)	(5,121)
Net income attributable to common stockholders			$ 193,580	$ 17,960	$ 253,490	$ 34,222
Net income attributable to common stockholders, per:
Basic common share (in dollars per share)			$ 1.09	$ 0.27	$ 1.42	$ 0.52
Diluted common share (in dollars per share)			$ 1.08	$ 0.27	$ 1.42	$ 0.52
Weighted-average number of common shares outstanding, basic (in shares)			178,314,750	65,438,739	178,304,733	65,396,146
Weighted-average number of common shares outstanding, diluted (in shares)			178,684,024	65,670,853	178,600,789	65,694,019
Dividends declared per common share (in dollars per share)	$ 0.45	$ 0.45	$ 0.45	$ 0.43	$ 0.90	$ 0.85

XML

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement of Comprehensive Income [Abstract]
Net income	$ 200,789	$ 20,536	$ 263,270	$ 39,327
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	261	698	(113)	140
Unrealized gain on cash flow hedges	3,338	97	13,236	825
Total other comprehensive income	3,599	795	13,123	965
Comprehensive income	204,388	21,331	276,393	40,292
Comprehensive (income) loss attributable to noncontrolling interest	(2)	(16)	(12)	16
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$ 204,386	$ 21,315	$ 276,381	$ 40,308

XML

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY - USD ($) $ in Thousands	Total	Total Stockholders’ Equity	Preferred Stock	Common Stock	Additional Paid-in Capital	Cumulative Distributions in Excess of Net Income	Accumulated Other Comprehensive Income (Loss)	Noncontrolling Interests
Balance (in shares) at Dec. 31, 2016			5,750,000	65,285,614
Balance at Dec. 31, 2016	$ 1,015,609	$ 1,015,574	$ 58	$ 653	$ 1,208,862	$ (192,201)	$ (1,798)	$ 35
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	39,327	39,343				39,343		(16)
Other comprehensive income	965	965					965
Amortization of stock-based compensation	4,848	4,848			4,848
Common stock issuance, net (in shares)				139,820
Common stock issuance, net	(2,814)	(2,814)		$ 1	(2,815)
Preferred dividends	(5,121)	(5,121)				(5,121)
Common dividends	(56,099)	(56,099)				(56,099)
Balance (in shares) at Jun. 30, 2017			5,750,000	65,425,434
Balance at Jun. 30, 2017	996,715	996,696	$ 58	$ 654	1,210,895	(214,078)	(833)	19
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Cumulative effect of ASU 2017-12 adoption	0	0				(795)	795
Balance (in shares) at Dec. 31, 2017			5,750,000	178,255,843
Balance at Dec. 31, 2017	3,437,249	3,432,807	$ 58	$ 1,783	3,636,913	(217,236)	11,289	4,442
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income (loss)	263,270	263,258				263,258		12
Other comprehensive income	12,328	12,328					12,328
Distributions to noncontrolling interests	(72)							(72)
Amortization of stock-based compensation	4,434	4,434			4,434
Preferred stock redemption			(5,750,000)
Preferred stock redemption	(143,750)	(143,750)	$ (58)		(138,191)	(5,501)
Common stock issuance, net (in shares)				27,747
Common stock issuance, net	(202)	(202)		$ 0	(202)
Preferred dividends	(4,267)	(4,267)				(4,267)
Common dividends	(161,065)	(161,065)				(161,065)
Balance (in shares) at Jun. 30, 2018			0	178,283,590
Balance at Jun. 30, 2018	$ 3,407,925	$ 3,403,543	$ 0	$ 1,783	$ 3,502,954	$ (125,606)	$ 24,412	$ 4,382

XML

CONDENSED CONSOLIDATED STATEMENTS OF EQUITY (Parenthetical) - $ / shares			3 Months Ended		6 Months Ended
	May 09, 2018	Feb. 05, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Statement of Stockholders' Equity [Abstract]
Common dividends (in dollars per share)	$ 0.45	$ 0.45	$ 0.45	$ 0.43	$ 0.90	$ 0.85

XML

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Cash flows from operating activities:
Net income	$ 263,270	$ 39,327
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	94,833	36,357
Amortization of above and below market lease intangibles, net	(1,368)	0
Non-cash interest income adjustments	(1,174)	51
Non-cash interest expense	4,997	3,244
Stock-based compensation expense	3,839	4,319
Straight-line rental income adjustments	(23,752)	(9,578)
(Recovery of) provision for doubtful accounts and loan losses	539	2,305
Change in fair value of contingent consideration	0	(822)
Net gain on sales of real estate	(142,431)	(4,032)
Impairment of real estate	1,413	0
Loss from unconsolidated joint venture	1,901	0
Distributions of earnings from unconsolidated joint venture	3,610	0
Changes in operating assets and liabilities:
Accounts receivable, prepaid expenses and other assets, net	(2,130)	(15,575)
Accounts payable and accrued liabilities	8,006	(1,314)
Net cash provided by operating activities	211,553	54,282
Cash flows from investing activities:
Acquisition of real estate	(213,982)	(14,456)
Origination and fundings of loans receivable	(28,157)	(927)
Origination and fundings of preferred equity investments	(945)	(76)
Additions to real estate	(16,817)	(1,294)
Repayments of loans receivable	38,887	1,547
Repayments of preferred equity investments	375	2,766
Investment in unconsolidated joint venture	(354,461)	0
Net proceeds from the sales of real estate	278,201	6,099
Net cash used in investing activities	(296,899)	(6,341)
Cash flows from financing activities:
Net borrowings from revolving credit facility	35,000	6,000
Principal payments on secured debt	(2,128)	(2,049)
Payments of deferred financing costs	(12)	(124)
Distributions to noncontrolling interests	(72)	0
Preferred stock redemption	(143,750)	0
Issuance of common stock, net	(499)	(3,224)
Dividends paid on common and preferred stock	(164,736)	(60,691)
Net cash used in financing activities	(276,197)	(60,088)
Net decrease in cash, cash equivalents and restricted cash	(361,543)	(12,147)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(252)	130
Cash, cash equivalents and restricted cash, beginning of period	587,449	34,665
Cash, cash equivalents and restricted cash, end of period	225,654	22,648
Supplemental disclosure of cash flow information:
Interest paid	$ 67,793	$ 28,944

XML

BUSINESS

6 Months Ended

Jun. 30, 2018

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BUSINESS

BUSINESS

Overview

Sabra Health Care REIT, Inc. (“Sabra” or the “Company”) was incorporated on May 10, 2010 as a wholly owned subsidiary of Sun Healthcare Group, Inc. (“Sun”) and commenced operations on November 15, 2010 following Sabra's separation from Sun. Sabra elected to be treated as a real estate investment trust (“REIT”) with the filing of its U.S. federal income tax return for the taxable year beginning January 1, 2011. Sabra believes that it has been organized and operated, and it intends to continue to operate, in a manner to qualify as a REIT. Sabra’s primary business consists of acquiring, financing and owning real estate property to be leased to third-party tenants in the healthcare sector. Sabra primarily generates revenues by leasing properties to tenants and operators throughout the United States and Canada. Sabra owns substantially all of its assets and properties and conducts its operations through Sabra Health Care Limited Partnership, a Delaware limited partnership (the “Operating Partnership”), of which Sabra is the sole general partner and Sabra’s wholly owned subsidiaries are currently the only limited partners, or by subsidiaries of the Operating Partnership. The Company’s investment portfolio is primarily comprised of skilled nursing/transitional care facilities, senior housing communities and specialty hospitals and other facilities, in each case leased to third-party operators; senior housing communities operated by third-party property managers pursuant to property management agreements (“Senior Housing - Managed”); investments in loans receivable; preferred equity investments; and an investment in an unconsolidated joint venture.

On May 7, 2017, the Company, the Operating Partnership, PR Sub, LLC, a Delaware limited liability company and wholly owned subsidiary of the Company (“Merger Sub”), Care Capital Properties, Inc., a Delaware corporation (“CCP”), and Care Capital Properties, L.P. (“CCPLP”), a Delaware limited partnership and wholly owned subsidiary of CCP, entered into an Agreement and Plan of Merger (the “Merger Agreement”), pursuant to which, on August 17, 2017, CCP merged with and into Merger Sub, with Merger Sub continuing as the surviving corporation (the “CCP Merger”), following which Merger Sub merged with and into the Company, with the Company continuing as the surviving entity (the “Subsequent Merger”), and, simultaneous with the Subsequent Merger, CCPLP merged with and into the Operating Partnership, with the Operating Partnership continuing as the surviving entity.

Pursuant to the Merger Agreement, as of the effective time of the CCP Merger, each share of CCP common stock, par value $0.01 per share, issued and outstanding immediately prior to the effective time of the CCP Merger (other than shares of CCP common stock owned directly by CCP, the Company or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, par value $0.01 per share, plus cash in lieu of any fractional shares. See Note 3, “CCP Merger and Recent Real Estate Acquisitions” for additional information regarding the CCP Merger.

The acquisition of CCP has been reflected in the Company’s condensed consolidated financial statements since the effective date of the CCP Merger.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Principles of Consolidation and Basis of Presentation

The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of June 30, 2018 and December 31, 2017 and for the periods ended June 30, 2018 and 2017. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC.

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis.

As of June 30, 2018, the Company determined it was the primary beneficiary of two variable interest entities—one exchange accommodation titleholder variable interest entity and a joint venture variable interest entity owning one skilled nursing/transitional care facility—and has consolidated the operations of these entities in the accompanying condensed consolidated financial statements. As of June 30, 2018, the Company determined that operations of these entities were not material to the Company’s results of operations, financial condition or cash flows.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At June 30, 2018, none of the Company’s investments in loans are accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests. As of June 30, 2018, the Company’s determination of which entity controls its investments in joint ventures has not changed as a result of any reassessment.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassifications

Certain amounts in the Company’s consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations of prior periods. As a result, certain reclassifications were made to the condensed consolidated statements of income and condensed consolidated statements of cash flows.

Investment in Unconsolidated Joint Venture

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s condensed consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture.

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment.

On January 2, 2018, the Company completed its transaction with affiliates of Enlivant and TPG Real Estate, the real estate platform of TPG, and contributed $352.7 million, before closing costs, to acquire a 49% equity interest in an entity that owns 172 senior housing communities managed by Enlivant (the “Enlivant Joint Venture”). At closing, the Enlivant Joint Venture had outstanding indebtedness of $791.3 million and net working capital of $22.9 million, and the Company’s investment in the Enlivant Joint Venture implied an aggregate portfolio value of $1.49 billion. The joint venture agreement includes an option for the Company to acquire the remainder of the outstanding equity interests in the Enlivant Joint Venture by January 2, 2021 and grants the Company the right of first offer if the Company’s partner in the Enlivant Joint Venture desires to transfer its equity interest (which it may do commencing on January 2, 2020). In addition, Sabra has the right to designate three directors on the seven member board of directors of the Enlivant Joint Venture and has other customary minority rights. As of June 30, 2018, the book value of the Company’s investment in the Enlivant Joint Venture was $349.0 million.

Net Investment in Direct Financing Lease

As of June 30, 2018, the Company had a $23.2 million net investment in one skilled nursing/transitional care facility leased to an operator under a direct financing lease, as the tenant is obligated to purchase the property at the end of the lease term. The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying condensed consolidated balance sheets and represents the total undiscounted rental payments, plus the estimated unguaranteed residual value, less the unearned lease income. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured. Income from the Company’s net investment in direct financing lease was $0.6 million and $1.3 million for the three and six months ended June 30, 2018, respectively, and is reflected in interest and other income on the accompanying condensed consolidated statements of income. Future minimum lease payments contractually due under the direct financing lease at June 30, 2018, were as follows: $1.1 million for the remainder of 2018; $2.2 million for 2019; $2.3 million for 2020; and $2.1 million for 2021.

Recently Issued Accounting Standards Update

Adopted

Between May 2014 and February 2017, the FASB issued four Accounting Standards Updates (each, an “ASU”) changing the requirements for recognizing and reporting revenue (together, herein referred to as the “Revenue ASUs”): (i) ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”) and (iv) ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. The Revenue ASUs became effective for the Company on January 1, 2018 with the Company electing to use the modified retrospective approach for its adoption. Further, the Company elected to reassess only contracts that were not completed as of the adoption date. The adoption of these ASUs did not have a material impact to beginning retained earnings as of January 1, 2018.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 provides specific guidance clarifying how certain cash receipts and payments should be classified. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-15 and ASU 2016-18 on January 1, 2018. The full retrospective approach of adoption is required for both ASUs and, accordingly, certain line items in the Company’s consolidated statements of cash flows have been reclassified to conform to the current period presentation. The following table illustrates changes in the Company’s cash flows as reported in the accompanying condensed consolidated statements of cash flows and as previously reported prior to the adoption (in thousands):

	Six Months Ended June 30, 2017
	As Reported		As Previously Reported
Net cash provided by operating activities	54,282		53,871
Net decrease in balance	(12,147	)	(12,558	)
Balance - beginning of the year	34,665		25,663
Balance - end of the year	22,648		13,235

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). ASU 2017-12 is intended to improve the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements and to simplify the application of the hedge accounting guidance in current GAAP. ASU 2017-12 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company adopted ASU 2017-12 effective beginning January 1, 2018. ASU 2017-12 requires a modified retrospective transition method in which the Company recognized the cumulative effect of the change on the opening balance of each affected component of equity in the condensed consolidated balance sheet as of the date of adoption, which resulted in a decrease to cumulative distributions in excess of net income and an increase to accumulated other comprehensive income of $0.8 million.

Issued but Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 supersedes guidance related to accounting for leases. ASU 2016-02 updates guidance around the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of ASU 2016-02 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. Under ASU 2016-02, entities currently are required to adopt the new lease requirements using a modified retrospective transition method whereby an entity initially applies the new lease requirements (subject to specific transition requirements and optional practical expedients) at the beginning of the earliest period presented in the financial statements. Upon adoption of ASU 2016-02, the Company will recognize its operating leases for which it is the lessee, mainly corporate office leases and ground leases, on its consolidated balance sheets. Further, as a result of adoption, the Company may be required to increase its revenue and expense for the amount of real estate taxes and insurance paid by its tenants under certain leasing arrangements with no net impact to net income.

In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”) that allows lessors to elect, as a practical expedient, not to separate lease and nonlease components (such as services rendered) in a contract for the purpose of revenue recognition and disclosure. The practical expedient can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. Further, ASU 2018-11 also provides for an additional (and optional) transition method to adopt the new lease requirements by allowing entities to initially apply the requirements by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company plans to elect this practical expedient and apply the optional transition method for its operating leases for which the Company is the lessee, using the cumulative-effect adjustment to the opening balance sheet as of January 1, 2019. The Company is still evaluating the full impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold in current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. ASU 2016-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in this update through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted.

XML

CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS

6 Months Ended

Jun. 30, 2018

Business Combinations [Abstract]

CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS

CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS

CCP Merger

On August 17, 2017, the Company completed the CCP Merger. Under the terms of the Merger Agreement, each share of CCP common stock issued and outstanding immediately prior to the effective time of the CCP Merger (other than any shares owned directly by CCP, the Company or their respective subsidiaries, in each case not held on behalf of third parties) was converted into the right to receive 1.123 newly issued shares of Company common stock, resulting in the issuance of approximately 94.0 million shares of Company common stock at the effective time of the CCP Merger. As a result of the CCP Merger, the Company acquired 330 properties (consisting of 296 skilled nursing/transitional care facilities, 13 senior housing communities and 21 specialty hospitals and other facilities), one skilled nursing/transitional care facility leased to an operator under a direct financing lease (see Note 2, “Summary of Significant Accounting Policies—Net Investment in Direct Financing Lease”), 18 investments in loans receivable (see Note 6, “Loans Receivable and Other Investments”) and one specialty valuation firm that was subsequently sold in March 2018. Sabra also assumed certain outstanding equity awards and other debt and liabilities of CCP (see Note 7, “Debt”). Based on the closing price of Sabra’s common stock on August 16, 2017, the Company estimates the fair value of the consideration exchanged or assumed to be approximately $2.1 billion.

The following table summarizes the purchase price allocation for the CCP Merger based on the Company’s valuation, including estimates and assumptions of the acquisition date fair value of the tangible and intangible assets acquired and liabilities assumed on August 17, 2017 (in thousands):

Real estate investments	$	3,727,310
Loans receivable and other investments	58,244
Cash and cash equivalents	77,859
Restricted cash	779
Lease intangible assets, net	145,786
Accounts receivable, prepaid expenses and other assets, net	35,873
Secured debt, net	(98,500		)
Revolving credit facility	(362,000		)
Unsecured term loans	(674,000		)
Senior unsecured notes, net	(616,873		)
Accounts payable and accrued liabilities	(134,802		)
Lease intangible liabilities, net	(102,643		)
Noncontrolling interests	(4,455		)
Total consideration	$	2,052,578

The lease intangible assets and lease intangible liabilities acquired in connection with the CCP Merger have weighted-average amortization periods as of the closing date of the CCP Merger of 10 years.

Recent Real Estate Acquisitions

During the six months ended June 30, 2018, the Company acquired 11 Senior Housing - Managed communities, five senior housing communities and two skilled nursing/transitional care facilities. During the six months ended June 30, 2017, the Company acquired one senior housing community. The consideration was allocated based on certain valuations and analyses. Certain valuations and analyses related to acquisitions during the six months ended June 30, 2018 have yet to be finalized, and accordingly, the allocations are subject to adjustment once the analyses are completed. Allocation of the consideration is as follows (in thousands):

	Six Months Ended June 30,
	2018		2017
Land	$	24,356	$	1,034
Building and improvements	187,903		13,128
Tenant origination and absorption costs intangible assets	1,312		223
Tenant relationship intangible assets	412		71
Total consideration	$	213,983	$	14,456

The tenant origination and absorption costs intangible assets and tenant relationship intangible assets acquired in connection with these acquisitions have weighted-average amortization periods as of the respective dates of acquisition of 13 years and 22 years, respectively, for acquisitions completed during the six months ended June 30, 2018, and 15 years and 25 years, respectively, for the acquisition completed during the six months ended June 30, 2017.

For the three and six months ended June 30, 2018, the Company recognized $10.7 million and $20.4 million of total revenues, respectively, and $1.6 million and $2.5 million of net income attributable to common stockholders, respectively, from the facilities acquired during the six months ended June 30, 2018. For both the three and six months ended June 30, 2017, the Company recognized $0.1 million of total revenues and net income attributable to common stockholders from the facility acquired during the six months ended June 30, 2017.

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT

6 Months Ended

Jun. 30, 2018

Real Estate Investments, Net [Abstract]

REAL ESTATE PROPERTIES HELD FOR INVESTMENT

REAL ESTATE PROPERTIES HELD FOR INVESTMENT

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of June 30, 2018

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	352	40,077	$	4,242,748	$	(223,777	)	$	4,018,971
Senior Housing - Leased	89	7,156	1,200,923		(113,020		)	1,087,903
Senior Housing - Managed	24	1,712	308,221		(15,961		)	292,260
Specialty Hospitals and Other	22	1,085	618,316		(24,109		)	594,207
	487	50,030	6,370,208		(376,867		)	5,993,341
Corporate Level			633		(292		)	341
			$	6,370,841	$	(377,159	)	$	5,993,682

As of December 31, 2017

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	384	43,223	$	4,364,387	$	(209,039	)	$	4,155,348
Senior Housing - Leased	88	8,137	1,166,687		(102,370		)	1,064,317
Senior Housing - Managed	13	1,113	189,120		(12,125		)	176,995
Specialty Hospitals and Other	22	1,085	614,068		(16,620		)	597,448
	507	53,558	6,334,262		(340,154		)	5,994,108
Corporate Level			593		(269		)	324
			$	6,334,855	$	(340,423	)	$	5,994,432

	June 30, 2018			December 31, 2017
Building and improvements	$	5,489,087		$	5,449,415
Furniture and equipment	236,838			232,889
Land improvements	1,971			3,456
Land	642,945			649,095
	6,370,841			6,334,855
Accumulated depreciation	(377,159		)	(340,423		)
	$	5,993,682		$	5,994,432

Operating Leases

As of June 30, 2018, the substantial majority of the Company’s real estate properties (excluding 24 Senior Housing - Managed communities) were leased under triple-net operating leases with expirations ranging from less than one year to 15 years. As of June 30, 2018, the leases had a weighted-average remaining term of nine years. The leases include provisions to extend the lease terms and other negotiated terms and conditions. The Company, through its subsidiaries, retains substantially all of the risks and benefits of ownership of the real estate assets leased to the tenants. The Company may receive additional security under these operating leases in the form of letters of credit and security deposits from the lessee or guarantees from the parent of the lessee. Security deposits received in cash related to tenant leases are included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets and totaled $17.9 million and $20.3 million as of June 30, 2018 and December 31, 2017, respectively, and letters of credit deposited with the Company totaled approximately $90 million and $96 million as of June 30, 2018 and December 31, 2017, respectively. In addition, our tenants have deposited with the Company $28.0 million and $28.3 million as of June 30, 2018 and December 31, 2017, respectively, for future real estate taxes, insurance expenditures and tenant improvements related to our properties and their operations.

As of June 30, 2018, the Company had a $1.1 million reserve for unpaid cash rental income and a $3.2 million reserve associated with accumulated straight-line rental income. As of December 31, 2017, the Company had a $3.2 million reserve for unpaid cash rental income and a $12.4 million reserve associated with accumulated straight-line rental income.

The Company has entered into memoranda of understanding with Genesis to market for sale up to all of its remaining Genesis facilities and to restructure its lease agreements with Genesis to increase the marketability of these facilities to potential buyers. Effective January 1, 2018, the annual base rent payable under the Genesis leases was reduced by $19.0 million pursuant to a lease restructuring agreement. During the six months ended June 30, 2018, the Company completed the sale of 27 facilities leased to Genesis and expects to complete the sale of 19 of its remaining 27 Genesis facilities during the remainder of 2018 and to retain eight facilities, although it cannot provide assurance that the sales will be completed in that timeframe, if at all.

The Company monitors the creditworthiness of its tenants by reviewing credit ratings (if available) and evaluating the ability of the tenants to meet their lease obligations to the Company based on the tenants’ financial performance, including the evaluation of any parent guarantees (or the guarantees of other related parties) of tenant lease obligations. As formal credit ratings may not be available for most of the Company’s tenants, the primary basis for the Company’s evaluation of the credit quality of its tenants (and more specifically the tenant’s ability to pay their rent obligations to the Company) is the tenant’s lease coverage ratio or the parent’s fixed charge coverage ratio for those entities with a parent guarantee. These coverage ratios include earnings before interest, taxes, depreciation, amortization and rent (“EBITDAR”) to rent and earnings before interest, taxes, depreciation, amortization, rent and management fees (“EBITDARM”) to rent at the lease level and consolidated EBITDAR to total fixed charges at the parent guarantor level when such a guarantee exists. The Company obtains various financial and operational information from its tenants each month and reviews this information in conjunction with the above-described coverage metrics to identify financial and operational trends, evaluate the impact of the industry’s operational and financial environment (including the impact of government reimbursement), and evaluate the management of the tenant’s operations. These metrics help the Company identify potential areas of concern relative to its tenants’ credit quality and ultimately the tenant’s ability to generate sufficient liquidity to meet its obligations, including its obligation to continue to pay the rent due to the Company.

For both the three and six months ended June 30, 2018, no tenant relationship represented 10% or more of the Company’s total revenues.

As of June 30, 2018, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows (in thousands):

July 1 through December 31, 2018	$	260,307
2019	529,844
2020	522,304
2021	520,553
2022	512,680
Thereafter	3,083,776
	$	5,429,464

XML

ASSET HELD FOR SALE DISPOSITIONS

6 Months Ended

Jun. 30, 2018

Discontinued Operations and Disposal Groups [Abstract]

ASSET HELD FOR SALE DISPOSITIONS

ASSET HELD FOR SALE AND DISPOSITIONS

Asset Held for Sale

As of June 30, 2018, the Company determined that one skilled nursing/transitional care facility, with a net book value of $6.0 million, met the criteria to be classified as held for sale. The net book value is included in accounts receivable, prepaid expenses and other assets, net on the condensed consolidated balance sheets. The facility was sold on July 2, 2018 for a gross sales price of $7.0 million.

2018 Dispositions

During the six months ended June 30, 2018, the Company completed the sale of 33 skilled nursing/transitional care facilities and four senior housing communities for aggregate consideration, net of closing costs, of $278.3 million. The net carrying value of the assets and liabilities of these facilities was $135.8 million, which resulted in an aggregate $142.5 million net gain on sale. The Company also recognized $0.1 million of additional selling expenses for sales completed in 2017.

During the six months ended June 30, 2018, the Company recognized a $1.4 million real estate impairment, of which $0.5 million related to one senior housing community sold during the period.

Excluding the net gain on sale and real estate impairment, the Company recognized $11.6 million and $15.4 million of net income during the six months ended June 30, 2018 and 2017, respectively, from these facilities. The sale of these facilities does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to these facilities have remained in continuing operations.

2017 Disposition

During the six months ended June 30, 2017, the Company completed the sale of one skilled nursing/transitional care facility for consideration, net of closing costs, of $6.1 million. The net carrying value of the assets and liabilities of this facility was $2.1 million, which resulted in a $4.0 million net gain on sale.

Excluding the net gain on sale, the Company recognized $0.1 million of net income during the six months ended June 30, 2017 from this facility. The sale of this facility does not represent a strategic shift that has or will have a major effect on the Company’s operations and financial results, and therefore the results of operations attributable to this facility have remained in continuing operations.

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS

6 Months Ended

Jun. 30, 2018

Receivables [Abstract]

LOANS RECEIVABLE AND OTHER INVESTMENTS

LOANS RECEIVABLE AND OTHER INVESTMENTS

As of June 30, 2018 and December 31, 2017, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

											June 30, 2018
Investment	Quantity as of June 30, 2018	Property Type	Principal Balance as of June 30, 2018 (1)		Book Value as of June 30, 2018			Book Value as of December 31, 2017			Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of June 30, 2018
Loans Receivable:
Mortgage	1	Specialty Hospital	$	15,332	$	15,332		$	12,351		10.0	%	10.0	%	01/31/27
Construction	2	Senior Housing	3,989		4,055			2,733			8.0	%	7.8	%	04/30/21- 09/30/22
Mezzanine	1	Skilled Nursing	25,000		2,301			10,239			10.0	%	41.9	%	05/25/20
Pre-development	1	Senior Housing	2,357		2,357			2,357			9.0	%	8.4	%	04/01/20
Other	17	Multiple	34,009		32,191			38,324			8.5	%	9.7	%	12/31/17- 04/30/27
	22		80,687		56,236			66,004			9.3	%	10.9	%
Loan loss reserve			—		(356		)	(97		)
			$	80,687	$	55,880		$	65,907
Other Investments:
Preferred Equity	13	Skilled Nursing / Senior Housing	50,856		51,348			48,483			12.6	%	12.6	%	N/A
Total	35		$	131,543	$	107,228		$	114,390		10.6	%	11.7	%

⁽¹⁾  Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

In connection with the CCP Merger, the Company acquired 18 loans receivable investments with a principal balance of $83.3 million and fair value of $58.2 million as of August 17, 2017.

Of the loans acquired in connection with the CCP Merger, eight loans receivable investments with a principal balance of $36.3 million were considered to have deteriorated credit quality, and based on the collateral or expected cash flows, the fair value was determined to be $11.3 million and the accretable yield was $3.5 million as of August 17, 2017. During the six months ended June 30, 2018, one loan with deteriorated credit quality was repaid in full. As of June 30, 2018 and December 31, 2017, the book value of these loans was $4.8 million and $10.0 million, respectively.

The following table presents changes in the accretable yield for the three and six months ended June 30, 2018 (in thousands):

	Three Months Ended			Six Months Ended
	June 30, 2018
Accretable yield, beginning of period	$	1,883		$	2,483
Accretion recognized in earnings	(1,529		)	(2,129		)
Net reclassification from nonaccretable difference	727			727
Accretable yield, end of period	$	1,081		$	1,081

During the three and six months ended June 30, 2018, the Company recorded no provision for specific loan losses and increased its portfolio-based loan loss reserve by $0.2 million and $0.3 million, respectively.

As of June 30, 2018, the Company had no specific loan loss reserve, and the portfolio-based loan loss reserve was $0.4 million. As of June 30, 2018, the Company did not consider any loans receivable investments to be impaired, and one loan receivable with a book value of $0 and three preferred equity investments totaling $14.5 million were on nonaccrual status. Additionally, as of June 30, 2018, the Company recognized interest income related to four loans receivable, with an aggregate book value of $10.6 million, that were more than 90 days past due.

As of December 31, 2017, the Company had no specific loan loss reserve, and the portfolio-based loan loss reserve was $0.1 million. As of December 31, 2017, the Company did not consider any loans receivable investments to be impaired, and one loan receivable with a book value of $0 was on nonaccrual status.

During the three and six months ended June 30, 2017, the Company recorded a provision for specific loan losses of $0.3 million and $1.8 million, respectively, related to five loans receivable investments, two of which were written-off during the three months ended June 30, 2017, and reduced its portfolio-based loan loss reserve by $0.1 million and $0.2 million, respectively.

XML

DEBT

6 Months Ended

Jun. 30, 2018

Debt Disclosure [Abstract]

DEBT

DEBT

Secured Indebtedness

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of June 30, 2018 (1)		Principal Balance as of December 31, 2017 (1)		Weighted Average Effective Interest Rate at June 30, 2018 (2)		Maturity Date
Fixed Rate	$	157,781	$	160,702	3.87	%	December 2021 -  August 2051
Variable Rate	98,500		98,500		3.89	%	July 2019
	$	256,281	$	259,202	3.88	%

⁽¹⁾   Principal balance does not include deferred financing costs, net of $2.7 million and $2.8 million as of June 30, 2018 and December 31, 2017, respectively.

⁽²⁾   Weighted average effective interest rate includes private mortgage insurance.

On August 17, 2017, in connection with the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”), the Company assumed a $98.5 million variable rate secured term loan that bears interest at LIBOR plus 1.80% and matures in July 2019.

Senior Unsecured Notes

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	June 30, 2018 (1)		December 31, 2017 (1)
5.5% senior unsecured notes due 2021 (“2021 Notes”)	February 1, 2021	$	500,000	$	500,000
5.375% senior unsecured notes due 2023 (“2023 Notes”)	June 1, 2023	200,000		200,000
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.38% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
		$	1,300,000	$	1,300,000

⁽¹⁾  Principal balance does not include premium, net of $15.2 million and deferred financing costs, net of $8.4 million as of June 30, 2018 and does not include premium, net of $15.9 million and deferred financing costs, net of $9.6 million as of December 31, 2017.

The 2021 Notes and the 2023 Notes were issued by the Operating Partnership and Sabra Capital Corporation, wholly owned subsidiaries of the Company (the “Issuers”). The 2021 Notes accrue interest at a rate of 5.5% per annum payable semiannually on February 1 and August 1 of each year, and the 2023 Notes accrue interest at a rate of 5.375% per annum payable semiannually on June 1 and December 1 of each year.

The 2026 Notes and the 2027 Notes were assumed as a result of the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”) and accrue interest at a rate of 5.125% and 5.38%, respectively, per annum. Interest is payable semiannually on February 15 and August 15 of each year for the 2026 Notes and on May 17 and November 17 of each year for the 2027 Notes.

The obligations under the 2021 Notes, 2023 Notes and 2027 Notes are fully and unconditionally guaranteed, jointly and severally, on an unsecured basis, by Sabra and certain subsidiaries of Sabra; provided, however, that such guarantees are subject to release under certain customary circumstances. The obligations under the 2026 Notes are fully and unconditionally guaranteed, on an unsecured basis, by Sabra; provided, however, that such guarantee is subject to release under certain customary circumstances. See Note 12, “Summarized Condensed Consolidating Information” for additional information concerning the circumstances pursuant to which the guarantors will be automatically and unconditionally released from their obligations under the guarantees.

The indentures and agreements (the “Senior Notes Indentures”) governing the 2021 Notes, 2023 Notes, 2026 Notes and 2027 Notes (collectively, the “Senior Notes”) include customary events of default and require the Company to comply with specified restrictive covenants. As of June 30, 2018, the Company was in compliance with all applicable financial covenants under the Senior Notes Indentures.

Credit Facility

Effective on August 17, 2017, the Operating Partnership and Sabra Canadian Holdings, LLC (together, the “Borrowers”), Sabra and the other parties thereto entered into a fourth amended and restated unsecured credit facility (the “Credit Facility”). The Credit Facility amends and restates the prior credit facility entered into by the Borrowers in January 2016 (the “Prior Credit Facility”). The Company recognized a $0.6 million loss on extinguishment of debt related to write-offs of deferred financing costs in connection with amending and restating the Prior Credit Facility.

The Credit Facility includes a $1.0 billion revolving credit facility (the “Revolving Credit Facility”), $1.1 billion in U.S. dollar term loans and a CAD $125.0 million Canadian dollar term loan (collectively, the “Term Loans”). Further, up to $175.0 million of the Revolving Credit Facility may be used for borrowings in certain foreign currencies. The Credit Facility also contains an accordion feature that can increase the total available borrowings to $2.5 billion, subject to terms and conditions.

The Revolving Credit Facility has a maturity date of August 17, 2021, and includes twosix-month extension options. $200.0 million of the U.S. dollar Term Loans has a maturity date of August 17, 2020, and the other Term Loans have a maturity date of August 17, 2022.

As of June 30, 2018, there was $676.0 million outstanding under the Revolving Credit Facility and $324.0 million available for borrowing.

Borrowings under the Revolving Credit Facility bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) a base rate determined as the greater of (i) the federal funds rate plus 0.5%, (ii) the prime rate, and (iii) one-month LIBOR plus 1.0% (the “Base Rate”). On August 17, 2017, Sabra’s ratings met the Investment Grade Ratings Criteria (as defined in the credit agreement), and Sabra elected to use the ratings-based applicable interest margin for borrowings which will vary based on the Debt Ratings, as defined in the credit agreement, and will range from 0.875% to 1.65% per annum for LIBOR based borrowings and 0.00% to 0.65% per annum for borrowings at the Base Rate. As of June 30, 2018, the interest rate on the Revolving Credit Facility was 3.34%. In addition, the Operating Partnership pays a facility fee ranging between 0.125% and 0.300% per annum based on the aggregate amount of commitments under the Revolving Credit Facility regardless of amounts outstanding thereunder.

The U.S. dollar Term Loans bear interest on the outstanding principal amount at a rate equal to an applicable interest margin plus, at the Operating Partnership’s option, either (a) LIBOR or (b) the Base Rate. The ratings-based applicable interest margin for borrowings will vary based on the Debt Ratings, as defined in the credit agreement, and will range from 0.90% to 1.90% per annum for LIBOR based borrowings and 0.00% to 0.90% per annum for borrowings at the Base Rate. The Canadian dollar Term Loan bears interest on the outstanding principal amount at a rate equal to the Canadian Dollar Offered Rate (“CDOR”) plus an interest margin that will range from 0.90% to 1.90% depending on the Debt Ratings.

On June 10, 2015, the Company entered into an interest rate swap agreement to fix the CDOR portion of the interest rate for CAD $90.0 million of its Canadian dollar Term Loan at 1.59%. In addition, CAD $90.0 million of the Canadian dollar Term Loan was designated as a net investment hedge. On August 10, 2016, the Company entered into two interest rate swap agreements to fix the LIBOR portion of the interest rate for $245.0 million of its U.S. dollar Term Loans at 0.90% and one interest rate swap agreement to fix the CDOR portion on CAD $35.0 million of its Canadian dollar Term Loan at 0.93%. See Note 8, “Derivative and Hedging Instruments” for further information.

As a result of the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”), the Company assumed eight interest rate swap agreements that fix the LIBOR portion of the interest rate for $600 million of the Company’s U.S. dollar Term Loans at a weighted average rate of 1.31%. See Note 8, “Derivative and Hedging Instruments” for further information.

The obligations of the Borrowers under the Credit Facility are guaranteed by Sabra and certain subsidiaries of Sabra.

The Credit Facility contains customary covenants that include restrictions or limitations on the ability to make acquisitions and other investments, pay dividends, incur additional indebtedness, engage in non-healthcare related business activities, enter into transactions with affiliates and sell or otherwise transfer certain assets as well as customary events of default. The Credit Facility also requires Sabra, through the Operating Partnership, to comply with specified financial covenants, which include a maximum leverage ratio, a minimum fixed charge coverage ratio and a minimum tangible net worth requirement. As of June 30, 2018, the Company was in compliance with all applicable financial covenants under the Credit Facility.

Interest Expense

During the three and six months ended June 30, 2018, the Company incurred interest expense of $36.8 million and $72.6 million, respectively, and $15.9 million and $31.7 million during the three and six months ended June 30, 2017, respectively. Interest expense includes non-cash interest expense of $2.5 million and $5.0 million for the three and six months ended June 30, 2018, respectively, and $1.7 million and $3.2 million for the three and six months ended June 30, 2017, respectively. As of June 30, 2018 and December 31, 2017, the Company had $24.5 million and $24.7 million, respectively, of accrued interest included in accounts payable and accrued liabilities on the accompanying condensed consolidated balance sheets.

Maturities

The following is a schedule of maturities for the Company’s outstanding debt as of June 30, 2018 (in thousands): 

	Secured Indebtedness			Revolving Credit     Facility (1)		Term Loans			Senior Notes			Total
July 1 through December 31, 2018	$	2,156		$	—	$	—		$	—		$	2,156
2019	102,920			—		—			—			102,920
2020	4,568			—		200,000			—			204,568
2021	19,757			676,000		—			500,000			1,195,757
2022	4,285			—		995,163			—			999,448
Thereafter	122,595			—		—			800,000			922,595
Total Debt	256,281			676,000		1,195,163			1,300,000			3,427,444
Premium, net	—			—		—			15,216			15,216
Deferred financing costs, net	(2,714		)	—		(7,765		)	(8,374		)	(18,853		)
Total Debt, Net	$	253,567		$	676,000	$	1,187,398		$	1,306,842		$	3,423,807

⁽¹⁾  Revolving Credit Facility is subject to twosix-month extension options.

XML

DERIVATIVE AND HEDGING INSTRUMENTS

6 Months Ended

Jun. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

DERIVATIVE AND HEDGING INSTRUMENTS

DERIVATIVE AND HEDGING INSTRUMENTS

The Company is exposed to various market risks, including the potential loss arising from adverse changes in interest rates and foreign exchange rates. The Company enters into derivative financial instruments to manage exposures that arise from business activities that result in the receipt or payment of future known and uncertain cash amounts, the value of which are determined by interest rates and foreign exchange rates. The Company’s derivative financial instruments are used to manage differences in the amount of the Company’s known or expected cash receipts and its known or expected cash payments principally related to the Company’s investments and borrowings.

Certain of the Company’s foreign operations expose the Company to fluctuations of foreign interest rates and exchange rates. These fluctuations may impact the value in the Company’s functional currency, the U.S. dollar, of the Company’s investment in foreign operations, the cash receipts and payments related to these foreign operations and payments of interest and principal under Canadian dollar denominated debt. The Company enters into derivative financial instruments to protect the value of its foreign investments and fix a portion of the interest payments for certain debt obligations. The Company does not enter into derivatives for speculative purposes.

Cash Flow Hedges

The Company’s objectives in using interest rate derivatives are to add stability to interest expense and to manage its exposure to interest rate movements. To accomplish these objectives, the Company primarily uses interest rate swaps as part of its interest rate risk management strategy. Approximately $6.6 million of gains, which are included in accumulated other comprehensive income, as of June 30, 2018, are expected to be reclassified into earnings in the next 12 months.

Net Investment Hedges

The Company is exposed to fluctuations in foreign exchange rates on investments it holds in Canada. The Company uses cross currency interest rate swaps to hedge its exposure to changes in foreign exchange rates on these foreign investments.

The following presents the notional amount of derivatives instruments as of the dates indicated (in thousands):

	June 30, 2018		December 31, 2017
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars	$	845,000	$	845,000
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	56,300	$	56,300
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at June 30, 2018 and December 31, 2017 (dollars in thousands):    

		Count as of June 30, 2018	Fair Value				Maturity Dates
Type	Designation		June 30, 2018		December 31, 2017			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	12	$	35,719	$	25,221	2020 - 2023	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	2,146		674		2025	Accounts receivable, prepaid expenses and other assets, net
			$	37,865	$	25,895
Liabilities:
CAD term loan	Net investment	1	95,163		99,588		2022	Term loans, net
			$	95,163	$	99,588

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three and six months ended June 30, 2018 and 2017 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income
	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017			Income Statement Location
Cash Flow Hedges:
Interest rate products	$	4,009	$	(136	)	$	13,132	$	125		Interest expense
Net Investment Hedges:
Foreign currency products	898		(242		)	1,505		(1,159		)	N/A
CAD term loan	1,750		(2,513		)	4,425		(3,288		)	N/A
	$	6,657	$	(2,891	)	$	19,062	$	(4,322	)

	Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017			Income Statement Location
Cash Flow Hedges:
Interest rate products	$	633	$	(399	)	$	583	$	(869	)	Interest expense
Net Investment Hedges:
Foreign currency products	—		—			—		—			N/A
CAD term loan	—		—			—		—			N/A
	$	633	$	(399	)	$	583	$	(869	)

The gain (loss) in the table above related to interest rate products, was reclassified from accumulated other comprehensive income into interest expense. Interest expense totaled $36.8 million and $72.6 million for the three and six months ended June 30, 2018, respectively, and $15.9 million and $31.7 million for the three and six months ended June 30, 2017, respectively.

During the three and six months ended June 30, 2018, no cash flow hedges were determined to be ineffective. During the three and six months ended June 30, 2017, the Company determined that a portion of a cash flow hedge was ineffective and recognized $14,000 and $0.1 million, respectively, of unrealized losses related to its interest rate swaps to other income in the condensed consolidated statements of income.

Offsetting Derivatives

The Company enters into master netting arrangements, which reduce credit risk by permitting net settlement of transactions with the same counterparty. The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of June 30, 2018 and December 31, 2017 (in thousands):

	As of June 30, 2018
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	37,865	$	—	$	37,865	$	—	$	—	$	37,865
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

	As of December 31, 2017
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	25,895	$	—	$	25,895	$	—	$	—	$	25,895
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

Credit-risk-related Contingent Features

The Company has agreements with each of its derivative counterparties that contain a provision pursuant to which the Company could be declared in default on the derivative obligation if the Company defaults on any of its indebtedness, including a default where repayment of the indebtedness has not been accelerated by the lender.

As of June 30, 2018, the Company had no derivatives with a fair value in a net liability position.

XML

FAIR VALUE DISCLOSURES

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

FAIR VALUE DISCLOSURES

FAIR VALUE DISCLOSURES

Financial Instruments

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Facility are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investment, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3.

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of June 30, 2018 and December 31, 2017 whose carrying amounts do not approximate their fair value (in thousands):

	June 30, 2018						December 31, 2017
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	80,687	$	55,880	$	58,656	$	91,280	$	65,907	$	65,892
Preferred equity investments	50,856		51,348		50,787		48,035		48,483		47,064
Financial liabilities:
Senior Notes	1,300,000		1,306,842		1,292,347		1,300,000		1,306,286		1,329,191
Secured indebtedness	256,281		253,567		236,862		259,202		256,430		246,461

⁽¹⁾  Face value represents amounts contractually due under the terms of the respective agreements.

⁽²⁾  Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

The Company determined the fair value of financial instruments as of June 30, 2018 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Financial assets:
Loans receivable	$	58,656	$	—	$	—	$	58,656
Preferred equity investments	50,787		—		—		50,787
Financial liabilities:
Senior Notes	1,292,347		—		1,292,347		—
Secured indebtedness	236,862		—		—		236,862

Disclosure of the fair value of financial instruments is based on pertinent information available to the Company at the applicable dates and requires a significant amount of judgment. Despite increased capital market and credit market activity, transaction volume for certain financial instruments remains relatively low. This has made the estimation of fair values difficult and, therefore, both the actual results and the Company’s estimate of fair value at a future date could be materially different.

Items Measured at Fair Value on a Recurring Basis

During the six months ended June 30, 2018, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Recurring Basis:
Financial assets:
Interest rate swap	$	35,719	$	—	$	35,719	$	—
Cross currency swap	2,146		—		2,146		—

XML

EQUITY

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

EQUITY

EQUITY

Preferred Stock

On March 21, 2013, the Company completed an underwritten public offering of 5,750,000 shares of 7.125% Series A Cumulative Redeemable Preferred Stock (the “Series A Preferred Stock”) at a price of $25.00 per share, pursuant to an effective registration statement. The Company received net proceeds of $138.3 million from the offering, after deducting underwriting discounts and other offering expenses. The Company classified the par value as preferred equity on its condensed consolidated balance sheets with the balance of the liquidation preference, net of any issuance costs, recorded as an increase in paid-in capital.

The Company redeemed all 5,750,000 shares of its Series A Preferred Stock on June 1, 2018 (the “Redemption Date”) for $25.00 per share, plus accrued and unpaid dividends to, but not including, the Redemption Date, without interest, in the amount of $0.4453125 per share of Series A Preferred Stock, for a total redemption price per share of Series A Preferred Stock equal to $25.4453125. As a result of the redemption, the Company incurred a charge of $5.5 million related to the original issuance costs of the Series A Preferred Stock. The charge is presented as an additional preferred stock dividend in the Company’s condensed consolidated statements of income.

Common Stock

As a result of the CCP Merger completed on August 17, 2017, the Company issued approximately 94.0 million shares of its common stock in exchange for shares of CCP common stock and shares underlying share-based awards assumed by the Company outstanding as of the effective time of the CCP Merger.

On September 28, 2017, the Company completed an underwritten public offering of 16.0 million newly issued shares of its common stock pursuant to an effective registration statement. The underwriters exercised their option to purchase additional shares, and on October 2, 2017, the Company issued an additional 2.4 million newly issued shares of its common stock pursuant to an effective registration statement. The Company received net proceeds, before expenses, of $370.9 million from the offering, after giving effect to the issuance and sale of all 18.4 million shares of common stock, at a price of $21.00 per share. These proceeds were used to repay borrowings outstanding under the Revolving Credit Facility.

The following table lists the cash dividends on common stock declared and paid by the Company during the six months ended June 30, 2018:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 5, 2018	February 15, 2018	$	0.45	February 28, 2018
May 9, 2018	May 21, 2018	$	0.45	May 31, 2018

During the six months ended June 30, 2018, the Company issued 27,747 shares of common stock as a result of restricted stock unit vestings.

Upon any payment of shares as a result of restricted stock unit vestings, the related tax withholding obligation will generally be satisfied by the Company, reducing the number of shares to be delivered by a number of shares necessary to satisfy the related applicable tax withholding obligation. During the six months ended June 30, 2018 and 2017, the Company incurred $0.2 million and $2.6 million, respectively, in tax withholding obligations on behalf of its employees that were satisfied through a reduction in the number of shares delivered to those participants.

Accumulated Other Comprehensive Income

The following is a summary of the Company’s accumulated other comprehensive income (in thousands):

	June 30, 2018			December 31, 2017
Foreign currency translation loss	$	(3,026	)	$	(2,913	)
Unrealized gains on cash flow hedges	27,438			14,202
Total accumulated other comprehensive income	$	24,412		$	11,289

XML

EARNINGS PER COMMON SHARE

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE

The following table illustrates the computation of basic and diluted earnings per share for the three and six months ended June 30, 2018 and 2017 (in thousands, except share and per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Numerator
Net income attributable to common stockholders	$	193,580	$	17,960	$	253,490	$	34,222
Denominator
Basic weighted average common shares and common equivalents	178,314,750		65,438,739		178,304,733		65,396,146
Dilutive restricted stock units	369,274		232,114		296,056		297,873
Diluted weighted average common shares	178,684,024		65,670,853		178,600,789		65,694,019
Net income attributable to common stockholders, per:
Basic common share	$	1.09	$	0.27	$	1.42	$	0.52
Diluted common share	$	1.08	$	0.27	$	1.42	$	0.52

During the three and six months ended June 30, 2018, approximately 35,300 and 46,000 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. During the three and six months ended June 30, 2017, approximately 15,900 and 19,300 restricted stock units, respectively, were not included in computing diluted earnings per share because they were considered anti-dilutive. No stock options were considered anti-dilutive during the three and six months ended June 30, 2018, and no stock options were outstanding during the three and six months ended June 30, 2017.

XML

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION

6 Months Ended

Jun. 30, 2018

Summarized Condensed Consolidating Information [Abstract]

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION

In connection with the offerings of the 2021 Notes and the 2023 Notes by the Issuers, the Company and certain 100% owned subsidiaries of the Company (the “Guarantors”) have, jointly and severally, fully and unconditionally guaranteed the 2021 Notes and the 2023 Notes, subject to release under certain customary circumstances as described below. In connection with the assumption of the 2026 Notes as a result of the CCP Merger (see Note 3, “CCP Merger and Recent Real Estate Acquisitions”), the Company has fully and unconditionally guaranteed the 2026 Notes, subject to release under certain circumstances as described below. These guarantees are subordinated to all existing and future senior debt and senior guarantees of the Guarantors and are unsecured. The Company conducts all of its business through and derives virtually all of its income from its subsidiaries. Therefore, the Company’s ability to make required payments with respect to its indebtedness (including the Senior Notes) and other obligations depends on the financial results and condition of its subsidiaries and its ability to receive funds from its subsidiaries.

A Guarantor will be automatically and unconditionally released from its obligations under the guarantees with respect to the 2021 Notes and the 2023 Notes in the event of:

• Any sale of the subsidiary Guarantor or of all or substantially all of its assets;

• A merger or consolidation of a subsidiary Guarantor with an issuer of the 2021 Notes or the 2023 Notes or another Guarantor, provided that the surviving entity remains a Guarantor;

• A subsidiary Guarantor is declared “unrestricted” for covenant purposes under the indentures governing the 2021 Notes or the 2023 Notes;

• The requirements for legal defeasance or covenant defeasance or to discharge the indentures governing the 2021 Notes or the 2023 Notes have been satisfied;

• A liquidation or dissolution, to the extent permitted under the indentures governing the 2021 Notes or the 2023 Notes, of a subsidiary Guarantor; or

• The release or discharge of the guaranty that resulted in the creation of the subsidiary guaranty, except a discharge or release by or as a result of payment under such guaranty.

The Company will be automatically and unconditionally released from its obligations under the guarantees with respect to the 2026 Notes in the event of:

• A liquidation or dissolution, to the extent permitted under the indenture governing the 2026 Notes;

• A merger or consolidation, provided that the surviving entity remains a Guarantor; or

• The requirements for legal defeasance or covenant defeasance or to discharge the indenture governing the 2026 Notes have been satisfied.

Pursuant to Rule 3-10 of Regulation S-X, the following summarized condensed consolidating information is provided for the Company (the “Parent Company”), the Operating Partnership, Sabra Capital Corporation, the Guarantors, and the Company’s non-Guarantor subsidiaries with respect to the 2021 Notes and the 2023 Notes. This summarized financial information has been prepared from the books and records maintained by the Company, the Operating Partnership, Sabra Capital Corporation, the Guarantors and the non-Guarantor subsidiaries. The summarized financial information may not necessarily be indicative of the results of operations or financial position had the Operating Partnership, Sabra Capital Corporation, the Guarantors or non-Guarantor subsidiaries operated as independent entities. Sabra’s investments in its consolidated subsidiaries are presented based upon Sabra’s proportionate share of each subsidiary’s net assets. The Guarantor subsidiaries’ investments in the non-Guarantor subsidiaries and non-Guarantor subsidiaries’ investments in Guarantor subsidiaries are presented under the equity method of accounting. Intercompany activities between subsidiaries and the Parent Company are presented within operating activities on the condensed consolidating statement of cash flows.

Condensed consolidating financial statements for the Company and its subsidiaries, including the Parent Company only, the Operating Partnership only, Sabra Capital Corporation only, the combined Guarantor subsidiaries and the combined non-Guarantor subsidiaries, are as follows:

CONDENSED CONSOLIDATING BALANCE SHEET

June 30, 2018

(in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)		Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	341		$	—	$	—	$	1,666,116	$	4,327,225	$	—		$	5,993,682
Loans receivable and other investments, net	(356		)	—		—		52,315		55,269		—			107,228
Investment in unconsolidated joint venture	—			—		—		—		348,950		—			348,950
Cash and cash equivalents	31,269			—		—		1,405		6,135		—			38,809
Restricted cash	—			—		—		174,913		11,932		—			186,845
Lease intangible assets, net	—			—		—		16,815		139,451		—			156,266
Accounts receivable, prepaid expenses and other assets, net	(536		)	46,700		—		84,809		73,017		(7,626		)	196,364
Intercompany	2,186,044			2,727,032		—		—		—		(4,913,076		)	—
Investment in subsidiaries	1,209,953			1,538,155		—		15,830		—		(2,763,938		)	—
Total assets	$	3,426,715		$	4,311,887	$	—	$	2,012,203	$	4,961,979	$	(7,684,640	)	$	7,028,144
Liabilities
Secured debt, net	$	—		$	—	$	—	$	—	$	253,567	$	—		$	253,567
Revolving credit facility	—			676,000		—		—		—		—			676,000
Term loans, net	—			1,093,314		—		94,084		—		—			1,187,398
Senior unsecured notes, net	—			1,306,842		—		—		—		—			1,306,842
Accounts payable and accrued liabilities	23,172			25,778		—		3,576		60,439		(7,626		)	105,339
Lease intangible liabilities, net	—			—		—		—		91,073		—			91,073
Intercompany	—			—		—		636,037		4,277,039		(4,913,076		)	—
Total liabilities	23,172			3,101,934		—		733,697		4,682,118		(4,920,702		)	3,620,219
Total Sabra Health Care REIT, Inc. stockholders' equity	3,403,543			1,209,953		—		1,278,506		275,479		(2,763,938		)	3,403,543
Noncontrolling interests	—			—		—		—		4,382		—			4,382
Total equity	3,403,543			1,209,953		—		1,278,506		279,861		(2,763,938		)	3,407,925
Total liabilities and equity	$	3,426,715		$	4,311,887	$	—	$	2,012,203	$	4,961,979	$	(7,684,640	)	$	7,028,144

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING BALANCE SHEET

December 31, 2017

(in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)		Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	324		$	—	$	—	$	1,756,933	$	4,237,175	$	—		$	5,994,432
Loans receivable and other investments, net	(97		)	—		—		55,297		59,190		—			114,390
Cash and cash equivalents	511,670			—		—		449		6,513		—			518,632
Restricted cash	—			—		—		36,910		31,907		—			68,817
Lease intangible assets, net	—			—		—		17,577		149,542		—			167,119
Accounts receivable, prepaid expenses and other assets, net	3,499			36,073		—		80,739		53,765		(5,189		)	168,887
Intercompany	2,043,402			2,721,979		—		—		—		(4,765,381		)	—
Investment in subsidiaries	890,462			1,198,305		—		14,661		—		(2,103,428		)	—
Total assets	$	3,449,260		$	3,956,357	$	—	$	1,962,566	$	4,538,092	$	(6,873,998	)	$	7,032,277
Liabilities
Secured debt, net	$	—		$	—	$	—	$	—	$	256,430	$	—		$	256,430
Revolving credit facility	—			641,000		—		—		—		—			641,000
Term loans, net	—			1,092,397		—		98,377		—		—			1,190,774
Senior unsecured notes, net	—			1,306,286		—		—		—		—			1,306,286
Accounts payable and accrued liabilities	16,453			26,212		—		3,560		61,487		(5,189		)	102,523
Lease intangible liabilities, net	—			—		—		—		98,015		—			98,015
Intercompany	—			—		—		785,120		3,980,261		(4,765,381		)	—
Total liabilities	16,453			3,065,895		—		887,057		4,396,193		(4,770,570		)	3,595,028
Total Sabra Health Care REIT, Inc. stockholders' equity	3,432,807			890,462		—		1,075,509		137,457		(2,103,428		)	3,432,807
Noncontrolling interests	—			—		—		—		4,442		—			4,442
Total equity	3,432,807			890,462		—		1,075,509		141,899		(2,103,428		)	3,437,249
Total liabilities and equity	$	3,449,260		$	3,956,357	$	—	$	1,962,566	$	4,538,092	$	(6,873,998	)	$	7,032,277

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Three Months EndedJune 30, 2018

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	44,560		$	103,989		$	(4,320	)	$	144,229
Interest and other income	40			96			—		1,198			3,315			(96		)	4,553
Resident fees and services	—			—			—		—			17,530			—			17,530
Total revenues	40			96			—		45,758			124,834			(4,416		)	166,312
Expenses:
Depreciation and amortization	222			—			—		14,146			32,460			—			46,828
Interest	—			33,415			—		810			2,628			(96		)	36,757
Operating expenses	—			—			—		—			16,619			(4,320		)	12,299
General and administrative	8,009			14			—		379			869			—			9,271
Merger and acquisition costs	112			—			—		—			—			—			112
Provision for (recovery of) doubtful accounts and loan losses	311			—			—		(985		)	—			—			(674		)
Impairment of real estate	—			—			—		881			—			—			881
Total expenses	8,654			33,429			—		15,231			52,576			(4,416		)	105,474
Other income:
Other income (expense)	—			32			—		(32		)	—			—			—
Net gain on sales of real estate	—			—			—		141,918			985			—			142,903
Total other income	—			32			—		141,886			985			—			142,903
Income in subsidiary	209,456			242,758			—		1,871			—			(454,085		)	—
Income before loss from unconsolidated joint venture and income tax expense	200,842			209,457			—		174,284			73,243			(454,085		)	203,741
Loss from unconsolidated joint venture	—			—			—		—			(2,347		)	—			(2,347		)
Income tax expense	(55		)	(1		)	—		(489		)	(60		)	—			(605		)
Net income	200,787			209,456			—		173,795			70,836			(454,085		)	200,789
Net income attributable to noncontrolling interests	—			—			—		—			(2		)	—			(2		)
Net income attributable to Sabra Health Care REIT, Inc.	200,787			209,456			—		173,795			70,834			(454,085		)	200,787
Preferred stock dividends	(7,207		)	—			—		—			—			—			(7,207		)
Net income attributable to common stockholders	$	193,580		$	209,456		$	—	$	173,795		$	70,834		$	(454,085	)	$	193,580
Net income attributable to common stockholders, per:
Basic common share																		$	1.09
Diluted common share																		$	1.08
Weighted-average number of common shares outstanding, basic																		178,314,750
Weighted-average number of common shares outstanding, diluted																		178,684,024

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Three Months EndedJune 30, 2017

(dollars in thousands, except per share amounts)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—	$	—	$	52,442		$	4,656		$	(1,194	)	$	55,904
Interest and other income	6			—		—		2,039			—			(18		)	2,027
Resident fees and services	—			—		—		—			6,805			—			6,805
Total revenues	6			—		—		54,481			11,461			(1,212		)	64,736
Expenses:
Depreciation and amortization	216			—		—		15,425			1,579			—			17,220
Interest	—			13,516		—		715			1,631			—			15,862
Operating expenses	—			—		—		—			5,619			(1,212		)	4,407
General and administrative	4,063			17		—		991			55			—			5,126
Merger and acquisition costs	5,883			—		—		4			—			—			5,887
Provision for doubtful accounts and loan losses	227			—		—		308			—			—			535
Total expenses	10,389			13,533		—		17,443			8,884			(1,212		)	49,037
Other income (expense):
Other income (expense)	916			703		—		(665		)	(13		)	—			941
Net gain on sales of real estate	—			—		—		4,026			6			—			4,032
Total other income (expense)	916			703		—		3,361			(7		)	—			4,973
Income in subsidiary	29,894			42,724		—		1,785			—			(74,403		)	—
Income before income tax benefit (expense)	20,427			29,894		—		42,184			2,570			(74,403		)	20,672
Income tax benefit (expense)	93			—		—		(227		)	(2		)	—			(136		)
Net income	20,520			29,894		—		41,957			2,568			(74,403		)	20,536
Net income attributable to noncontrolling interests	—			—		—		—			(16		)	—			(16		)
Net income attributable to Sabra Health Care REIT, Inc.	20,520			29,894		—		41,957			2,552			(74,403		)	20,520
Preferred stock dividends	(2,560		)	—		—		—			—			—			(2,560		)
Net income attributable to common stockholders	$	17,960		$	29,894	$	—	$	41,957		$	2,552		$	(74,403	)	$	17,960
Net income attributable to common stockholders, per:
Basic common share																	$	0.27
Diluted common share																	$	0.27
Weighted-average number of common shares outstanding, basic																	65,438,739
Weighted-average number of common shares outstanding, diluted																	65,670,853

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Six Months EndedJune 30, 2018

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	90,024		$	207,013		$	(8,553	)	$	288,484
Interest and other income	50			208			—		2,465			6,376			(208		)	8,891
Resident fees and services	—			—			—		—			35,023			—			35,023
Total revenues	50			208			—		92,489			248,412			(8,761		)	332,398
Expenses:
Depreciation and amortization	443			—			—		29,076			65,314			—			94,833
Interest	—			65,980			—		1,601			5,202			(208		)	72,575
Operating expenses	—			—			—		—			32,976			(8,553		)	24,423
General and administrative	13,831			29			—		810			2,468			—			17,138
Merger and acquisition costs	448			—			—		—			(6		)	—			442
Provision for (recovery of) doubtful accounts and loan losses	2,492			—			—		(1,956		)	3			—			539
Impairment of real estate	—			—			—		1,413			—			—			1,413
Total expenses	17,214			66,009			—		30,944			105,957			(8,761		)	211,363
Other income:
Other income	1,977			233			—		378			232			—			2,820
Net gain on sales of real estate	—			—			—		141,862			569			—			142,431
Total other income	1,977			233			—		142,240			801			—			145,251
Income in subsidiary	278,798			344,367			—		3,725			—			(626,890		)	—
Income before loss from unconsolidated joint venture and income tax expense	263,611			278,799			—		207,510			143,256			(626,890		)	266,286
Loss from unconsolidated joint venture	—			—			—		—			(1,901		)	—			(1,901		)
Income tax expense	(353		)	(1		)	—		(542		)	(219		)	—			(1,115		)
Net income	263,258			278,798			—		206,968			141,136			(626,890		)	263,270
Net income attributable to noncontrolling interests	—			—			—		—			(12		)	—			(12		)
Net income attributable to Sabra Health Care REIT, Inc.	263,258			278,798			—		206,968			141,124			(626,890		)	263,258
Preferred stock dividends	(9,768		)	—			—		—			—			—			(9,768		)
Net income attributable to common stockholders	$	253,490		$	278,798		$	—	$	206,968		$	141,124		$	(626,890	)	$	253,490
Net income attributable to common stockholders, per:
Basic common share																		$	1.42
Diluted common share																		$	1.42
Weighted-average number of common shares outstanding, basic																		178,304,733
Weighted-average number of common shares outstanding, diluted																		178,600,789

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Six Months EndedJune 30, 2017

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	105,481		$	9,625		$	(1,978	)	$	113,128
Interest and other income	13			—			—		3,977			—			(18		)	3,972
Resident fees and services	—			—			—		—			10,286			—			10,286
Total revenues	13			—			—		109,458			19,911			(1,996		)	127,386
Expenses:
Depreciation and amortization	432			—			—		32,381			3,544			—			36,357
Interest	—			26,924			—		1,445			3,281			—			31,650
Operating expenses	—			—			—		—			8,823			(1,996		)	6,827
General and administrative	9,322			31			—		1,758			104			—			11,215
Merger and acquisition costs	6,417			—			—		34			—			—			6,451
Provision for doubtful accounts and loan losses	82			—			—		2,223			—			—			2,305
Total expenses	16,253			26,955			—		37,841			15,752			(1,996		)	94,805
Other income:
Other income	2,283			737			—		50			—			—			3,070
Net gain on sales of real estate	—			—			—		4,026			6			—			4,032
Total other income	2,283			737			—		4,076			6			—			7,102
Income in subsidiary	53,331			79,550			—		3,564			—			(136,445		)	—
Income before income tax expense	39,374			53,332			—		79,257			4,165			(136,445		)	39,683
Income tax expense	(31		)	(1		)	—		(227		)	(97		)	—			(356		)
Net income	39,343			53,331			—		79,030			4,068			(136,445		)	39,327
Net loss attributable to noncontrolling interests	—			—			—		—			16			—			16
Net income attributable to Sabra Health Care REIT, Inc.	39,343			53,331			—		79,030			4,084			(136,445		)	39,343
Preferred stock dividends	(5,121		)	—			—		—			—			—			(5,121		)
Net income attributable to common stockholders	$	34,222		$	53,331		$	—	$	79,030		$	4,084		$	(136,445	)	$	34,222
Net income attributable to common stockholders, per:
Basic common share																		$	0.52
Diluted common share																		$	0.52
Weighted-average number of common shares outstanding, basic																		65,396,146
Weighted-average number of common shares outstanding, diluted																		65,694,019

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months EndedJune 30, 2018

(dollars in thousands)

(unaudited)

					Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	200,787	$	209,456	$	—	$	173,795		$	70,836		$	(454,085	)	$	200,789
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		1,064		—		(608		)	(195		)	—			261
Unrealized gain on cash flow hedges	—		3,335		—		3			—			—			3,338
Total other comprehensive income (loss)	—		4,399		—		(605		)	(195		)	—			3,599
Comprehensive income	200,787		213,855		—		173,190			70,641			(454,085		)	204,388
Comprehensive income attributable to noncontrolling interest	—		—		—		—			(2		)	—			(2		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	200,787	$	213,855	$	—	$	173,190		$	70,639		$	(454,085	)	$	204,386

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months EndedJune 30, 2017

(dollars in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	20,520	$	29,894		$	—	$	41,957		$	2,568		$	(74,403	)	$	20,536
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(415		)	—		833			280			—			698
Unrealized gain (loss) on cash flow hedges	—		285			—		(188		)	—			—			97
Total other comprehensive (loss) income	—		(130		)	—		645			280			—			795
Comprehensive income	20,520		29,764			—		42,602			2,848			(74,403		)	21,331
Comprehensive income attributable to noncontrolling interest	—		—			—		—			(16		)	—			(16		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	20,520	$	29,764		$	—	$	42,602		$	2,832		$	(74,403	)	$	21,315

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Six Months EndedJune 30, 2018

(dollars in thousands)

(unaudited)

					Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	263,258	$	278,798	$	—	$	206,968		$	141,136		$	(626,890	)	$	263,270
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		1,905		—		(1,536		)	(482		)	—			(113		)
Unrealized gain (loss) on cash flow hedges	—		13,238		—		(2		)	—			—			13,236
Total other comprehensive income (loss)	—		15,143		—		(1,538		)	(482		)	—			13,123
Comprehensive income	263,258		293,941		—		205,430			140,654			(626,890		)	276,393
Comprehensive income attributable to noncontrolling interest	—		—		—		—			(12		)	—			(12		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	263,258	$	293,941	$	—	$	205,430		$	140,642		$	(626,890	)	$	276,381

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Six Months EndedJune 30, 2017

(dollars in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Net income	$	39,343	$	53,331		$	—	$	79,030		$	4,068	$	(136,445	)	$	39,327
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(1,367		)	—		1,131			376		—			140
Unrealized gain (loss) on cash flow hedges	—		1,013			—		(188		)	—		—			825
Total other comprehensive (loss) income	—		(354		)	—		943			376		—			965
Comprehensive income	39,343		52,977			—		79,973			4,444		(136,445		)	40,292
Comprehensive loss attributable to noncontrolling interest	—		—			—		—			16		—			16
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	39,343	$	52,977		$	—	$	79,973		$	4,460	$	(136,445	)	$	40,308

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2018

(in thousands)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net cash provided by operating activities	$	204,440		$	—		$	—	$	1,041		$	6,072		$	—		$	211,553
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(29,711		)	(184,271		)	—			(213,982		)
Origination and fundings of loans receivable	—			—			—		(1,973		)	(26,184		)	—			(28,157		)
Origination and fundings of preferred equity investments	—			—			—		(945		)	—			—			(945		)
Additions to real estate	(40		)	—			—		(4,660		)	(12,117		)	—			(16,817		)
Repayments of loans receivable	—			—			—		6,577			32,310			—			38,887
Repayments of preferred equity investments	—			—			—		375			—			—			375
Investment in unconsolidated JV	—			—			—		—			(354,461		)	—			(354,461		)
Net proceeds from the sales of real estate	—			—			—		232,059			46,142			—			278,201
Distribution from subsidiaries	2,669			2,669			—		—			—			(5,338		)	—
Intercompany financing	(378,485		)	(413,473		)	—		—			—			791,958			—
Net cash (used in) provided by investing activities	(375,856		)	(410,804		)	—		201,722			(498,581		)	786,620			(296,899		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			35,000			—		—			—			—			35,000
Principal payments on secured debt	—			—			—		—			(2,128		)	—			(2,128		)
Payments of deferred financing costs	—			(12		)	—		—			—			—			(12		)
Distributions to noncontrolling interest	—			—			—		—			(72		)	—			(72		)
Preferred stock redemption	(143,750		)	—			—		—			—			—			(143,750		)
Issuance of common stock, net	(499		)	—			—		—			—			—			(499		)
Dividends paid on common and preferred stock	(164,736		)	—			—		—			—			—			(164,736		)
Distribution to parent	—			(2,669		)	—		—			(2,669		)	5,338			—
Intercompany financing	—			378,485			—		(63,658		)	477,131			(791,958		)	—
Net cash (used in) provided by financing activities	(308,985		)	410,804			—		(63,658		)	472,262			(786,620		)	(276,197		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(480,401		)	—			—		139,105			(20,247		)	—			(361,543		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		(146		)	(106		)	—			(252		)
Cash, cash equivalents and restricted cash, beginning of period	511,670			—			—		37,359			38,420			—			587,449
Cash, cash equivalents and restricted cash, end of period	$	31,269		$	—		$	—	$	176,318		$	18,067		$	—		$	225,654

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2017

(in thousands)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net cash provided by (used in) operating activities	$	49,670		$	—		$	—	$	(1,693	)	$	6,305		$	—		$	54,282
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(14,456		)	—			—			(14,456		)
Origination and fundings of loans receivable	—			—			—		(927		)	—			—			(927		)
Origination and fundings of preferred equity investments	—			—			—		(76		)	—			—			(76		)
Additions to real estate	(12		)	—			—		(1,106		)	(176		)	—			(1,294		)
Repayments of loans receivable	—			—			—		1,547			—			—			1,547
Repayments of preferred equity investments	—			—			—		2,766			—			—			2,766
Net proceeds from the sale of real estate	—			—			—		6,099			—			—			6,099
Distribution from subsidiaries	2,474			2,474			—		—			—			(4,948		)	—
Intercompany financing	(1,667		)	(7,543		)	—		—			—			9,210			—
Net cash provided by (used in) investing activities	795			(5,069		)	—		(6,153		)	(176		)	4,262			(6,341		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			6,000			—		—			—			—			6,000
Principal payments on secured debt	—			—			—		—			(2,049		)	—			(2,049		)
Payments of deferred financing costs	—			(124		)	—		—			—			—			(124		)
Issuance of common stock, net	(3,224		)	—			—		—			—			—			(3,224		)
Dividends paid on common and preferred stock	(60,691		)	—			—		—			—			—			(60,691		)
Distribution to parent	—			(2,474		)	—		—			(2,474		)	4,948			—
Intercompany financing	—			1,667			—		7,543			—			(9,210		)	—
Net cash (used in) provided by financing activities	(63,915		)	5,069			—		7,543			(4,523		)	(4,262		)	(60,088		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(13,450		)	—			—		(303		)	1,606			—			(12,147		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		69			61			—			130
Cash, cash equivalents and restricted cash, beginning of period	18,168			—			—		2,732			13,765			—			34,665
Cash, cash equivalents and restricted cash, end of period	$	4,718		$	—		$	—	$	2,498		$	15,432		$	—		$	22,648

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

XML

COMMITMENTS AND CONTINGENCIES

6 Months Ended

Jun. 30, 2018

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES

Environmental

As an owner of real estate, the Company is subject to various environmental laws of federal, state and local governments. The Company is not aware of any environmental liability that could have a material adverse effect on its financial condition or results of operations. However, changes in applicable environmental laws and regulations, the uses and conditions of properties in the vicinity of the Company’s properties, the activities of its tenants and other environmental conditions of which the Company is unaware with respect to the properties could result in future environmental liabilities. As of June 30, 2018, the Company does not expect that compliance with existing environmental laws will have a material adverse effect on the Company’s financial condition and results of operations.

Legal Matters

From time to time, the Company is party to legal proceedings that arise in the ordinary course of its business. Management is not aware of any legal proceedings where the likelihood of a loss contingency is reasonably possible and the amount or range of reasonably possible losses is material to the Company’s results of operations, financial condition or cash flows.

XML

SUBSEQUENT EVENTS

6 Months Ended

Jun. 30, 2018

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS

The Company evaluates subsequent events up until the date the condensed consolidated financial statements are issued.

Dividend Declaration

On August 8, 2018, the Company announced that its board of directors declared a quarterly cash dividend of $0.45 per share of common stock. The dividend will be paid on August 31, 2018 to common stockholders of record as of the close of business on August 18, 2018.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Basis of Accounting

The accompanying condensed consolidated financial statements include the accounts of Sabra and its wholly owned subsidiaries as of June 30, 2018 and December 31, 2017 and for the periods ended June 30, 2018 and 2017. All significant intercompany transactions and balances have been eliminated in consolidation.

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information as contained within the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) and the rules and regulations of the SEC, including the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the unaudited condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for financial statements. In the opinion of management, the financial statements for the unaudited interim periods presented include all adjustments, which are of a normal and recurring nature, necessary for a fair statement of the results for such periods. Operating results for the three and six months ended June 30, 2018 are not necessarily indicative of the results that may be expected for the year ending December 31, 2018. For further information, refer to the Company’s consolidated financial statements and notes thereto for the year ended December 31, 2017 included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2017 filed with the SEC.

Variable Interest Entities

GAAP requires the Company to identify entities for which control is achieved through voting rights or other means and to determine which business enterprise is the primary beneficiary of variable interest entities (“VIEs”). A VIE is broadly defined as an entity with one or more of the following characteristics: (a) the total equity investment at risk is insufficient to finance the entity’s activities without additional subordinated financial support; (b) as a group, the holders of the equity investment at risk lack (i) the ability to make decisions about the entity’s activities through voting or similar rights, (ii) the obligation to absorb the expected losses of the entity, or (iii) the right to receive the expected residual returns of the entity; or (c) the equity investors have voting rights that are not proportional to their economic interests, and substantially all of the entity’s activities either involve, or are conducted on behalf of, an investor that has disproportionately few voting rights. If the Company were determined to be the primary beneficiary of the VIE, the Company would consolidate investments in the VIE. The Company may change its original assessment of a VIE due to events such as modifications of contractual arrangements that affect the characteristics or adequacy of the entity’s equity investments at risk and the disposal of all or a portion of an interest held by the primary beneficiary.

The Company identifies the primary beneficiary of a VIE as the enterprise that has both: (i) the power to direct the activities of the VIE that most significantly impact the entity’s economic performance; and (ii) the obligation to absorb losses or the right to receive benefits of the VIE that could be significant to the entity. The Company performs this analysis on an ongoing basis.

As of June 30, 2018, the Company determined it was the primary beneficiary of two variable interest entities—one exchange accommodation titleholder variable interest entity and a joint venture variable interest entity owning one skilled nursing/transitional care facility—and has consolidated the operations of these entities in the accompanying condensed consolidated financial statements. As of June 30, 2018, the Company determined that operations of these entities were not material to the Company’s results of operations, financial condition or cash flows.

As it relates to investments in loans, in addition to the Company’s assessment of VIEs and whether the Company is the primary beneficiary of those VIEs, the Company evaluates the loan terms and other pertinent facts to determine whether the loan investment should be accounted for as a loan or as a real estate joint venture. If an investment has the characteristics of a real estate joint venture, including if the Company participates in the majority of the borrower’s expected residual profit, the Company would account for the investment as an investment in a real estate joint venture and not as a loan investment. Expected residual profit is defined as the amount of profit, whether called interest or another name, such as an equity kicker, above a reasonable amount of interest and fees expected to be earned by a lender. At June 30, 2018, none of the Company’s investments in loans are accounted for as real estate joint ventures.

As it relates to investments in joint ventures, the Company assesses any limited partners’ rights and their impact on the presumption of control of the limited partnership by any single partner. The Company also applies this guidance to managing member interests in limited liability companies. The Company reassesses its determination of which entity controls the joint venture if: there is a change to the terms or in the exercisability of the rights of any partners or members, the sole general partner or managing member increases or decreases its ownership interests, or there is an increase or decrease in the number of outstanding ownership interests.

Use of Estimates

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the condensed consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates.

Reclassification

Certain amounts in the Company’s consolidated financial statements for prior periods have been reclassified to conform to the current period presentation. These reclassifications have not changed the results of operations of prior periods. As a result, certain reclassifications were made to the condensed consolidated statements of income and condensed consolidated statements of cash flows.

Investment in Unconsolidated Joint Venture

The Company reports investments in unconsolidated entities over whose operating and financial policies it has the ability to exercise significant influence under the equity method of accounting. Under this method of accounting, the Company’s share of the investee’s earnings or losses is included in the Company’s condensed consolidated statements of income. The initial carrying value of the investment is based on the amount paid to purchase the joint venture interest. Differences between the Company’s cost basis and the basis reflected at the joint venture level are generally amortized over the lives of the related assets and liabilities, and such amortization is included in the Company’s share of earnings of the joint venture.

The Company continually monitors events and changes in circumstances that could indicate that the carrying amounts of its equity method investments may not be recoverable or realized. When indicators of potential impairment are identified, the Company evaluates its equity method investments for impairment based on a comparison of the fair value of the investment to its carrying value. The fair value is estimated based on discounted cash flows that include all estimated cash inflows and outflows over a specified holding period and any estimated debt premiums or discounts. If, based on this analysis, the Company does not believe that it will be able to recover the carrying value of its equity method investment, the Company would record an impairment loss to the extent that the carrying value exceeds the estimated fair value of its equity method investment.

Net Investment in Direct Financing Lease

The net investment in direct financing lease is recorded in accounts receivable, prepaid expenses and other assets, net on the accompanying condensed consolidated balance sheets and represents the total undiscounted rental payments, plus the estimated unguaranteed residual value, less the unearned lease income. Unearned lease income represents the excess of the minimum lease payments and residual value over the cost of the investment. Unearned lease income is deferred and amortized to income over the lease term to provide a constant yield when collectability of the lease payments is reasonably assured.

Recently Issued Accounting Standards Update

Recently Issued Accounting Standards Update

Adopted

Between May 2014 and February 2017, the FASB issued four Accounting Standards Updates (each, an “ASU”) changing the requirements for recognizing and reporting revenue (together, herein referred to as the “Revenue ASUs”): (i) ASU No. 2014-09, Revenue from Contracts with Customers (“ASU 2014-09”), (ii) ASU No. 2016-08, Principal versus Agent Considerations (Reporting Revenue Gross versus Net) (“ASU 2016-08”), (iii) ASU No. 2016-12, Narrow-Scope Improvements and Practical Expedients (“ASU 2016-12”) and (iv) ASU No. 2017-05, Clarifying the Scope of Asset Derecognition Guidance and Accounting for Partial Sales of Nonfinancial Assets (“ASU 2017-05”). ASU 2014-09 provides guidance for revenue recognition to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. ASU 2016-08 is intended to improve the operability and understandability of the implementation guidance on principal versus agent considerations. ASU 2016-12 provides practical expedients and improvements on the previously narrow scope of ASU 2014-09. The Revenue ASUs became effective for the Company on January 1, 2018 with the Company electing to use the modified retrospective approach for its adoption. Further, the Company elected to reassess only contracts that were not completed as of the adoption date. The adoption of these ASUs did not have a material impact to beginning retained earnings as of January 1, 2018.

In August 2016, the FASB issued ASU 2016-15, Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments (“ASU 2016-15”). ASU 2016-15 provides specific guidance clarifying how certain cash receipts and payments should be classified. In November 2016, the FASB issued ASU 2016-18, Statement of Cash Flows (Topic 230): Restricted Cash (“ASU 2016-18”). ASU 2016-18 requires that a statement of cash flows explain the change during the period in the total of cash, cash equivalents, and amounts generally described as restricted cash or restricted cash equivalents. The Company adopted ASU 2016-15 and ASU 2016-18 on January 1, 2018. The full retrospective approach of adoption is required for both ASUs and, accordingly, certain line items in the Company’s consolidated statements of cash flows have been reclassified to conform to the current period presentation. The following table illustrates changes in the Company’s cash flows as reported in the accompanying condensed consolidated statements of cash flows and as previously reported prior to the adoption (in thousands):

	Six Months Ended June 30, 2017
	As Reported		As Previously Reported
Net cash provided by operating activities	54,282		53,871
Net decrease in balance	(12,147	)	(12,558	)
Balance - beginning of the year	34,665		25,663
Balance - end of the year	22,648		13,235

In August 2017, the FASB issued ASU 2017-12, Derivatives and Hedging (Topic 815): Targeted Improvements to Accounting for Hedging Activities (“ASU 2017-12”). ASU 2017-12 is intended to improve the financial reporting of hedging relationships to better portray the economic results of an entity’s risk management activities in its financial statements and to simplify the application of the hedge accounting guidance in current GAAP. ASU 2017-12 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. The Company adopted ASU 2017-12 effective beginning January 1, 2018. ASU 2017-12 requires a modified retrospective transition method in which the Company recognized the cumulative effect of the change on the opening balance of each affected component of equity in the condensed consolidated balance sheet as of the date of adoption, which resulted in a decrease to cumulative distributions in excess of net income and an increase to accumulated other comprehensive income of $0.8 million.

Issued but Not Yet Adopted

In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 supersedes guidance related to accounting for leases. ASU 2016-02 updates guidance around the recognition of lease assets and lease liabilities by lessees for those leases classified as operating leases under previous GAAP. The objective of ASU 2016-02 is to establish the principles that lessees and lessors shall apply to report useful information to users of financial statements about the amount, timing, and uncertainty of cash flows arising from a lease. ASU 2016-02 does not fundamentally change lessor accounting; however, some changes have been made to lessor accounting to conform and align that guidance with the lessee guidance and other areas within GAAP. ASU 2016-02 is effective for fiscal years and interim periods within those years beginning after December 15, 2018, with early adoption permitted. Under ASU 2016-02, entities currently are required to adopt the new lease requirements using a modified retrospective transition method whereby an entity initially applies the new lease requirements (subject to specific transition requirements and optional practical expedients) at the beginning of the earliest period presented in the financial statements. Upon adoption of ASU 2016-02, the Company will recognize its operating leases for which it is the lessee, mainly corporate office leases and ground leases, on its consolidated balance sheets. Further, as a result of adoption, the Company may be required to increase its revenue and expense for the amount of real estate taxes and insurance paid by its tenants under certain leasing arrangements with no net impact to net income.

In July 2018, the FASB issued ASU 2018-11, Leases (Topic 842): Targeted Improvements (“ASU 2018-11”) that allows lessors to elect, as a practical expedient, not to separate lease and nonlease components (such as services rendered) in a contract for the purpose of revenue recognition and disclosure. The practical expedient can only be applied to leasing arrangements for which (i) the timing and pattern of transfer are the same for the lease and nonlease components and (ii) the lease component, if accounted for separately, would be classified as an operating lease. Under this practical expedient, contracts that are predominantly lease-based would be accounted for under Topic 842, and contracts that are predominantly service-based would be accounted for under Topic 606, Revenue from Contracts with Customers. Further, ASU 2018-11 also provides for an additional (and optional) transition method to adopt the new lease requirements by allowing entities to initially apply the requirements by recognizing a cumulative-effect adjustment to the opening balance of retained earnings in the period of adoption. The Company plans to elect this practical expedient and apply the optional transition method for its operating leases for which the Company is the lessee, using the cumulative-effect adjustment to the opening balance sheet as of January 1, 2019. The Company is still evaluating the full impact of the adoption of ASU 2016-02 on January 1, 2019 to its consolidated financial statements.

In June 2016, the FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments (“ASU 2016-13”). ASU 2016-13 requires that a financial asset (or a group of financial assets) measured at amortized cost basis be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. The amendments in ASU 2016-13 are an improvement because they eliminate the probable initial recognition threshold in current GAAP and, instead, reflect an entity’s current estimate of all expected credit losses. Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss. ASU 2016-13 is effective for fiscal years and interim periods within those years beginning after December 15, 2019, with early adoption permitted as of the fiscal years beginning after December 15, 2018. An entity will apply the amendments in this update through a cumulative-effect adjustment to retained earnings as of the beginning of the first reporting period in which the guidance is effective (that is, a modified-retrospective approach). The Company is currently evaluating the impact this guidance will have on its consolidated financial statements when adopted.

Fair Value Disclosures

The fair value for certain financial instruments is derived using a combination of market quotes, pricing models and other valuation techniques that involve significant management judgment. The price transparency of financial instruments is a key determinant of the degree of judgment involved in determining the fair value of the Company’s financial instruments.

Financial instruments for which actively quoted prices or pricing parameters are available and whose markets contain orderly transactions will generally have a higher degree of price transparency than financial instruments whose markets are inactive or consist of non-orderly trades. The Company evaluates several factors when determining if a market is inactive or when market transactions are not orderly. The carrying values of cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and the Credit Facility are reasonable estimates of fair value because of the short-term maturities of these instruments. Fair values for other financial instruments are derived as follows:

Loans receivable: These instruments are presented on the accompanying condensed consolidated balance sheets at their amortized cost and not at fair value. The fair values of the loans receivable were estimated using an internal valuation model that considered the expected cash flows for the loans receivable, as well as the underlying collateral value and other credit enhancements as applicable. As such, the Company classifies these instruments as Level 3.

Preferred equity investments: These instruments are presented on the accompanying condensed consolidated balance sheets at their cost and not at fair value. The fair values of the preferred equity investments were estimated using an internal valuation model that considered the expected future cash flows for the preferred equity investment, the underlying collateral value and other credit enhancements. As such, the Company classifies these instruments as Level 3.

Derivative instruments: The Company’s derivative instruments are presented at fair value on the accompanying condensed consolidated balance sheets. The Company estimates the fair value of derivative instruments, including its interest rate swaps and cross currency swaps, using the assistance of a third party using inputs that are observable in the market, which include forward yield curves and other relevant information. Although the Company has determined that the majority of the inputs used to value its derivative financial instruments fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with its derivative financial instruments utilize Level 3 inputs, such as estimates of current credit spreads, to evaluate the likelihood of default by itself and its counterparties. The Company has assessed the significance of the impact of the credit valuation adjustments on the overall valuation of its derivative positions and has determined that the credit valuation adjustments are not significant to the overall valuation of its derivative financial instruments. As a result, the Company has determined that its derivative financial instruments valuations in their entirety are classified in Level 2 of the fair value hierarchy.

Senior Notes: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Senior Notes were determined using third-party market quotes derived from orderly trades. As such, the Company classifies these instruments as Level 2.

Secured indebtedness: These instruments are presented on the accompanying condensed consolidated balance sheets at their outstanding principal balance, net of unamortized deferred financing costs and premiums/discounts and not at fair value. The fair values of the Company’s secured debt were estimated using a discounted cash flow analysis based on management’s estimates of current market interest rates for instruments with similar characteristics, including remaining loan term, loan-to-value ratio, type of collateral and other credit enhancements. As such, the Company classifies these instruments as Level 3.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

6 Months Ended

Jun. 30, 2018

Accounting Policies [Abstract]

Changes in Cash Flows Due to Adoption of ASU 2016-15

The following table illustrates changes in the Company’s cash flows as reported in the accompanying condensed consolidated statements of cash flows and as previously reported prior to the adoption (in thousands):

	Six Months Ended June 30, 2017
	As Reported		As Previously Reported
Net cash provided by operating activities	54,282		53,871
Net decrease in balance	(12,147	)	(12,558	)
Balance - beginning of the year	34,665		25,663
Balance - end of the year	22,648		13,235

XML

CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS (Tables)

6 Months Ended

Jun. 30, 2018

Business Combinations [Abstract]

Purchase Price Allocation

The consideration was allocated based on certain valuations and analyses. Certain valuations and analyses related to acquisitions during the six months ended June 30, 2018 have yet to be finalized, and accordingly, the allocations are subject to adjustment once the analyses are completed. Allocation of the consideration is as follows (in thousands):

	Six Months Ended June 30,
	2018		2017
Land	$	24,356	$	1,034
Building and improvements	187,903		13,128
Tenant origination and absorption costs intangible assets	1,312		223
Tenant relationship intangible assets	412		71
Total consideration	$	213,983	$	14,456

The following table summarizes the purchase price allocation for the CCP Merger based on the Company’s valuation, including estimates and assumptions of the acquisition date fair value of the tangible and intangible assets acquired and liabilities assumed on August 17, 2017 (in thousands):

Real estate investments	$	3,727,310
Loans receivable and other investments	58,244
Cash and cash equivalents	77,859
Restricted cash	779
Lease intangible assets, net	145,786
Accounts receivable, prepaid expenses and other assets, net	35,873
Secured debt, net	(98,500		)
Revolving credit facility	(362,000		)
Unsecured term loans	(674,000		)
Senior unsecured notes, net	(616,873		)
Accounts payable and accrued liabilities	(134,802		)
Lease intangible liabilities, net	(102,643		)
Noncontrolling interests	(4,455		)
Total consideration	$	2,052,578

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT (Tables)

6 Months Ended

Jun. 30, 2018

Real Estate Investments, Net [Abstract]

Real Estate Properties Held for Investment

The Company’s real estate properties held for investment consisted of the following (dollars in thousands):

As of June 30, 2018

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	352	40,077	$	4,242,748	$	(223,777	)	$	4,018,971
Senior Housing - Leased	89	7,156	1,200,923		(113,020		)	1,087,903
Senior Housing - Managed	24	1,712	308,221		(15,961		)	292,260
Specialty Hospitals and Other	22	1,085	618,316		(24,109		)	594,207
	487	50,030	6,370,208		(376,867		)	5,993,341
Corporate Level			633		(292		)	341
			$	6,370,841	$	(377,159	)	$	5,993,682

As of December 31, 2017

Property Type	Number of Properties	Number of Beds/Units	Total Real Estate at Cost		Accumulated Depreciation			Total Real Estate Investments, Net
Skilled Nursing/Transitional Care	384	43,223	$	4,364,387	$	(209,039	)	$	4,155,348
Senior Housing - Leased	88	8,137	1,166,687		(102,370		)	1,064,317
Senior Housing - Managed	13	1,113	189,120		(12,125		)	176,995
Specialty Hospitals and Other	22	1,085	614,068		(16,620		)	597,448
	507	53,558	6,334,262		(340,154		)	5,994,108
Corporate Level			593		(269		)	324
			$	6,334,855	$	(340,423	)	$	5,994,432

	June 30, 2018			December 31, 2017
Building and improvements	$	5,489,087		$	5,449,415
Furniture and equipment	236,838			232,889
Land improvements	1,971			3,456
Land	642,945			649,095
	6,370,841			6,334,855
Accumulated depreciation	(377,159		)	(340,423		)
	$	5,993,682		$	5,994,432

Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases

As of June 30, 2018, the future minimum rental payments from the Company’s properties held for investment under non-cancelable operating leases were as follows (in thousands):

July 1 through December 31, 2018	$	260,307
2019	529,844
2020	522,304
2021	520,553
2022	512,680
Thereafter	3,083,776
	$	5,429,464

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS (Tables)

6 Months Ended

Jun. 30, 2018

Receivables [Abstract]

Loans Receivable and Other Investments

As of June 30, 2018 and December 31, 2017, the Company’s loans receivable and other investments consisted of the following (dollars in thousands):

											June 30, 2018
Investment	Quantity as of June 30, 2018	Property Type	Principal Balance as of June 30, 2018 (1)		Book Value as of June 30, 2018			Book Value as of December 31, 2017			Weighted Average Contractual Interest Rate / Rate of Return		Weighted Average Annualized Effective Interest Rate / Rate of Return		Maturity Date as of June 30, 2018
Loans Receivable:
Mortgage	1	Specialty Hospital	$	15,332	$	15,332		$	12,351		10.0	%	10.0	%	01/31/27
Construction	2	Senior Housing	3,989		4,055			2,733			8.0	%	7.8	%	04/30/21- 09/30/22
Mezzanine	1	Skilled Nursing	25,000		2,301			10,239			10.0	%	41.9	%	05/25/20
Pre-development	1	Senior Housing	2,357		2,357			2,357			9.0	%	8.4	%	04/01/20
Other	17	Multiple	34,009		32,191			38,324			8.5	%	9.7	%	12/31/17- 04/30/27
	22		80,687		56,236			66,004			9.3	%	10.9	%
Loan loss reserve			—		(356		)	(97		)
			$	80,687	$	55,880		$	65,907
Other Investments:
Preferred Equity	13	Skilled Nursing / Senior Housing	50,856		51,348			48,483			12.6	%	12.6	%	N/A
Total	35		$	131,543	$	107,228		$	114,390		10.6	%	11.7	%

⁽¹⁾  Principal balance includes amounts funded and accrued but unpaid interest / preferred return and excludes capitalizable fees.

Changes in Accretable Yield of Loans with Deteriorated Credit Quality

The following table presents changes in the accretable yield for the three and six months ended June 30, 2018 (in thousands):

	Three Months Ended			Six Months Ended
	June 30, 2018
Accretable yield, beginning of period	$	1,883		$	2,483
Accretion recognized in earnings	(1,529		)	(2,129		)
Net reclassification from nonaccretable difference	727			727
Accretable yield, end of period	$	1,081		$	1,081

XML

DEBT (Tables)

6 Months Ended

Jun. 30, 2018

Debt Instrument [Line Items]

Schedule of Maturities for Outstanding Debt

The following is a schedule of maturities for the Company’s outstanding debt as of June 30, 2018 (in thousands): 

	Secured Indebtedness			Revolving Credit     Facility (1)		Term Loans			Senior Notes			Total
July 1 through December 31, 2018	$	2,156		$	—	$	—		$	—		$	2,156
2019	102,920			—		—			—			102,920
2020	4,568			—		200,000			—			204,568
2021	19,757			676,000		—			500,000			1,195,757
2022	4,285			—		995,163			—			999,448
Thereafter	122,595			—		—			800,000			922,595
Total Debt	256,281			676,000		1,195,163			1,300,000			3,427,444
Premium, net	—			—		—			15,216			15,216
Deferred financing costs, net	(2,714		)	—		(7,765		)	(8,374		)	(18,853		)
Total Debt, Net	$	253,567		$	676,000	$	1,187,398		$	1,306,842		$	3,423,807

⁽¹⁾  Revolving Credit Facility is subject to twosix-month extension options.

Secured Debt

Debt Instrument [Line Items]

Debt

The Company’s secured debt consists of the following (dollars in thousands):

Interest Rate Type	Principal Balance as of June 30, 2018 (1)		Principal Balance as of December 31, 2017 (1)		Weighted Average Effective Interest Rate at June 30, 2018 (2)		Maturity Date
Fixed Rate	$	157,781	$	160,702	3.87	%	December 2021 -  August 2051
Variable Rate	98,500		98,500		3.89	%	July 2019
	$	256,281	$	259,202	3.88	%

⁽¹⁾   Principal balance does not include deferred financing costs, net of $2.7 million and $2.8 million as of June 30, 2018 and December 31, 2017, respectively.

⁽²⁾   Weighted average effective interest rate includes private mortgage insurance.

Senior Notes

Debt Instrument [Line Items]

Debt

The Company’s senior unsecured notes consist of the following (dollars in thousands):

		Principal Balance as of
Title	Maturity Date	June 30, 2018 (1)		December 31, 2017 (1)
5.5% senior unsecured notes due 2021 (“2021 Notes”)	February 1, 2021	$	500,000	$	500,000
5.375% senior unsecured notes due 2023 (“2023 Notes”)	June 1, 2023	200,000		200,000
5.125% senior unsecured notes due 2026 (“2026 Notes”)	August 15, 2026	500,000		500,000
5.38% senior unsecured notes due 2027 (“2027 Notes”)	May 17, 2027	100,000		100,000
		$	1,300,000	$	1,300,000

⁽¹⁾  Principal balance does not include premium, net of $15.2 million and deferred financing costs, net of $8.4 million as of June 30, 2018 and does not include premium, net of $15.9 million and deferred financing costs, net of $9.6 million as of December 31, 2017.

XML

DERIVATIVE AND HEDGING INSTRUMENTS (Tables)

6 Months Ended

Jun. 30, 2018

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Notional Amount of Derivatives Instruments

The following presents the notional amount of derivatives instruments as of the dates indicated (in thousands):

	June 30, 2018		December 31, 2017
Derivatives designated as cash flow hedges:
Denominated in U.S. Dollars	$	845,000	$	845,000
Denominated in Canadian Dollars	$	125,000	$	125,000
Derivatives designated as net investment hedges:
Denominated in Canadian Dollars	$	56,300	$	56,300
Financial instrument designated as net investment hedge:
Denominated in Canadian Dollars	$	125,000	$	125,000

Derivative and Financial Instruments Designated as Hedging Instruments

The following is a summary of the derivative and financial instruments designated as hedging instruments held by the Company at June 30, 2018 and December 31, 2017 (dollars in thousands):    

		Count as of June 30, 2018	Fair Value				Maturity Dates
Type	Designation		June 30, 2018		December 31, 2017			Balance Sheet Location
Assets:
Interest rate swaps	Cash flow	12	$	35,719	$	25,221	2020 - 2023	Accounts receivable, prepaid expenses and other assets, net
Cross currency interest rate swaps	Net investment	2	2,146		674		2025	Accounts receivable, prepaid expenses and other assets, net
			$	37,865	$	25,895
Liabilities:
CAD term loan	Net investment	1	95,163		99,588		2022	Term loans, net
			$	95,163	$	99,588

Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity

The following presents the effect of the Company’s derivative and financial instruments designated as hedging instruments on the condensed consolidated statements of income and the condensed consolidated statements of equity for the three and six months ended June 30, 2018 and 2017 (in thousands):

	Gain (Loss) Recognized in Other Comprehensive Income
	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017			Income Statement Location
Cash Flow Hedges:
Interest rate products	$	4,009	$	(136	)	$	13,132	$	125		Interest expense
Net Investment Hedges:
Foreign currency products	898		(242		)	1,505		(1,159		)	N/A
CAD term loan	1,750		(2,513		)	4,425		(3,288		)	N/A
	$	6,657	$	(2,891	)	$	19,062	$	(4,322	)

	Gain (Loss) Reclassified from Accumulated Other Comprehensive Income into Income
	Three Months Ended June 30,					Six Months Ended June 30,
	2018		2017			2018		2017			Income Statement Location
Cash Flow Hedges:
Interest rate products	$	633	$	(399	)	$	583	$	(869	)	Interest expense
Net Investment Hedges:
Foreign currency products	—		—			—		—			N/A
CAD term loan	—		—			—		—			N/A
	$	633	$	(399	)	$	583	$	(869	)

Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Assets

The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of June 30, 2018 and December 31, 2017 (in thousands):

	As of June 30, 2018
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	37,865	$	—	$	37,865	$	—	$	—	$	37,865
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

	As of December 31, 2017
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	25,895	$	—	$	25,895	$	—	$	—	$	25,895
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives - Liabilities

The table below presents a gross presentation, the effects of offsetting, and a net presentation of the Company’s derivatives as of June 30, 2018 and December 31, 2017 (in thousands):

	As of June 30, 2018
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	37,865	$	—	$	37,865	$	—	$	—	$	37,865
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

	As of December 31, 2017
	Gross Amounts of Recognized Assets / Liabilities		Gross Amounts Offset in the Balance Sheet		Net Amounts of Assets / Liabilities presented in the Balance Sheet		Gross Amounts Not Offset in the Balance Sheet
							Financial Instruments		Cash Collateral Received		Net Amount
Offsetting Assets:
Derivatives	$	25,895	$	—	$	25,895	$	—	$	—	$	25,895
Offsetting Liabilities:
Derivatives	$	—	$	—	$	—	$	—	$	—	$	—

XML

FAIR VALUE DISCLOSURES (Tables)

6 Months Ended

Jun. 30, 2018

Fair Value Disclosures [Abstract]

Face Values, Carrying Amounts and Fair Values of Financial Instruments

The following are the face values, carrying amounts and fair values of the Company’s financial instruments as of June 30, 2018 and December 31, 2017 whose carrying amounts do not approximate their fair value (in thousands):

	June 30, 2018						December 31, 2017
	Face Value (1)		Carrying Amount (2)		Fair Value		Face Value (1)		Carrying Amount (2)		Fair Value
Financial assets:
Loans receivable	$	80,687	$	55,880	$	58,656	$	91,280	$	65,907	$	65,892
Preferred equity investments	50,856		51,348		50,787		48,035		48,483		47,064
Financial liabilities:
Senior Notes	1,300,000		1,306,842		1,292,347		1,300,000		1,306,286		1,329,191
Secured indebtedness	256,281		253,567		236,862		259,202		256,430		246,461

⁽¹⁾  Face value represents amounts contractually due under the terms of the respective agreements.

⁽²⁾  Carrying amount represents the book value of financial instruments, including unamortized premiums/discounts and deferred financing costs.

Fair Value of Financial Instruments

The Company determined the fair value of financial instruments as of June 30, 2018 whose carrying amounts do not approximate their fair value with valuation methods utilizing the following types of inputs (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Financial assets:
Loans receivable	$	58,656	$	—	$	—	$	58,656
Preferred equity investments	50,787		—		—		50,787
Financial liabilities:
Senior Notes	1,292,347		—		1,292,347		—
Secured indebtedness	236,862		—		—		236,862

Items Measured at Fair Value on a Recurring Basis

During the six months ended June 30, 2018, the Company recorded the following amounts measured at fair value (in thousands):

			Fair Value Measurements Using
			Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
	Total
Recurring Basis:
Financial assets:
Interest rate swap	$	35,719	$	—	$	35,719	$	—
Cross currency swap	2,146		—		2,146		—

XML

EQUITY (Tables)

6 Months Ended

Jun. 30, 2018

Equity [Abstract]

Cash Dividends on Common Stock Declared and Paid

The following table lists the cash dividends on common stock declared and paid by the Company during the six months ended June 30, 2018:

Declaration Date	Record Date	Amount Per Share		Dividend Payable Date
February 5, 2018	February 15, 2018	$	0.45	February 28, 2018
May 9, 2018	May 21, 2018	$	0.45	May 31, 2018

Accumulated Other Comprehensive Income

The following is a summary of the Company’s accumulated other comprehensive income (in thousands):

	June 30, 2018			December 31, 2017
Foreign currency translation loss	$	(3,026	)	$	(2,913	)
Unrealized gains on cash flow hedges	27,438			14,202
Total accumulated other comprehensive income	$	24,412		$	11,289

XML

EARNINGS PER COMMON SHARE (Tables)

6 Months Ended

Jun. 30, 2018

Earnings Per Share [Abstract]

Computation of Basic and Diluted Earnings Per Share

The following table illustrates the computation of basic and diluted earnings per share for the three and six months ended June 30, 2018 and 2017 (in thousands, except share and per share amounts):

	Three Months Ended June 30,				Six Months Ended June 30,
	2018		2017		2018		2017
Numerator
Net income attributable to common stockholders	$	193,580	$	17,960	$	253,490	$	34,222
Denominator
Basic weighted average common shares and common equivalents	178,314,750		65,438,739		178,304,733		65,396,146
Dilutive restricted stock units	369,274		232,114		296,056		297,873
Diluted weighted average common shares	178,684,024		65,670,853		178,600,789		65,694,019
Net income attributable to common stockholders, per:
Basic common share	$	1.09	$	0.27	$	1.42	$	0.52
Diluted common share	$	1.08	$	0.27	$	1.42	$	0.52

XML

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION (Tables)

6 Months Ended

Jun. 30, 2018

Summarized Condensed Consolidating Information [Abstract]

Condensed Consolidating Balance Sheet

CONDENSED CONSOLIDATING BALANCE SHEET

June 30, 2018

(in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)		Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	341		$	—	$	—	$	1,666,116	$	4,327,225	$	—		$	5,993,682
Loans receivable and other investments, net	(356		)	—		—		52,315		55,269		—			107,228
Investment in unconsolidated joint venture	—			—		—		—		348,950		—			348,950
Cash and cash equivalents	31,269			—		—		1,405		6,135		—			38,809
Restricted cash	—			—		—		174,913		11,932		—			186,845
Lease intangible assets, net	—			—		—		16,815		139,451		—			156,266
Accounts receivable, prepaid expenses and other assets, net	(536		)	46,700		—		84,809		73,017		(7,626		)	196,364
Intercompany	2,186,044			2,727,032		—		—		—		(4,913,076		)	—
Investment in subsidiaries	1,209,953			1,538,155		—		15,830		—		(2,763,938		)	—
Total assets	$	3,426,715		$	4,311,887	$	—	$	2,012,203	$	4,961,979	$	(7,684,640	)	$	7,028,144
Liabilities
Secured debt, net	$	—		$	—	$	—	$	—	$	253,567	$	—		$	253,567
Revolving credit facility	—			676,000		—		—		—		—			676,000
Term loans, net	—			1,093,314		—		94,084		—		—			1,187,398
Senior unsecured notes, net	—			1,306,842		—		—		—		—			1,306,842
Accounts payable and accrued liabilities	23,172			25,778		—		3,576		60,439		(7,626		)	105,339
Lease intangible liabilities, net	—			—		—		—		91,073		—			91,073
Intercompany	—			—		—		636,037		4,277,039		(4,913,076		)	—
Total liabilities	23,172			3,101,934		—		733,697		4,682,118		(4,920,702		)	3,620,219
Total Sabra Health Care REIT, Inc. stockholders' equity	3,403,543			1,209,953		—		1,278,506		275,479		(2,763,938		)	3,403,543
Noncontrolling interests	—			—		—		—		4,382		—			4,382
Total equity	3,403,543			1,209,953		—		1,278,506		279,861		(2,763,938		)	3,407,925
Total liabilities and equity	$	3,426,715		$	4,311,887	$	—	$	2,012,203	$	4,961,979	$	(7,684,640	)	$	7,028,144

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING BALANCE SHEET

December 31, 2017

(in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)		Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Assets
Real estate investments, net of accumulated depreciation	$	324		$	—	$	—	$	1,756,933	$	4,237,175	$	—		$	5,994,432
Loans receivable and other investments, net	(97		)	—		—		55,297		59,190		—			114,390
Cash and cash equivalents	511,670			—		—		449		6,513		—			518,632
Restricted cash	—			—		—		36,910		31,907		—			68,817
Lease intangible assets, net	—			—		—		17,577		149,542		—			167,119
Accounts receivable, prepaid expenses and other assets, net	3,499			36,073		—		80,739		53,765		(5,189		)	168,887
Intercompany	2,043,402			2,721,979		—		—		—		(4,765,381		)	—
Investment in subsidiaries	890,462			1,198,305		—		14,661		—		(2,103,428		)	—
Total assets	$	3,449,260		$	3,956,357	$	—	$	1,962,566	$	4,538,092	$	(6,873,998	)	$	7,032,277
Liabilities
Secured debt, net	$	—		$	—	$	—	$	—	$	256,430	$	—		$	256,430
Revolving credit facility	—			641,000		—		—		—		—			641,000
Term loans, net	—			1,092,397		—		98,377		—		—			1,190,774
Senior unsecured notes, net	—			1,306,286		—		—		—		—			1,306,286
Accounts payable and accrued liabilities	16,453			26,212		—		3,560		61,487		(5,189		)	102,523
Lease intangible liabilities, net	—			—		—		—		98,015		—			98,015
Intercompany	—			—		—		785,120		3,980,261		(4,765,381		)	—
Total liabilities	16,453			3,065,895		—		887,057		4,396,193		(4,770,570		)	3,595,028
Total Sabra Health Care REIT, Inc. stockholders' equity	3,432,807			890,462		—		1,075,509		137,457		(2,103,428		)	3,432,807
Noncontrolling interests	—			—		—		—		4,442		—			4,442
Total equity	3,432,807			890,462		—		1,075,509		141,899		(2,103,428		)	3,437,249
Total liabilities and equity	$	3,449,260		$	3,956,357	$	—	$	1,962,566	$	4,538,092	$	(6,873,998	)	$	7,032,277

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Condensed Consolidating Statement of Income

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Three Months EndedJune 30, 2018

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	44,560		$	103,989		$	(4,320	)	$	144,229
Interest and other income	40			96			—		1,198			3,315			(96		)	4,553
Resident fees and services	—			—			—		—			17,530			—			17,530
Total revenues	40			96			—		45,758			124,834			(4,416		)	166,312
Expenses:
Depreciation and amortization	222			—			—		14,146			32,460			—			46,828
Interest	—			33,415			—		810			2,628			(96		)	36,757
Operating expenses	—			—			—		—			16,619			(4,320		)	12,299
General and administrative	8,009			14			—		379			869			—			9,271
Merger and acquisition costs	112			—			—		—			—			—			112
Provision for (recovery of) doubtful accounts and loan losses	311			—			—		(985		)	—			—			(674		)
Impairment of real estate	—			—			—		881			—			—			881
Total expenses	8,654			33,429			—		15,231			52,576			(4,416		)	105,474
Other income:
Other income (expense)	—			32			—		(32		)	—			—			—
Net gain on sales of real estate	—			—			—		141,918			985			—			142,903
Total other income	—			32			—		141,886			985			—			142,903
Income in subsidiary	209,456			242,758			—		1,871			—			(454,085		)	—
Income before loss from unconsolidated joint venture and income tax expense	200,842			209,457			—		174,284			73,243			(454,085		)	203,741
Loss from unconsolidated joint venture	—			—			—		—			(2,347		)	—			(2,347		)
Income tax expense	(55		)	(1		)	—		(489		)	(60		)	—			(605		)
Net income	200,787			209,456			—		173,795			70,836			(454,085		)	200,789
Net income attributable to noncontrolling interests	—			—			—		—			(2		)	—			(2		)
Net income attributable to Sabra Health Care REIT, Inc.	200,787			209,456			—		173,795			70,834			(454,085		)	200,787
Preferred stock dividends	(7,207		)	—			—		—			—			—			(7,207		)
Net income attributable to common stockholders	$	193,580		$	209,456		$	—	$	173,795		$	70,834		$	(454,085	)	$	193,580
Net income attributable to common stockholders, per:
Basic common share																		$	1.09
Diluted common share																		$	1.08
Weighted-average number of common shares outstanding, basic																		178,314,750
Weighted-average number of common shares outstanding, diluted																		178,684,024

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Three Months EndedJune 30, 2017

(dollars in thousands, except per share amounts)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—	$	—	$	52,442		$	4,656		$	(1,194	)	$	55,904
Interest and other income	6			—		—		2,039			—			(18		)	2,027
Resident fees and services	—			—		—		—			6,805			—			6,805
Total revenues	6			—		—		54,481			11,461			(1,212		)	64,736
Expenses:
Depreciation and amortization	216			—		—		15,425			1,579			—			17,220
Interest	—			13,516		—		715			1,631			—			15,862
Operating expenses	—			—		—		—			5,619			(1,212		)	4,407
General and administrative	4,063			17		—		991			55			—			5,126
Merger and acquisition costs	5,883			—		—		4			—			—			5,887
Provision for doubtful accounts and loan losses	227			—		—		308			—			—			535
Total expenses	10,389			13,533		—		17,443			8,884			(1,212		)	49,037
Other income (expense):
Other income (expense)	916			703		—		(665		)	(13		)	—			941
Net gain on sales of real estate	—			—		—		4,026			6			—			4,032
Total other income (expense)	916			703		—		3,361			(7		)	—			4,973
Income in subsidiary	29,894			42,724		—		1,785			—			(74,403		)	—
Income before income tax benefit (expense)	20,427			29,894		—		42,184			2,570			(74,403		)	20,672
Income tax benefit (expense)	93			—		—		(227		)	(2		)	—			(136		)
Net income	20,520			29,894		—		41,957			2,568			(74,403		)	20,536
Net income attributable to noncontrolling interests	—			—		—		—			(16		)	—			(16		)
Net income attributable to Sabra Health Care REIT, Inc.	20,520			29,894		—		41,957			2,552			(74,403		)	20,520
Preferred stock dividends	(2,560		)	—		—		—			—			—			(2,560		)
Net income attributable to common stockholders	$	17,960		$	29,894	$	—	$	41,957		$	2,552		$	(74,403	)	$	17,960
Net income attributable to common stockholders, per:
Basic common share																	$	0.27
Diluted common share																	$	0.27
Weighted-average number of common shares outstanding, basic																	65,438,739
Weighted-average number of common shares outstanding, diluted																	65,670,853

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Six Months EndedJune 30, 2018

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	90,024		$	207,013		$	(8,553	)	$	288,484
Interest and other income	50			208			—		2,465			6,376			(208		)	8,891
Resident fees and services	—			—			—		—			35,023			—			35,023
Total revenues	50			208			—		92,489			248,412			(8,761		)	332,398
Expenses:
Depreciation and amortization	443			—			—		29,076			65,314			—			94,833
Interest	—			65,980			—		1,601			5,202			(208		)	72,575
Operating expenses	—			—			—		—			32,976			(8,553		)	24,423
General and administrative	13,831			29			—		810			2,468			—			17,138
Merger and acquisition costs	448			—			—		—			(6		)	—			442
Provision for (recovery of) doubtful accounts and loan losses	2,492			—			—		(1,956		)	3			—			539
Impairment of real estate	—			—			—		1,413			—			—			1,413
Total expenses	17,214			66,009			—		30,944			105,957			(8,761		)	211,363
Other income:
Other income	1,977			233			—		378			232			—			2,820
Net gain on sales of real estate	—			—			—		141,862			569			—			142,431
Total other income	1,977			233			—		142,240			801			—			145,251
Income in subsidiary	278,798			344,367			—		3,725			—			(626,890		)	—
Income before loss from unconsolidated joint venture and income tax expense	263,611			278,799			—		207,510			143,256			(626,890		)	266,286
Loss from unconsolidated joint venture	—			—			—		—			(1,901		)	—			(1,901		)
Income tax expense	(353		)	(1		)	—		(542		)	(219		)	—			(1,115		)
Net income	263,258			278,798			—		206,968			141,136			(626,890		)	263,270
Net income attributable to noncontrolling interests	—			—			—		—			(12		)	—			(12		)
Net income attributable to Sabra Health Care REIT, Inc.	263,258			278,798			—		206,968			141,124			(626,890		)	263,258
Preferred stock dividends	(9,768		)	—			—		—			—			—			(9,768		)
Net income attributable to common stockholders	$	253,490		$	278,798		$	—	$	206,968		$	141,124		$	(626,890	)	$	253,490
Net income attributable to common stockholders, per:
Basic common share																		$	1.42
Diluted common share																		$	1.42
Weighted-average number of common shares outstanding, basic																		178,304,733
Weighted-average number of common shares outstanding, diluted																		178,600,789

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF INCOME

For the Six Months EndedJune 30, 2017

(dollars in thousands, except per share amounts)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Revenues:
Rental income	$	—		$	—		$	—	$	105,481		$	9,625		$	(1,978	)	$	113,128
Interest and other income	13			—			—		3,977			—			(18		)	3,972
Resident fees and services	—			—			—		—			10,286			—			10,286
Total revenues	13			—			—		109,458			19,911			(1,996		)	127,386
Expenses:
Depreciation and amortization	432			—			—		32,381			3,544			—			36,357
Interest	—			26,924			—		1,445			3,281			—			31,650
Operating expenses	—			—			—		—			8,823			(1,996		)	6,827
General and administrative	9,322			31			—		1,758			104			—			11,215
Merger and acquisition costs	6,417			—			—		34			—			—			6,451
Provision for doubtful accounts and loan losses	82			—			—		2,223			—			—			2,305
Total expenses	16,253			26,955			—		37,841			15,752			(1,996		)	94,805
Other income:
Other income	2,283			737			—		50			—			—			3,070
Net gain on sales of real estate	—			—			—		4,026			6			—			4,032
Total other income	2,283			737			—		4,076			6			—			7,102
Income in subsidiary	53,331			79,550			—		3,564			—			(136,445		)	—
Income before income tax expense	39,374			53,332			—		79,257			4,165			(136,445		)	39,683
Income tax expense	(31		)	(1		)	—		(227		)	(97		)	—			(356		)
Net income	39,343			53,331			—		79,030			4,068			(136,445		)	39,327
Net loss attributable to noncontrolling interests	—			—			—		—			16			—			16
Net income attributable to Sabra Health Care REIT, Inc.	39,343			53,331			—		79,030			4,084			(136,445		)	39,343
Preferred stock dividends	(5,121		)	—			—		—			—			—			(5,121		)
Net income attributable to common stockholders	$	34,222		$	53,331		$	—	$	79,030		$	4,084		$	(136,445	)	$	34,222
Net income attributable to common stockholders, per:
Basic common share																		$	0.52
Diluted common share																		$	0.52
Weighted-average number of common shares outstanding, basic																		65,396,146
Weighted-average number of common shares outstanding, diluted																		65,694,019

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Condensed Consolidating Statement of Comprehensive Income

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months EndedJune 30, 2018

(dollars in thousands)

(unaudited)

					Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	200,787	$	209,456	$	—	$	173,795		$	70,836		$	(454,085	)	$	200,789
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		1,064		—		(608		)	(195		)	—			261
Unrealized gain on cash flow hedges	—		3,335		—		3			—			—			3,338
Total other comprehensive income (loss)	—		4,399		—		(605		)	(195		)	—			3,599
Comprehensive income	200,787		213,855		—		173,190			70,641			(454,085		)	204,388
Comprehensive income attributable to noncontrolling interest	—		—		—		—			(2		)	—			(2		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	200,787	$	213,855	$	—	$	173,190		$	70,639		$	(454,085	)	$	204,386

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Three Months EndedJune 30, 2017

(dollars in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	20,520	$	29,894		$	—	$	41,957		$	2,568		$	(74,403	)	$	20,536
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(415		)	—		833			280			—			698
Unrealized gain (loss) on cash flow hedges	—		285			—		(188		)	—			—			97
Total other comprehensive (loss) income	—		(130		)	—		645			280			—			795
Comprehensive income	20,520		29,764			—		42,602			2,848			(74,403		)	21,331
Comprehensive income attributable to noncontrolling interest	—		—			—		—			(16		)	—			(16		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	20,520	$	29,764		$	—	$	42,602		$	2,832		$	(74,403	)	$	21,315

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Six Months EndedJune 30, 2018

(dollars in thousands)

(unaudited)

					Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)		Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net income	$	263,258	$	278,798	$	—	$	206,968		$	141,136		$	(626,890	)	$	263,270
Other comprehensive income (loss):
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	—		1,905		—		(1,536		)	(482		)	—			(113		)
Unrealized gain (loss) on cash flow hedges	—		13,238		—		(2		)	—			—			13,236
Total other comprehensive income (loss)	—		15,143		—		(1,538		)	(482		)	—			13,123
Comprehensive income	263,258		293,941		—		205,430			140,654			(626,890		)	276,393
Comprehensive income attributable to noncontrolling interest	—		—		—		—			(12		)	—			(12		)
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	263,258	$	293,941	$	—	$	205,430		$	140,642		$	(626,890	)	$	276,381

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF COMPREHENSIVE INCOME

For the Six Months EndedJune 30, 2017

(dollars in thousands)

(unaudited)

						Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)		Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)		Elimination			Consolidated
Net income	$	39,343	$	53,331		$	—	$	79,030		$	4,068	$	(136,445	)	$	39,327
Other comprehensive (loss) income:
Unrealized gain (loss), net of tax:
Foreign currency translation (loss) gain	—		(1,367		)	—		1,131			376		—			140
Unrealized gain (loss) on cash flow hedges	—		1,013			—		(188		)	—		—			825
Total other comprehensive (loss) income	—		(354		)	—		943			376		—			965
Comprehensive income	39,343		52,977			—		79,973			4,444		(136,445		)	40,292
Comprehensive loss attributable to noncontrolling interest	—		—			—		—			16		—			16
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$	39,343	$	52,977		$	—	$	79,973		$	4,460	$	(136,445	)	$	40,308

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

Condensed Consolidating Statement of Cash Flows

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2018

(in thousands)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net cash provided by operating activities	$	204,440		$	—		$	—	$	1,041		$	6,072		$	—		$	211,553
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(29,711		)	(184,271		)	—			(213,982		)
Origination and fundings of loans receivable	—			—			—		(1,973		)	(26,184		)	—			(28,157		)
Origination and fundings of preferred equity investments	—			—			—		(945		)	—			—			(945		)
Additions to real estate	(40		)	—			—		(4,660		)	(12,117		)	—			(16,817		)
Repayments of loans receivable	—			—			—		6,577			32,310			—			38,887
Repayments of preferred equity investments	—			—			—		375			—			—			375
Investment in unconsolidated JV	—			—			—		—			(354,461		)	—			(354,461		)
Net proceeds from the sales of real estate	—			—			—		232,059			46,142			—			278,201
Distribution from subsidiaries	2,669			2,669			—		—			—			(5,338		)	—
Intercompany financing	(378,485		)	(413,473		)	—		—			—			791,958			—
Net cash (used in) provided by investing activities	(375,856		)	(410,804		)	—		201,722			(498,581		)	786,620			(296,899		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			35,000			—		—			—			—			35,000
Principal payments on secured debt	—			—			—		—			(2,128		)	—			(2,128		)
Payments of deferred financing costs	—			(12		)	—		—			—			—			(12		)
Distributions to noncontrolling interest	—			—			—		—			(72		)	—			(72		)
Preferred stock redemption	(143,750		)	—			—		—			—			—			(143,750		)
Issuance of common stock, net	(499		)	—			—		—			—			—			(499		)
Dividends paid on common and preferred stock	(164,736		)	—			—		—			—			—			(164,736		)
Distribution to parent	—			(2,669		)	—		—			(2,669		)	5,338			—
Intercompany financing	—			378,485			—		(63,658		)	477,131			(791,958		)	—
Net cash (used in) provided by financing activities	(308,985		)	410,804			—		(63,658		)	472,262			(786,620		)	(276,197		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(480,401		)	—			—		139,105			(20,247		)	—			(361,543		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		(146		)	(106		)	—			(252		)
Cash, cash equivalents and restricted cash, beginning of period	511,670			—			—		37,359			38,420			—			587,449
Cash, cash equivalents and restricted cash, end of period	$	31,269		$	—		$	—	$	176,318		$	18,067		$	—		$	225,654

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

CONDENSED CONSOLIDATING STATEMENT OF CASH FLOWS

For the Six Months Ended June 30, 2017

(in thousands)

(unaudited)

							Combined Non-Guarantor Subsidiaries of 2026 Notes(6)
	Parent Company(1)			Operating Partnership(2)			Sabra Capital Corporation(3)		Combined Guarantor Subsidiaries of 2021 Notes and 2023 Notes(4)			Combined Non- Guarantor Subsidiaries of 2021 Notes and 2023 Notes(5)			Elimination			Consolidated
Net cash provided by (used in) operating activities	$	49,670		$	—		$	—	$	(1,693	)	$	6,305		$	—		$	54,282
Cash flows from investing activities:
Acquisition of real estate	—			—			—		(14,456		)	—			—			(14,456		)
Origination and fundings of loans receivable	—			—			—		(927		)	—			—			(927		)
Origination and fundings of preferred equity investments	—			—			—		(76		)	—			—			(76		)
Additions to real estate	(12		)	—			—		(1,106		)	(176		)	—			(1,294		)
Repayments of loans receivable	—			—			—		1,547			—			—			1,547
Repayments of preferred equity investments	—			—			—		2,766			—			—			2,766
Net proceeds from the sale of real estate	—			—			—		6,099			—			—			6,099
Distribution from subsidiaries	2,474			2,474			—		—			—			(4,948		)	—
Intercompany financing	(1,667		)	(7,543		)	—		—			—			9,210			—
Net cash provided by (used in) investing activities	795			(5,069		)	—		(6,153		)	(176		)	4,262			(6,341		)
Cash flows from financing activities:
Net borrowings from revolving credit facility	—			6,000			—		—			—			—			6,000
Principal payments on secured debt	—			—			—		—			(2,049		)	—			(2,049		)
Payments of deferred financing costs	—			(124		)	—		—			—			—			(124		)
Issuance of common stock, net	(3,224		)	—			—		—			—			—			(3,224		)
Dividends paid on common and preferred stock	(60,691		)	—			—		—			—			—			(60,691		)
Distribution to parent	—			(2,474		)	—		—			(2,474		)	4,948			—
Intercompany financing	—			1,667			—		7,543			—			(9,210		)	—
Net cash (used in) provided by financing activities	(63,915		)	5,069			—		7,543			(4,523		)	(4,262		)	(60,088		)
Net (decrease) increase in cash, cash equivalents and restricted cash	(13,450		)	—			—		(303		)	1,606			—			(12,147		)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	—			—			—		69			61			—			130
Cash, cash equivalents and restricted cash, beginning of period	18,168			—			—		2,732			13,765			—			34,665
Cash, cash equivalents and restricted cash, end of period	$	4,718		$	—		$	—	$	2,498		$	15,432		$	—		$	22,648

⁽¹⁾  The Parent Company guarantees the 2021 Notes, the 2023 Notes and the 2026 Notes.

⁽²⁾  The Operating Partnership is the co-issuer of the 2021 Notes and the 2023 Notes and the issuer of the 2026 Notes.

⁽³⁾  Sabra Capital Corporation is the co-issuer of the 2021 Notes and the 2023 Notes.

⁽⁴⁾  The Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2021 Notes and the 2023 Notes.

⁽⁵⁾  The Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes consist of the subsidiaries that do not guarantee the 2021 Notes and the 2023 Notes.

⁽⁶⁾  None of Sabra Capital Corporation, the Combined Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes, nor the Combined Non-Guarantor Subsidiaries of the 2021 Notes and the 2023 Notes guarantee the 2026 Notes.

XML

BUSINESS (Details) - $ / shares	Aug. 17, 2017	Jun. 30, 2018	Dec. 31, 2017
Business [Line Items]
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01	$ 0.01
Care Capital Properties
Business [Line Items]
Common stock, par value (in dollars per share)	$ 0.01
Shares of Sabra common stock issued per share of CCP common stock (in shares)	1.123

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Principles of Consolidation and Basis of Presentation (Details)	6 Months Ended
	Jun. 30, 2018 variable_interest_entity Investment
Variable Interest Entity [Line Items]
Number of investments in loans accounted for as real estate joint ventures | Investment	0
Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	2
Exchange Accommodation Titleholder | Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	1
Skilled Nursing Transitional Care Facilities | Primary Beneficiary
Variable Interest Entity [Line Items]
Number of VIEs	1

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Investment in Unconsolidated Joint Venture (Details) $ in Thousands	Jan. 02, 2018 USD ($) Property director	Jun. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)
Schedule of Equity Method Investments [Line Items]
Investment in joint venture		$ 348,950	$ 0
Enlivant Joint Venture
Schedule of Equity Method Investments [Line Items]
Number of properties | Property	172
Enlivant Joint Venture
Schedule of Equity Method Investments [Line Items]
Cash contributed to acquire equity interests	$ 352,700
Equity interest in joint venture	49.00%
Outstanding indebtedness	$ 791,300
Net working capital	22,900
Aggregate portfolio value	$ 1,490,000
Number of directors appointed by Sabra | director	3
Number of directors on board | director	7
Investment in joint venture		$ 349,000

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Net Investment in Direct Financing Lease (Details) - Skilled Nursing Transitional Care Facilities $ in Millions	3 Months Ended	6 Months Ended
	Jun. 30, 2018 USD ($) Property	Jun. 30, 2018 USD ($) Property
Lessor, Lease, Description [Line Items]
Net investment in direct financing lease	$ 23.2	$ 23.2
Number of properties in direct financing lease | Property	1	1
Lease income	$ 0.6	$ 1.3
Minimum lease payments contractually due under direct financing leases
Due for the remainder of 2018	1.1	1.1
Due in 2019	2.2	2.2
Due in 2020	2.3	2.3
Due in 2021	$ 2.1	$ 2.1

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Changes in Cash Flows Due to Adoption of ASU 2016-15 (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Dec. 31, 2017	Dec. 31, 2016
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net cash provided by (used in) operating activities	$ 211,553	$ 54,282
Net decrease in balance	(361,543)	(12,147)
Balance	$ 225,654	22,648	$ 587,449	$ 34,665
As Previously Reported
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Net cash provided by (used in) operating activities		53,871
Net decrease in balance		(12,558)
Balance		$ 13,235		$ 25,663

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recently Issued Accounting Update (Details) $ in Thousands	Dec. 31, 2017 USD ($)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cumulative effect of ASU 2017-12 adoption	$ 0
Accumulated Other Comprehensive Income (Loss)
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cumulative effect of ASU 2017-12 adoption	795
Accumulated Other Comprehensive Income (Loss) | Accounting Standards Update 2017-12
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cumulative effect of ASU 2017-12 adoption	800
Cumulative Distributions in Excess of Net Income
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cumulative effect of ASU 2017-12 adoption	(795)
Cumulative Distributions in Excess of Net Income | Accounting Standards Update 2017-12
Error Corrections and Prior Period Adjustments Restatement [Line Items]
Cumulative effect of ASU 2017-12 adoption	$ (800)

XML

CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS - Narrative (Details) $ in Thousands							3 Months Ended		6 Months Ended
	Aug. 17, 2017 USD ($)	Aug. 17, 2017 USD ($) Property	Aug. 17, 2017 USD ($) shares	Aug. 17, 2017 USD ($) direct_financing_lease_property	Aug. 17, 2017 USD ($) firm	Aug. 17, 2017 USD ($) Investment	Jun. 30, 2018 USD ($)	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) Facilitiy	Jun. 30, 2017 USD ($) Facilitiy
Care Capital Properties
Business Acquisition [Line Items]
Shares of Sabra common stock issued per share of CCP common stock (in shares) | shares			1.123
Shares of common stock issued in merger (in shares) | shares			94,000,000
Number of acquired properties | Property		330
Number of loan receivable investments acquired | Investment						18
Number of specialty valuation firms | firm					1
Fair value of consideration exchanged or assumed	$ 2,052,578	$ 2,052,578	$ 2,052,578	$ 2,052,578	$ 2,052,578	$ 2,052,578
Care Capital Properties | Lease Intangible Assets and Liabilities
Business Acquisition [Line Items]
Weighted average amortization period of finite-lived intangible assets	10 years
Weighted average amortization period of finite-lived intangible liabilities	10 years
Care Capital Properties | Skilled Nursing/Transitional Care
Business Acquisition [Line Items]
Number of acquired properties		296		1
Care Capital Properties | Senior Housing Facilities
Business Acquisition [Line Items]
Number of acquired properties | Property		13
Care Capital Properties | Specialty Hospitals and Other
Business Acquisition [Line Items]
Number of acquired properties | Property		21
Recent Real Estate Acquisitions
Business Acquisition [Line Items]
Fair value of consideration exchanged or assumed							$ 213,983	$ 14,456	$ 213,983	$ 14,456
Total revenues							10,700	100	20,400	100
Net income attributable to common stockholders							$ 1,600	$ 100	$ 2,500	$ 100
Recent Real Estate Acquisitions | Tenant Origination and Absorption Costs
Business Acquisition [Line Items]
Weighted average amortization period of finite-lived intangible assets									13 years	15 years
Recent Real Estate Acquisitions | Tenant Relationship
Business Acquisition [Line Items]
Weighted average amortization period of finite-lived intangible assets									22 years	25 years
Recent Real Estate Acquisitions | Skilled Nursing/Transitional Care
Business Acquisition [Line Items]
Number of acquired properties | Facilitiy									2
Recent Real Estate Acquisitions | Senior Housing Facilities
Business Acquisition [Line Items]
Number of acquired properties | Facilitiy									5	1
Recent Real Estate Acquisitions | Senior Housing - Managed
Business Acquisition [Line Items]
Number of acquired properties | Facilitiy									11

XML

CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS - Purchase Price Allocation for CCP Merger (Details) - Care Capital Properties $ in Thousands	Aug. 17, 2017 USD ($)
Business Acquisition [Line Items]
Real estate investments	$ 3,727,310
Loans receivable and other investments	58,244
Cash and cash equivalents	77,859
Restricted cash	779
Lease intangible assets, net	145,786
Accounts receivable, prepaid expenses and other assets, net	35,873
Secured debt, net	(98,500)
Revolving credit facility	(362,000)
Unsecured term loans	(674,000)
Senior unsecured notes, net	(616,873)
Accounts payable and accrued liabilities	(134,802)
Lease intangible liabilities, net	(102,643)
Noncontrolling interests	(4,455)
Total consideration	$ 2,052,578

XML

CCP MERGER AND RECENT REAL ESTATE ACQUISITIONS - Purchase Price Allocation for Recent Real Estate Acquisitions (Details) - Recent Real Estate Acquisitions - USD ($) $ in Thousands	Jun. 30, 2018	Jun. 30, 2017
Business Acquisition [Line Items]
Land	$ 24,356	$ 1,034
Building and improvements	187,903	13,128
Total consideration	213,983	14,456
Tenant Origination and Absorption Costs
Business Acquisition [Line Items]
Tenant intangible assets	1,312	223
Tenant Relationship
Business Acquisition [Line Items]
Tenant intangible assets	$ 412	$ 71

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Real Estate Properties Held for Investment (Details) $ in Thousands	Jun. 30, 2018 USD ($) Bed Facilitiy	Dec. 31, 2017 USD ($) Bed Facilitiy
Real Estate Properties [Line Items]
Building and improvements	$ 5,489,087	$ 5,449,415
Furniture and equipment	236,838	232,889
Land improvements	1,971	3,456
Land	642,945	649,095
Total Real Estate at Cost	6,370,841	6,334,855
Accumulated Depreciation	(377,159)	(340,423)
Total Real Estate Investments, Net	$ 5,993,682	$ 5,994,432
Operating Segments
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	487	507
Number of Beds/Units | Bed	50,030	53,558
Total Real Estate at Cost	$ 6,370,208	$ 6,334,262
Accumulated Depreciation	(376,867)	(340,154)
Total Real Estate Investments, Net	$ 5,993,341	$ 5,994,108
Operating Segments | Skilled Nursing/Transitional Care
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	352	384
Number of Beds/Units | Bed	40,077	43,223
Total Real Estate at Cost	$ 4,242,748	$ 4,364,387
Accumulated Depreciation	(223,777)	(209,039)
Total Real Estate Investments, Net	$ 4,018,971	$ 4,155,348
Operating Segments | Senior Housing - Leased
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	89	88
Number of Beds/Units | Bed	7,156	8,137
Total Real Estate at Cost	$ 1,200,923	$ 1,166,687
Accumulated Depreciation	(113,020)	(102,370)
Total Real Estate Investments, Net	$ 1,087,903	$ 1,064,317
Operating Segments | Senior Housing - Managed
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	24	13
Number of Beds/Units | Bed	1,712	1,113
Total Real Estate at Cost	$ 308,221	$ 189,120
Accumulated Depreciation	(15,961)	(12,125)
Total Real Estate Investments, Net	$ 292,260	$ 176,995
Operating Segments | Specialty Hospitals and Other
Real Estate Properties [Line Items]
Number of Properties | Facilitiy	22	22
Number of Beds/Units | Bed	1,085	1,085
Total Real Estate at Cost	$ 618,316	$ 614,068
Accumulated Depreciation	(24,109)	(16,620)
Total Real Estate Investments, Net	594,207	597,448
Corporate Level
Real Estate Properties [Line Items]
Total Real Estate at Cost	633	593
Accumulated Depreciation	(292)	(269)
Total Real Estate Investments, Net	$ 341	$ 324

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Operating Leases (Details) $ in Millions	6 Months Ended
	Jun. 30, 2018 USD ($) Facilitiy	Jan. 01, 2018 USD ($)	Dec. 31, 2017 USD ($)
Real Estate Properties [Line Items]
Security deposit liability	$ 17.9		$ 20.3
Letters of credit deposited	90.0		96.0
Tenant deposits for future real estate taxes, insurance expenditures, and tenant improvements	28.0		28.3
Reserve for unpaid cash rents	1.1		3.2
Reserve for accumulated straight-line rental income	$ 3.2		$ 12.4
Genesis
Real Estate Properties [Line Items]
Number of properties | Facilitiy	27
Reduction of annual base rent payable under operating leases		$ 19.0
Number of facilities expected to be sold | Facilitiy	19
Number of facilities expected to be retained | Facilitiy	8
Minimum
Real Estate Properties [Line Items]
Lease expiration period	1 year
Maximum
Real Estate Properties [Line Items]
Lease expiration period	15 years
Weighted Average
Real Estate Properties [Line Items]
Weighted average lease expiration period	9 years
Skilled Nursing Transitional Care Facilities | Disposed of by Sale | Genesis
Real Estate Properties [Line Items]
Number of facilities sold | Facilitiy	27
Senior Housing - Managed Communities | Operating Segments
Real Estate Properties [Line Items]
Number of properties | Facilitiy	24

XML

REAL ESTATE PROPERTIES HELD FOR INVESTMENT - Future Minimum Rental Payments Receivable for Properties Held for Investment Under Non-Cancelable Operating Leases (Details) $ in Thousands	Jun. 30, 2018 USD ($)
Operating Leases, Future Minimum Payments Receivable [Abstract]
July 1 through December 31, 2018	$ 260,307
2019	529,844
2020	522,304
2021	520,553
2022	512,680
Thereafter	3,083,776
Total	$ 5,429,464

XML

ASSET HELD FOR SALE DISPOSITIONS (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018 USD ($) Facilitiy	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) Facilitiy	Jun. 30, 2017 USD ($) Facilitiy	Jul. 02, 2018 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Real estate impairment	$ 881	$ 0	$ 1,413	$ 0
Skilled Nursing Transitional Care Facilities | Assets Held for Sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities held for sale | Facilitiy	1		1
Carrying value of assets and liabilities of facility	$ 6,000		$ 6,000
Skilled Nursing Transitional Care Facilities | Assets Held for Sale | Subsequent Event
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Aggregate sale price of facility					$ 7,000
2018 Dispositions | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Carrying value of assets and liabilities of facility	135,800		135,800
Aggregate sale price of facility	$ 278,300		278,300
Net gain on sale			$ 142,500
2018 Dispositions | Skilled Nursing Transitional Care Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | Facilitiy			33
Net income from facilities			$ 11,600	$ 15,400
2018 Dispositions | Senior Housing Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | Facilitiy			4
Real estate impairment			$ 500
Number of facilities sold with related impairment | Facilitiy			1
2017 Disposition | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of facilities sold | Facilitiy				1
Carrying value of assets and liabilities of facility		2,100		$ 2,100
Aggregate sale price of facility		$ 6,100		6,100
Net gain on sale				4,000
Selling expenses			$ 100
2017 Disposition | Skilled Nursing Transitional Care Facilities | Dispositions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Net income from facilities				$ 100

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Composition of Loans Receivable and Other Investments (Details) $ in Thousands	Jun. 30, 2018 USD ($) loan	Dec. 31, 2017 USD ($)
Loans Receivable:
Quantity | loan	22
Loans receivable	$ 80,687	$ 91,280
Book Value	$ 56,236	66,004
Weighted Average Contractual Interest Rate / Rate of Return	9.30%
Weighted Average Annualized Effective Interest Rate / Rate of Return	10.90%
Loan loss reserve	$ (356)	(97)
Loans receivable, net amount	$ 55,880	65,907
Other Investments:
Quantity | loan	13
Principal Balance	$ 50,856	48,035
Book Value	$ 51,348	48,483
Weighted Average Contractual Interest Rate / Rate of Return	12.60%
Weighted Average Annualized Effective Interest Rate / Rate of Return	12.60%
Total Quantity | loan	35
Total Principal Balance	$ 131,543
Total Book Value	$ 107,228	114,390
Total Weighted Average Contractual Interest Rate / Rate of Return	10.60%
Total Weighted Average Annualized Effective Interest Rate / Rate of Return	11.70%
Mortgage
Loans Receivable:
Quantity | loan	1
Loans receivable	$ 15,332
Book Value	$ 15,332	12,351
Weighted Average Contractual Interest Rate / Rate of Return	10.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	10.00%
Construction
Loans Receivable:
Quantity | loan	2
Loans receivable	$ 3,989
Book Value	$ 4,055	2,733
Weighted Average Contractual Interest Rate / Rate of Return	8.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	7.80%
Mezzanine
Loans Receivable:
Quantity | loan	1
Loans receivable	$ 25,000
Book Value	$ 2,301	10,239
Weighted Average Contractual Interest Rate / Rate of Return	10.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	41.90%
Pre-development
Loans Receivable:
Quantity | loan	1
Loans receivable	$ 2,357
Book Value	$ 2,357	2,357
Weighted Average Contractual Interest Rate / Rate of Return	9.00%
Weighted Average Annualized Effective Interest Rate / Rate of Return	8.40%
Other
Loans Receivable:
Quantity | loan	17
Loans receivable	$ 34,009
Book Value	$ 32,191	$ 38,324
Weighted Average Contractual Interest Rate / Rate of Return	8.50%
Weighted Average Annualized Effective Interest Rate / Rate of Return	9.70%

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Narrative (Details)	3 Months Ended		6 Months Ended
	Jun. 30, 2018 USD ($) loan preferred_equity_investment	Jun. 30, 2017 USD ($) loan	Jun. 30, 2018 USD ($) loan preferred_equity_investment	Jun. 30, 2017 USD ($) loan	Dec. 31, 2017 USD ($) loan	Aug. 17, 2017 USD ($) loan
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable instruments acquired | loan	22		22
Principal balance	$ 80,687,000		$ 80,687,000		$ 91,280,000
Loan loss reserve	$ 356,000		$ 356,000		97,000
Number of loans accruing interest and more than 90 days past due | loan	4		4
Aggregate book value of receivables accruing interest more than 90 days past due	$ 10,600,000		$ 10,600,000
Portfolio-Based Loans Receivable
Accounts, Notes, Loans and Financing Receivable [Line Items]
Increase (decrease) in portfolio-based loan loss reserve	200,000	$ (100,000)	300,000	$ (200,000)
Loan loss reserve	400,000		400,000		100,000
Specific Loans
Accounts, Notes, Loans and Financing Receivable [Line Items]
Loan loss reserve in period	0	$ 300,000	0	$ 1,800,000
Loan loss reserve	$ 0		$ 0		$ 0
Number of loans on which provision for losses were recorded | loan				5
Number of loans written off in period | loan		2
Nonperforming Financial Instruments
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable on nonaccrual status | loan	1		1		1
Book value of loans receivable on nonaccrual status	$ 0		$ 0		$ 0
Number of preferred equity investments on nonaccrual status | preferred_equity_investment	3		3
Book value of preferred equity investments on nonaccrual status	$ 14,500,000		$ 14,500,000
Care Capital Properties
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable instruments acquired | loan						18
Principal balance						$ 83,300,000
Fair value of loans receivable						$ 58,200,000
Care Capital Properties | Receivables Acquired with Deteriorated Credit Quality
Accounts, Notes, Loans and Financing Receivable [Line Items]
Number of loans receivable instruments acquired | loan						8
Principal balance						$ 36,300,000
Fair value of loans receivable						11,300,000
Accretable yield						$ 3,500,000
Number of loans repaid in full | loan	1		1
Book value of loans receivable	$ 4,800,000		$ 4,800,000		$ 10,000,000

XML

LOANS RECEIVABLE AND OTHER INVESTMENTS - Changes in the Accretable Yield (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2018
Certain Loans Acquired in Transfer Not Accounted for as Debt Securities, Accretable Yield Movement Schedule [Roll Forward]
Accretable yield, beginning of period	$ 1,883	$ 2,483
Accretion recognized in earnings	(1,529)	(2,129)
Net reclassification from nonaccretable difference	727	727
Accretable yield, end of period	$ 1,081	$ 1,081

XML

DEBT - Secured Debt (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Deferred financing costs, net	$ 18,853
Secured Debt
Debt Instrument [Line Items]
Fixed rate, principal amount	157,781	$ 160,702
Variable rate, principal amount	98,500	98,500
Total principal amount	$ 256,281	259,202
Weighted average effective interest rate	3.88%
Deferred financing costs, net	$ 2,714	$ 2,800
Secured Debt | Fixed Rate
Debt Instrument [Line Items]
Weighted average effective interest rate	3.87%
Secured Debt | Variable Rate
Debt Instrument [Line Items]
Weighted average effective interest rate	3.89%

XML

DEBT - Narrative (Details)		3 Months Ended		6 Months Ended
	Aug. 17, 2017 USD ($) extension_option	Jun. 30, 2018 USD ($) instrument	Jun. 30, 2017 USD ($)	Jun. 30, 2018 USD ($) instrument	Jun. 30, 2017 USD ($)	Dec. 31, 2017 USD ($)	Aug. 17, 2017 CAD ($) extension_option	Aug. 10, 2016 USD ($) agreement	Aug. 10, 2016 CAD ($) agreement	Jun. 10, 2015 CAD ($)
Debt Instrument [Line Items]
Amount outstanding under credit facility		$ 676,000,000		$ 676,000,000		$ 641,000,000
Interest expense		36,757,000	$ 15,862,000	72,575,000	$ 31,650,000
Non-cash interest expense		2,500,000	$ 1,700,000	5,000,000	$ 3,200,000
Accrued interest		24,500,000		24,500,000		24,700,000
Secured Debt
Debt Instrument [Line Items]
Face amount of debt		$ 256,281,000		$ 256,281,000		$ 259,202,000
5.5% Senior Unsecured Notes due 2021
Debt Instrument [Line Items]
Interest rate		5.50%		5.50%
5.375% Senior Unsecured Notes due 2023
Debt Instrument [Line Items]
Interest rate		5.375%		5.375%
5.125% Senior Unsecured Notes due 2026
Debt Instrument [Line Items]
Interest rate		5.125%		5.125%
5.38% Senior Unsecured Notes due 2027
Debt Instrument [Line Items]
Interest rate		5.38%		5.38%
Prior Credit Facility
Debt Instrument [Line Items]
Loss on extinguishment of debt	$ 600,000
Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Borrowing capacity	1,000,000,000.0
Borrowing capacity in certain foreign currencies (up to)	$ 175,000,000
Number of extension options | extension_option	2						2
Extension period	6 months
Interest rate		3.34%		3.34%
Credit Agreement | Revolving Credit Facility | Minimum
Debt Instrument [Line Items]
Annum percent unused borrowing fee	0.125%
Credit Agreement | Revolving Credit Facility | Maximum
Debt Instrument [Line Items]
Annum percent unused borrowing fee	0.30%
Credit Agreement | Revolving Credit Facility | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.875%
Credit Agreement | Revolving Credit Facility | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.65%
Credit Agreement | Revolving Credit Facility | Prime Rate
Debt Instrument [Line Items]
Basis spread on variable rate				0.50%
Credit Agreement | Revolving Credit Facility | Base Rate
Debt Instrument [Line Items]
Basis spread on variable rate				1.00%
Credit Agreement | Revolving Credit Facility | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.00%
Credit Agreement | Revolving Credit Facility | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	0.65%
Credit Agreement | Line of Credit
Debt Instrument [Line Items]
Borrowing capacity	$ 2,500,000,000.0
U.S. Dollar Term Loan
Debt Instrument [Line Items]
Face amount of debt								$ 245,000,000.0
U.S. Dollar Term Loan | Interest Rate Swap
Debt Instrument [Line Items]
Fixed interest rate under swap								0.90%	0.90%
Number of derivative agreements | agreement								2	2
U.S. Dollar Term Loan | LIBOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.90%
U.S. Dollar Term Loan | LIBOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.90%
U.S. Dollar Term Loan | Base Rate | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.00%
U.S. Dollar Term Loan | Base Rate | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	0.90%
U.S. Dollar Term Loan | CDOR | Minimum
Debt Instrument [Line Items]
Basis spread on variable rate	0.90%
U.S. Dollar Term Loan | CDOR | Maximum
Debt Instrument [Line Items]
Basis spread on variable rate	1.90%
U.S. Dollar Term Loan | Redemption Period One
Debt Instrument [Line Items]
Face amount of debt	$ 1,100,000,000.0
U.S. Dollar Term Loan | Redemption Period Two
Debt Instrument [Line Items]
Face amount of debt	200,000,000
Canadian Term Loan
Debt Instrument [Line Items]
Face amount of debt							$ 125,000,000.0		$ 35,000,000.0
Canadian Term Loan | Interest Rate Swap
Debt Instrument [Line Items]
Fixed interest rate under swap								0.93%	0.93%
Number of derivative agreements | agreement								1	1
Revolving Credit Facility | Revolving Credit Facility
Debt Instrument [Line Items]
Amount outstanding under credit facility		$ 676,000,000		$ 676,000,000
Available borrowing capacity		$ 324,000,000		$ 324,000,000
Prior Canadian Term Loan
Debt Instrument [Line Items]
Face amount of debt										$ 90,000,000.0
Fixed interest rate under swap										1.59%
Care Capital Properties | Interest Rate Swap
Debt Instrument [Line Items]
Fixed interest rate under swap		1.31%		1.31%
Number of derivative agreements | instrument		8		8
Care Capital Properties | Variable Rate Term Loan | Secured Debt
Debt Instrument [Line Items]
Face amount of debt	$ 98,500,000.0
Care Capital Properties | Variable Rate Term Loan | Secured Debt | LIBOR
Debt Instrument [Line Items]
Basis spread on variable rate	1.80%
Care Capital Properties | U.S. Dollar Term Loan
Debt Instrument [Line Items]
Face amount of debt		$ 600,000,000		$ 600,000,000

XML

DEBT - Senior Unsecured Notes (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Debt Instrument [Line Items]
Premium, net	$ 15,216
Deferred financing costs	18,853
Senior Notes
Debt Instrument [Line Items]
Principal balance	1,300,000	$ 1,300,000
Premium, net	15,216	15,900
Deferred financing costs	8,374	9,600
Senior Notes | 5.5% Senior Unsecured Notes due 2021
Debt Instrument [Line Items]
Principal balance	500,000	500,000
Senior Notes | 5.375% Senior Unsecured Notes due 2023
Debt Instrument [Line Items]
Principal balance	200,000	200,000
Senior Notes | 5.125% Senior Unsecured Notes due 2026
Debt Instrument [Line Items]
Principal balance	500,000	500,000
Senior Notes | 5.38% Senior Unsecured Notes due 2027
Debt Instrument [Line Items]
Principal balance	$ 100,000	$ 100,000

XML

DEBT - Schedule of Maturities for Outstanding Debt (Details) $ in Thousands	Aug. 17, 2017 extension_option	Jun. 30, 2018 USD ($)	Dec. 31, 2017 USD ($)
Debt Instrument [Line Items]
July 1 through December 31, 2018		$ 2,156
2019		102,920
2020		204,568
2021		1,195,757
2022		999,448
Thereafter		922,595
Total Debt		3,427,444
Premium, net		15,216
Deferred financing costs, net		(18,853)
Total Debt, Net		3,423,807
Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Number of extension options | extension_option	2
Extension period	6 months
Secured Indebtedness
Debt Instrument [Line Items]
July 1 through December 31, 2018		2,156
2019		102,920
2020		4,568
2021		19,757
2022		4,285
Thereafter		122,595
Total Debt		256,281
Premium, net		0
Deferred financing costs, net		(2,714)	$ (2,800)
Total Debt, Net		253,567
Revolving Credit Facility
Debt Instrument [Line Items]
July 1 through December 31, 2018		0
2019		0
2020		0
2021		676,000
2022		0
Thereafter		0
Total Debt		676,000
Premium, net		0
Deferred financing costs, net		0
Total Debt, Net		676,000
Term Loans
Debt Instrument [Line Items]
July 1 through December 31, 2018		0
2019		0
2020		200,000
2021		0
2022		995,163
Thereafter		0
Total Debt		1,195,163
Premium, net		0
Deferred financing costs, net		(7,765)
Total Debt, Net		1,187,398
Senior Notes
Debt Instrument [Line Items]
July 1 through December 31, 2018		0
2019		0
2020		0
2021		500,000
2022		0
Thereafter		800,000
Total Debt		1,300,000
Premium, net		15,216	15,900
Deferred financing costs, net		(8,374)	$ (9,600)
Total Debt, Net		$ 1,306,842

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Derivative [Line Items]
Interest expense	$ 36,757,000	$ 15,862,000	$ 72,575,000	$ 31,650,000
Cash Flow Hedges | Interest Rate Swap
Derivative [Line Items]
Unrealized gains (losses) recognized in other income	$ 0	$ (14,000)	0	$ (100,000)
Designated as Hedging Instrument | Cash Flow Hedges
Derivative [Line Items]
Gains included in accumulated other comprehensive loss which are expected to be reclassified into earnings in the next 12 months			$ 6,600,000

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Notional Amount of Derivatives Instruments (Details) - Cross Currency Interest Rate Swaps - Designated as Hedging Instrument $ in Thousands, $ in Thousands	Jun. 30, 2018 USD ($)	Jun. 30, 2018 CAD ($)	Dec. 31, 2017 USD ($)	Dec. 31, 2017 CAD ($)
Cash Flow Hedges
Derivative [Line Items]
Notional amount	$ 845,000	$ 125,000	$ 845,000	$ 125,000
Net Investment Hedges
Derivative [Line Items]
Notional amount		56,300		56,300
Notional amount		$ 125,000		$ 125,000

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Derivative and Financial Instruments Designated as Hedging Instruments (Details) $ in Thousands	Jun. 30, 2018 USD ($) instrument	Dec. 31, 2017 USD ($)
Assets:
Fair Value	$ 37,865	$ 25,895
Liabilities:
Fair Value	0	0
Designated as Hedging Instrument
Assets:
Fair Value	37,865	25,895
Liabilities:
Fair Value	$ 95,163	99,588
Designated as Hedging Instrument | Interest rate swaps | Cash flow | Accounts receivable, prepaid expenses and other assets, net
Assets:
Count | instrument	12
Fair Value	$ 35,719	25,221
Designated as Hedging Instrument | Cross currency interest rate swaps | Net investment | Accounts receivable, prepaid expenses and other assets, net
Assets:
Count | instrument	2
Fair Value	$ 2,146	674
Designated as Hedging Instrument | CAD term loan | Net investment | Term loans, net
Liabilities:
Count | instrument	1
Fair Value	$ 95,163	$ 99,588

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Effect of Derivative Financial Instruments on the Condensed Consolidated Statements of Income and Condensed Consolidated Statements of Equity (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, cash flow hedges	$ 3,338	$ 97	$ 13,236	$ 825
Gain (loss) recognized in other comprehensive income, cash flow hedges and net investment hedges	6,657	(2,891)	19,062	(4,322)
Gain (loss) reclassified from accumulated other comprehensive income into income, cash flow hedges and net investment hedges	633	(399)	583	(869)
Interest rate products
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, cash flow hedges	4,009	(136)	13,132	125
Interest rate products | Interest expense
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) reclassified from accumulated other comprehensive income into income, cash flow hedges	633	(399)	583	(869)
Foreign currency products
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, net investment hedges	898	(242)	1,505	(1,159)
Gain (loss) reclassified from accumulated other comprehensive income into income, net investment hedges	0	0	0	0
CAD term loan
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in other comprehensive income, net investment hedges	1,750	(2,513)	4,425	(3,288)
Gain (loss) reclassified from accumulated other comprehensive income into income, net investment hedges	$ 0	$ 0	$ 0	$ 0

XML

DERIVATIVE AND HEDGING INSTRUMENTS - Gross Presentation, Effects of Offsetting, and Net Presentation of Derivatives (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Offsetting Assets:
Gross amounts of recognized assets	$ 37,865	$ 25,895
Gross amounts offset in the balance sheet	0	0
Net amounts of assets presented in the balance sheet	37,865	25,895
Financial instruments	0	0
Cash collateral received	0	0
Net amount	37,865	25,895
Offsetting Liabilities:
Gross amounts of recognized liabilities	0	0
Gross amounts offset in the balance sheet	0	0
Liabilities presented in the balance sheet	0	0
Financial instruments	0	0
Cash collateral received	0	0
Net amount	$ 0	$ 0

XML

FAIR VALUE DISCLOSURES - Face Values, Carrying Amounts and Fair Values of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Financial assets:
Loans receivable	$ 80,687	$ 91,280
Preferred equity investments	50,856	48,035
Senior Notes
Financial liabilities:
Financial liabilities	1,300,000	1,300,000
Secured Indebtedness
Financial liabilities:
Financial liabilities	256,281	259,202
Carrying Amount
Financial assets:
Loans receivable	55,880	65,907
Preferred equity investments	51,348	48,483
Carrying Amount | Senior Notes
Financial liabilities:
Financial liabilities	1,306,842	1,306,286
Carrying Amount | Secured Indebtedness
Financial liabilities:
Financial liabilities	253,567	256,430
Fair Value
Financial assets:
Loans receivable	58,656	65,892
Preferred equity investments	50,787	47,064
Fair Value | Senior Notes
Financial liabilities:
Financial liabilities	1,292,347	1,329,191
Fair Value | Secured Indebtedness
Financial liabilities:
Financial liabilities	$ 236,862	$ 246,461

XML

FAIR VALUE DISCLOSURES - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	$ 58,656	$ 65,892
Preferred equity investments	50,787	47,064
Total | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,292,347	1,329,191
Total | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	236,862	$ 246,461
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	0
Preferred equity investments	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,292,347
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	58,656
Preferred equity investments	50,787
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	236,862
Measured on a Recurring Basis | Total
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Loans receivable	58,656
Preferred equity investments	50,787
Measured on a Recurring Basis | Total | Senior Notes
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	1,292,347
Measured on a Recurring Basis | Total | Secured Indebtedness
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial liabilities	$ 236,862

XML

FAIR VALUE DISCLOSURES - Items Measured at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 37,865	$ 25,895
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Measured on a Recurring Basis | Quoted Prices in Active Markets for Identical Assets (Level 1) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	35,719
Measured on a Recurring Basis | Significant Other Observable Inputs (Level 2) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	2,146
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Measured on a Recurring Basis | Significant Unobservable Inputs (Level 3) | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	0
Measured on a Recurring Basis | Total | Interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	35,719
Measured on a Recurring Basis | Total | Cross currency interest rate swaps
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Financial assets	$ 2,146

XML

EQUITY - Preferred Stock (Details) - USD ($) $ / shares in Units, $ in Millions			6 Months Ended
	Jun. 01, 2018	Mar. 21, 2013	Jun. 30, 2018	Dec. 31, 2017
Class of Stock [Line Items]
Shares of preferred stock issued (in shares)		5,750,000.00		5,750,000
Preferred stock dividend rate		7.125%
Price per share of preferred stock (in dollars per share)		$ 25.00
Net proceeds from preferred stock offering		$ 138.3
Redemption price (in dollars per share)	$ 25.00
Accrued and unpaid dividends (in dollars per share)	0.4453125
Total redemption price (in dollars per share)	$ 25.4453125
Redemption charge related to original issuance costs	$ 5.5
Preferred Stock
Class of Stock [Line Items]
Shares of preferred stock redeemed (in shares)	5,750,000		5,750,000

XML

EQUITY - Common Stock (Details) - USD ($) $ / shares in Units, $ in Millions				6 Months Ended
	Oct. 02, 2017	Sep. 28, 2017	Aug. 17, 2017	Jun. 30, 2018	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Tax withholding obligations incurred on behalf of employees				$ 0.2	$ 2.6
Restricted Stock Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued upon vesting (in shares)				27,747
Underwritten Public Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares sold in offering (in shares)	18,400,000	16,000,000
Proceeds from offering	$ 370.9
Share price (in dollars per share)	$ 21	$ 21
Over-Allotment Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares sold in offering (in shares)	2,400,000
Care Capital Properties
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares issued in merger (in shares)			94,000,000

XML

EQUITY - Cash Dividends on Common Stock Declared and Paid (Details) - $ / shares			3 Months Ended		6 Months Ended
	May 09, 2018	Feb. 05, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Equity [Abstract]
Common dividends (in dollars per share)	$ 0.45	$ 0.45	$ 0.45	$ 0.43	$ 0.90	$ 0.85

XML

EQUITY - Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	$ 3,407,925	$ 3,437,249	$ 996,715	$ 1,015,609
Total accumulated other comprehensive income
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	24,412	11,289	$ (833)	$ (1,798)
Foreign currency translation loss
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	(3,026)	(2,913)
Unrealized gains on cash flow hedges
Accumulated Other Comprehensive Income (Loss) [Line Items]
Accumulated other comprehensive income	$ 27,438	$ 14,202

XML

EARNINGS PER COMMON SHARE - Computation of Basic and Diluted Earnings Per Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Numerator
Net income attributable to common stockholders	$ 193,580	$ 17,960	$ 253,490	$ 34,222
Denominator
Basic weighted average common shares and common equivalents (in shares)	178,314,750	65,438,739	178,304,733	65,396,146
Dilutive restricted stock units (in shares)	369,274	232,114	296,056	297,873
Diluted weighted average common shares (in shares)	178,684,024	65,670,853	178,600,789	65,694,019
Net income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ 1.09	$ 0.27	$ 1.42	$ 0.52
Diluted common share (in dollars per share)	$ 1.08	$ 0.27	$ 1.42	$ 0.52

XML

EARNINGS PER COMMON SHARE - Narrative (Details) - shares	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock options outstanding (in shares)		0		0
Restricted Stock Units
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in computation of diluted earnings per share (in shares)	35,300	15,900	46,000	19,300
Employee Stock Option
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive securities not included in computation of diluted earnings per share (in shares)	0		0

XML

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Balance Sheet (Details) - USD ($) $ in Thousands	Jun. 30, 2018	Dec. 31, 2017	Jun. 30, 2017	Dec. 31, 2016
Assets
Real estate investments, net of accumulated depreciation	$ 5,993,682	$ 5,994,432
Loans receivable and other investments, net	107,228	114,390
Investment in unconsolidated joint venture	348,950	0
Cash and cash equivalents	38,809	518,632
Restricted cash	186,845	68,817
Lease intangible assets, net	156,266	167,119
Accounts receivable, prepaid expenses and other assets, net	196,364	168,887
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	7,028,144	7,032,277
Liabilities
Secured debt, net	253,567	256,430
Revolving credit facility	676,000	641,000
Term loans, net	1,187,398	1,190,774
Senior unsecured notes, net	1,306,842	1,306,286
Accounts payable and accrued liabilities	105,339	102,523
Lease intangible liabilities, net	91,073	98,015
Intercompany	0	0
Total liabilities	3,620,219	3,595,028
Total Sabra Health Care REIT, Inc. stockholders' equity	3,403,543	3,432,807
Noncontrolling interests	4,382	4,442
Total equity	3,407,925	3,437,249	$ 996,715	$ 1,015,609
Total liabilities and equity	7,028,144	7,032,277
Elimination
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	(7,626)	(5,189)
Intercompany	(4,913,076)	(4,765,381)
Investment in subsidiaries	(2,763,938)	(2,103,428)
Total assets	(7,684,640)	(6,873,998)
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	(7,626)	(5,189)
Lease intangible liabilities, net	0	0
Intercompany	(4,913,076)	(4,765,381)
Total liabilities	(4,920,702)	(4,770,570)
Total Sabra Health Care REIT, Inc. stockholders' equity	(2,763,938)	(2,103,428)
Noncontrolling interests	0	0
Total equity	(2,763,938)	(2,103,428)
Total liabilities and equity	(7,684,640)	(6,873,998)
Parent Company | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	341	324
Loans receivable and other investments, net	(356)	(97)
Investment in unconsolidated joint venture	0
Cash and cash equivalents	31,269	511,670
Restricted cash	0	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	(536)	3,499
Intercompany	2,186,044	2,043,402
Investment in subsidiaries	1,209,953	890,462
Total assets	3,426,715	3,449,260
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	23,172	16,453
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	23,172	16,453
Total Sabra Health Care REIT, Inc. stockholders' equity	3,403,543	3,432,807
Noncontrolling interests	0	0
Total equity	3,403,543	3,432,807
Total liabilities and equity	3,426,715	3,449,260
Operating Partnership | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	46,700	36,073
Intercompany	2,727,032	2,721,979
Investment in subsidiaries	1,538,155	1,198,305
Total assets	4,311,887	3,956,357
Liabilities
Secured debt, net	0	0
Revolving credit facility	676,000	641,000
Term loans, net	1,093,314	1,092,397
Senior unsecured notes, net	1,306,842	1,306,286
Accounts payable and accrued liabilities	25,778	26,212
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	3,101,934	3,065,895
Total Sabra Health Care REIT, Inc. stockholders' equity	1,209,953	890,462
Noncontrolling interests	0	0
Total equity	1,209,953	890,462
Total liabilities and equity	4,311,887	3,956,357
Sabra Capital Corporation | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	0	0
Loans receivable and other investments, net	0	0
Investment in unconsolidated joint venture	0
Cash and cash equivalents	0	0
Restricted cash	0	0
Lease intangible assets, net	0	0
Accounts receivable, prepaid expenses and other assets, net	0	0
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	0	0
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	0	0
Lease intangible liabilities, net	0	0
Intercompany	0	0
Total liabilities	0	0
Total Sabra Health Care REIT, Inc. stockholders' equity	0	0
Noncontrolling interests	0	0
Total equity	0	0
Total liabilities and equity	0	0
Combined Guarantor Subsidiaries | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	1,666,116	1,756,933
Loans receivable and other investments, net	52,315	55,297
Investment in unconsolidated joint venture	0
Cash and cash equivalents	1,405	449
Restricted cash	174,913	36,910
Lease intangible assets, net	16,815	17,577
Accounts receivable, prepaid expenses and other assets, net	84,809	80,739
Intercompany	0	0
Investment in subsidiaries	15,830	14,661
Total assets	2,012,203	1,962,566
Liabilities
Secured debt, net	0	0
Revolving credit facility	0	0
Term loans, net	94,084	98,377
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	3,576	3,560
Lease intangible liabilities, net	0	0
Intercompany	636,037	785,120
Total liabilities	733,697	887,057
Total Sabra Health Care REIT, Inc. stockholders' equity	1,278,506	1,075,509
Noncontrolling interests	0	0
Total equity	1,278,506	1,075,509
Total liabilities and equity	2,012,203	1,962,566
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Assets
Real estate investments, net of accumulated depreciation	4,327,225	4,237,175
Loans receivable and other investments, net	55,269	59,190
Investment in unconsolidated joint venture	348,950
Cash and cash equivalents	6,135	6,513
Restricted cash	11,932	31,907
Lease intangible assets, net	139,451	149,542
Accounts receivable, prepaid expenses and other assets, net	73,017	53,765
Intercompany	0	0
Investment in subsidiaries	0	0
Total assets	4,961,979	4,538,092
Liabilities
Secured debt, net	253,567	256,430
Revolving credit facility	0	0
Term loans, net	0	0
Senior unsecured notes, net	0	0
Accounts payable and accrued liabilities	60,439	61,487
Lease intangible liabilities, net	91,073	98,015
Intercompany	4,277,039	3,980,261
Total liabilities	4,682,118	4,396,193
Total Sabra Health Care REIT, Inc. stockholders' equity	275,479	137,457
Noncontrolling interests	4,382	4,442
Total equity	279,861	141,899
Total liabilities and equity	$ 4,961,979	$ 4,538,092

XML

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Income (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Revenues:
Rental income	$ 144,229	$ 55,904	$ 288,484	$ 113,128
Interest and other income	4,553	2,027	8,891	3,972
Resident fees and services	17,530	6,805	35,023	10,286
Total revenues	166,312	64,736	332,398	127,386
Expenses:
Depreciation and amortization	46,828	17,220	94,833	36,357
Interest	36,757	15,862	72,575	31,650
Operating expenses	12,299	4,407	24,423	6,827
General and administrative	9,271	5,126	17,138	11,215
Merger and acquisition costs	112	5,887	442	6,451
Provision for (recovery of) doubtful accounts and loan losses	(674)	535	539	2,305
Impairment of real estate	881	0	1,413	0
Total expenses	105,474	49,037	211,363	94,805
Other income:
Other income (expense)	0	941	2,820	3,070
Net gain on sales of real estate	142,903	4,032	142,431	4,032
Total other income	142,903	4,973	145,251	7,102
Income in subsidiary	0	0	0	0
Income before loss from unconsolidated joint venture and income tax expense	203,741	20,672	266,286	39,683
Loss from unconsolidated joint venture	(2,347)	0	(1,901)	0
Income tax benefit (expense)	(605)	(136)	(1,115)	(356)
Net income	200,789	20,536	263,270	39,327
Net income attributable to noncontrolling interests	(2)	(16)	(12)	16
Net income attributable to Sabra Health Care REIT, Inc.	200,787	20,520	263,258	39,343
Preferred stock dividends	(7,207)	(2,560)	(9,768)	(5,121)
Net income attributable to common stockholders	$ 193,580	$ 17,960	$ 253,490	$ 34,222
Net income attributable to common stockholders, per:
Basic common share (in dollars per share)	$ 1.09	$ 0.27	$ 1.42	$ 0.52
Diluted common share (in dollars per share)	$ 1.08	$ 0.27	$ 1.42	$ 0.52
Weighted-average number of common shares outstanding, basic (in shares)	178,314,750	65,438,739	178,304,733	65,396,146
Weighted-average number of common shares outstanding, diluted (in shares)	178,684,024	65,670,853	178,600,789	65,694,019
Elimination
Revenues:
Rental income	$ (4,320)	$ (1,194)	$ (8,553)	$ (1,978)
Interest and other income	(96)	(18)	(208)	(18)
Resident fees and services	0	0	0	0
Total revenues	(4,416)	(1,212)	(8,761)	(1,996)
Expenses:
Depreciation and amortization	0	0	0	0
Interest	(96)	0	(208)	0
Operating expenses	(4,320)	(1,212)	(8,553)	(1,996)
General and administrative	0	0	0	0
Merger and acquisition costs	0	0	0	0
Provision for (recovery of) doubtful accounts and loan losses	0	0	0	0
Impairment of real estate	0		0
Total expenses	(4,416)	(1,212)	(8,761)	(1,996)
Other income:
Other income (expense)	0	0	0	0
Net gain on sales of real estate	0	0	0	0
Total other income	0	0	0	0
Income in subsidiary	(454,085)	(74,403)	(626,890)	(136,445)
Income before loss from unconsolidated joint venture and income tax expense	(454,085)	(74,403)	(626,890)	(136,445)
Loss from unconsolidated joint venture	0		0
Income tax benefit (expense)	0	0	0	0
Net income	(454,085)	(74,403)	(626,890)	(136,445)
Net income attributable to noncontrolling interests	0	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.	(454,085)	(74,403)	(626,890)	(136,445)
Preferred stock dividends	0	0	0	0
Net income attributable to common stockholders	(454,085)	(74,403)	(626,890)	(136,445)
Parent Company | Reportable Legal Entities
Revenues:
Rental income	0	0	0	0
Interest and other income	40	6	50	13
Resident fees and services	0	0	0	0
Total revenues	40	6	50	13
Expenses:
Depreciation and amortization	222	216	443	432
Interest	0	0	0	0
Operating expenses	0	0	0	0
General and administrative	8,009	4,063	13,831	9,322
Merger and acquisition costs	112	5,883	448	6,417
Provision for (recovery of) doubtful accounts and loan losses	311	227	2,492	82
Impairment of real estate	0		0
Total expenses	8,654	10,389	17,214	16,253
Other income:
Other income (expense)	0	916	1,977	2,283
Net gain on sales of real estate	0	0	0	0
Total other income	0	916	1,977	2,283
Income in subsidiary	209,456	29,894	278,798	53,331
Income before loss from unconsolidated joint venture and income tax expense	200,842	20,427	263,611	39,374
Loss from unconsolidated joint venture	0		0
Income tax benefit (expense)	(55)	93	(353)	(31)
Net income	200,787	20,520	263,258	39,343
Net income attributable to noncontrolling interests	0	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.	200,787	20,520	263,258	39,343
Preferred stock dividends	(7,207)	(2,560)	(9,768)	(5,121)
Net income attributable to common stockholders	193,580	17,960	253,490	34,222
Operating Partnership | Reportable Legal Entities
Revenues:
Rental income	0	0	0	0
Interest and other income	96	0	208	0
Resident fees and services	0	0	0	0
Total revenues	96	0	208	0
Expenses:
Depreciation and amortization	0	0	0	0
Interest	33,415	13,516	65,980	26,924
Operating expenses	0	0	0	0
General and administrative	14	17	29	31
Merger and acquisition costs	0	0	0	0
Provision for (recovery of) doubtful accounts and loan losses	0	0	0	0
Impairment of real estate	0		0
Total expenses	33,429	13,533	66,009	26,955
Other income:
Other income (expense)	32	703	233	737
Net gain on sales of real estate	0	0	0	0
Total other income	32	703	233	737
Income in subsidiary	242,758	42,724	344,367	79,550
Income before loss from unconsolidated joint venture and income tax expense	209,457	29,894	278,799	53,332
Loss from unconsolidated joint venture	0		0
Income tax benefit (expense)	(1)	0	(1)	(1)
Net income	209,456	29,894	278,798	53,331
Net income attributable to noncontrolling interests	0	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.	209,456	29,894	278,798	53,331
Preferred stock dividends	0	0	0	0
Net income attributable to common stockholders	209,456	29,894	278,798	53,331
Sabra Capital Corporation | Reportable Legal Entities
Revenues:
Rental income	0	0	0	0
Interest and other income	0	0	0	0
Resident fees and services	0	0	0	0
Total revenues	0	0	0	0
Expenses:
Depreciation and amortization	0	0	0	0
Interest	0	0	0	0
Operating expenses	0	0	0	0
General and administrative	0	0	0	0
Merger and acquisition costs	0	0	0	0
Provision for (recovery of) doubtful accounts and loan losses	0	0	0	0
Impairment of real estate	0		0
Total expenses	0	0	0	0
Other income:
Other income (expense)	0	0	0	0
Net gain on sales of real estate	0	0	0	0
Total other income	0	0	0	0
Income in subsidiary	0	0	0	0
Income before loss from unconsolidated joint venture and income tax expense	0	0	0	0
Loss from unconsolidated joint venture	0		0
Income tax benefit (expense)	0	0	0	0
Net income	0	0	0	0
Net income attributable to noncontrolling interests	0	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.	0	0	0	0
Preferred stock dividends	0	0	0	0
Net income attributable to common stockholders	0	0	0	0
Combined Guarantor Subsidiaries | Reportable Legal Entities
Revenues:
Rental income	44,560	52,442	90,024	105,481
Interest and other income	1,198	2,039	2,465	3,977
Resident fees and services	0	0	0	0
Total revenues	45,758	54,481	92,489	109,458
Expenses:
Depreciation and amortization	14,146	15,425	29,076	32,381
Interest	810	715	1,601	1,445
Operating expenses	0	0	0	0
General and administrative	379	991	810	1,758
Merger and acquisition costs	0	4	0	34
Provision for (recovery of) doubtful accounts and loan losses	(985)	308	(1,956)	2,223
Impairment of real estate	881		1,413
Total expenses	15,231	17,443	30,944	37,841
Other income:
Other income (expense)	(32)	(665)	378	50
Net gain on sales of real estate	141,918	4,026	141,862	4,026
Total other income	141,886	3,361	142,240	4,076
Income in subsidiary	1,871	1,785	3,725	3,564
Income before loss from unconsolidated joint venture and income tax expense	174,284	42,184	207,510	79,257
Loss from unconsolidated joint venture	0		0
Income tax benefit (expense)	(489)	(227)	(542)	(227)
Net income	173,795	41,957	206,968	79,030
Net income attributable to noncontrolling interests	0	0	0	0
Net income attributable to Sabra Health Care REIT, Inc.	173,795	41,957	206,968	79,030
Preferred stock dividends	0	0	0	0
Net income attributable to common stockholders	173,795	41,957	206,968	79,030
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Revenues:
Rental income	103,989	4,656	207,013	9,625
Interest and other income	3,315	0	6,376	0
Resident fees and services	17,530	6,805	35,023	10,286
Total revenues	124,834	11,461	248,412	19,911
Expenses:
Depreciation and amortization	32,460	1,579	65,314	3,544
Interest	2,628	1,631	5,202	3,281
Operating expenses	16,619	5,619	32,976	8,823
General and administrative	869	55	2,468	104
Merger and acquisition costs	0	0	(6)	0
Provision for (recovery of) doubtful accounts and loan losses	0	0	3	0
Impairment of real estate	0		0
Total expenses	52,576	8,884	105,957	15,752
Other income:
Other income (expense)	0	(13)	232	0
Net gain on sales of real estate	985	6	569	6
Total other income	985	(7)	801	6
Income in subsidiary	0	0	0	0
Income before loss from unconsolidated joint venture and income tax expense	73,243	2,570	143,256	4,165
Loss from unconsolidated joint venture	(2,347)		(1,901)
Income tax benefit (expense)	(60)	(2)	(219)	(97)
Net income	70,836	2,568	141,136	4,068
Net income attributable to noncontrolling interests	(2)	(16)	(12)	16
Net income attributable to Sabra Health Care REIT, Inc.	70,834	2,552	141,124	4,084
Preferred stock dividends	0	0	0	0
Net income attributable to common stockholders	$ 70,834	$ 2,552	$ 141,124	$ 4,084

XML

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Condensed Financial Statements, Captions [Line Items]
Net income	$ 200,789	$ 20,536	$ 263,270	$ 39,327
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	261	698	(113)	140
Unrealized gain on cash flow hedges	3,338	97	13,236	825
Total other comprehensive income	3,599	795	13,123	965
Comprehensive income	204,388	21,331	276,393	40,292
Comprehensive income attributable to noncontrolling interest	(2)	(16)	(12)	16
Comprehensive income attributable to Sabra Health Care REIT, Inc.	204,386	21,315	276,381	40,308
Elimination
Condensed Financial Statements, Captions [Line Items]
Net income	(454,085)	(74,403)	(626,890)	(136,445)
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	0	0	0	0
Unrealized gain on cash flow hedges	0	0	0	0
Total other comprehensive income	0	0	0	0
Comprehensive income	(454,085)	(74,403)	(626,890)	(136,445)
Comprehensive income attributable to noncontrolling interest	0	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	(454,085)	(74,403)	(626,890)	(136,445)
Parent Company | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	200,787	20,520	263,258	39,343
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	0	0	0	0
Unrealized gain on cash flow hedges	0	0	0	0
Total other comprehensive income	0	0	0	0
Comprehensive income	200,787	20,520	263,258	39,343
Comprehensive income attributable to noncontrolling interest	0	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	200,787	20,520	263,258	39,343
Operating Partnership | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	209,456	29,894	278,798	53,331
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	1,064	(415)	1,905	(1,367)
Unrealized gain on cash flow hedges	3,335	285	13,238	1,013
Total other comprehensive income	4,399	(130)	15,143	(354)
Comprehensive income	213,855	29,764	293,941	52,977
Comprehensive income attributable to noncontrolling interest	0	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	213,855	29,764	293,941	52,977
Sabra Capital Corporation | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	0	0	0	0
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	0	0	0	0
Unrealized gain on cash flow hedges	0	0	0	0
Total other comprehensive income	0	0	0	0
Comprehensive income	0	0	0	0
Comprehensive income attributable to noncontrolling interest	0	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	0	0	0	0
Combined Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	173,795	41,957	206,968	79,030
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	(608)	833	(1,536)	1,131
Unrealized gain on cash flow hedges	3	(188)	(2)	(188)
Total other comprehensive income	(605)	645	(1,538)	943
Comprehensive income	173,190	42,602	205,430	79,973
Comprehensive income attributable to noncontrolling interest	0	0	0	0
Comprehensive income attributable to Sabra Health Care REIT, Inc.	173,190	42,602	205,430	79,973
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net income	70,836	2,568	141,136	4,068
Unrealized gain (loss), net of tax:
Foreign currency translation gain (loss)	(195)	280	(482)	376
Unrealized gain on cash flow hedges	0	0	0	0
Total other comprehensive income	(195)	280	(482)	376
Comprehensive income	70,641	2,848	140,654	4,444
Comprehensive income attributable to noncontrolling interest	(2)	(16)	(12)	16
Comprehensive income attributable to Sabra Health Care REIT, Inc.	$ 70,639	$ 2,832	$ 140,642	$ 4,460

XML

SUMMARIZED CONDENSED CONSOLIDATING INFORMATION - Condensed Consolidating Statement of Cash Flows (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2018	Jun. 30, 2017
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	$ 211,553	$ 54,282
Cash flows from investing activities:
Acquisition of real estate	(213,982)	(14,456)
Origination and fundings of loans receivable	(28,157)	(927)
Origination and fundings of preferred equity investments	(945)	(76)
Additions to real estate	(16,817)	(1,294)
Repayments of loans receivable	38,887	1,547
Repayments of preferred equity investments	375	2,766
Investment in unconsolidated JV	(354,461)	0
Net proceeds from the sales of real estate	278,201	6,099
Distribution from subsidiaries	0	0
Intercompany financing	0	0
Net cash used in investing activities	(296,899)	(6,341)
Cash flows from financing activities:
Net borrowings from revolving credit facility	35,000	6,000
Principal payments on secured debt	(2,128)	(2,049)
Payments of deferred financing costs	(12)	(124)
Distributions to noncontrolling interests	(72)	0
Preferred stock redemption	(143,750)	0
Issuance of common stock, net	(499)	(3,224)
Dividends paid on common and preferred stock	(164,736)	(60,691)
Distribution to parent	0	0
Intercompany financing	0	0
Net cash used in financing activities	(276,197)	(60,088)
Net decrease in cash, cash equivalents and restricted cash	(361,543)	(12,147)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(252)	130
Cash, cash equivalents and restricted cash, beginning of period	587,449	34,665
Cash, cash equivalents and restricted cash, end of period	225,654	22,648
Elimination
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	0	0
Repayments of loans receivable	0	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated JV	0
Net proceeds from the sales of real estate	0	0
Distribution from subsidiaries	(5,338)	(4,948)
Intercompany financing	791,958	9,210
Net cash used in investing activities	786,620	4,262
Cash flows from financing activities:
Net borrowings from revolving credit facility	0	0
Principal payments on secured debt	0	0
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	0
Preferred stock redemption	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	5,338	4,948
Intercompany financing	(791,958)	(9,210)
Net cash used in financing activities	(786,620)	(4,262)
Net decrease in cash, cash equivalents and restricted cash	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0
Cash, cash equivalents and restricted cash, end of period	0	0
Parent Company | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	204,440	49,670
Cash flows from investing activities:
Acquisition of real estate	0	0
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	(40)	(12)
Repayments of loans receivable	0	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated JV	0
Net proceeds from the sales of real estate	0	0
Distribution from subsidiaries	2,669	2,474
Intercompany financing	(378,485)	(1,667)
Net cash used in investing activities	(375,856)	795
Cash flows from financing activities:
Net borrowings from revolving credit facility	0	0
Principal payments on secured debt	0	0
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	0
Preferred stock redemption	(143,750)
Issuance of common stock, net	(499)	(3,224)
Dividends paid on common and preferred stock	(164,736)	(60,691)
Distribution to parent	0	0
Intercompany financing	0	0
Net cash used in financing activities	(308,985)	(63,915)
Net decrease in cash, cash equivalents and restricted cash	(480,401)	(13,450)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash, beginning of period	511,670	18,168
Cash, cash equivalents and restricted cash, end of period	31,269	4,718
Operating Partnership | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	0	0
Repayments of loans receivable	0	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated JV	0
Net proceeds from the sales of real estate	0	0
Distribution from subsidiaries	2,669	2,474
Intercompany financing	(413,473)	(7,543)
Net cash used in investing activities	(410,804)	(5,069)
Cash flows from financing activities:
Net borrowings from revolving credit facility	35,000	6,000
Principal payments on secured debt	0	0
Payments of deferred financing costs	(12)	(124)
Distributions to noncontrolling interests	0
Preferred stock redemption	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	(2,669)	(2,474)
Intercompany financing	378,485	1,667
Net cash used in financing activities	410,804	5,069
Net decrease in cash, cash equivalents and restricted cash	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0
Cash, cash equivalents and restricted cash, end of period	0	0
Sabra Capital Corporation | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	0	0
Cash flows from investing activities:
Acquisition of real estate	0	0
Origination and fundings of loans receivable	0	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	0	0
Repayments of loans receivable	0	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated JV	0
Net proceeds from the sales of real estate	0	0
Distribution from subsidiaries	0	0
Intercompany financing	0	0
Net cash used in investing activities	0	0
Cash flows from financing activities:
Net borrowings from revolving credit facility	0	0
Principal payments on secured debt	0	0
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	0
Preferred stock redemption	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	0	0
Intercompany financing	0	0
Net cash used in financing activities	0	0
Net decrease in cash, cash equivalents and restricted cash	0	0
Effect of foreign currency translation on cash, cash equivalents and restricted cash	0	0
Cash, cash equivalents and restricted cash, beginning of period	0	0
Cash, cash equivalents and restricted cash, end of period	0	0
Combined Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	1,041	(1,693)
Cash flows from investing activities:
Acquisition of real estate	(29,711)	(14,456)
Origination and fundings of loans receivable	(1,973)	(927)
Origination and fundings of preferred equity investments	(945)	(76)
Additions to real estate	(4,660)	(1,106)
Repayments of loans receivable	6,577	1,547
Repayments of preferred equity investments	375	2,766
Investment in unconsolidated JV	0
Net proceeds from the sales of real estate	232,059	6,099
Distribution from subsidiaries	0	0
Intercompany financing	0	0
Net cash used in investing activities	201,722	(6,153)
Cash flows from financing activities:
Net borrowings from revolving credit facility	0	0
Principal payments on secured debt	0	0
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	0
Preferred stock redemption	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	0	0
Intercompany financing	(63,658)	7,543
Net cash used in financing activities	(63,658)	7,543
Net decrease in cash, cash equivalents and restricted cash	139,105	(303)
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(146)	69
Cash, cash equivalents and restricted cash, beginning of period	37,359	2,732
Cash, cash equivalents and restricted cash, end of period	176,318	2,498
Combined Non-Guarantor Subsidiaries | Reportable Legal Entities
Condensed Financial Statements, Captions [Line Items]
Net cash provided by (used in) operating activities	6,072	6,305
Cash flows from investing activities:
Acquisition of real estate	(184,271)	0
Origination and fundings of loans receivable	(26,184)	0
Origination and fundings of preferred equity investments	0	0
Additions to real estate	(12,117)	(176)
Repayments of loans receivable	32,310	0
Repayments of preferred equity investments	0	0
Investment in unconsolidated JV	(354,461)
Net proceeds from the sales of real estate	46,142	0
Distribution from subsidiaries	0	0
Intercompany financing	0	0
Net cash used in investing activities	(498,581)	(176)
Cash flows from financing activities:
Net borrowings from revolving credit facility	0	0
Principal payments on secured debt	(2,128)	(2,049)
Payments of deferred financing costs	0	0
Distributions to noncontrolling interests	(72)
Preferred stock redemption	0
Issuance of common stock, net	0	0
Dividends paid on common and preferred stock	0	0
Distribution to parent	(2,669)	(2,474)
Intercompany financing	477,131	0
Net cash used in financing activities	472,262	(4,523)
Net decrease in cash, cash equivalents and restricted cash	(20,247)	1,606
Effect of foreign currency translation on cash, cash equivalents and restricted cash	(106)	61
Cash, cash equivalents and restricted cash, beginning of period	38,420	13,765
Cash, cash equivalents and restricted cash, end of period	$ 18,067	$ 15,432

XML

SUBSEQUENT EVENTS - Narrative (Details) - $ / shares				3 Months Ended		6 Months Ended
	Aug. 08, 2018	May 09, 2018	Feb. 05, 2018	Jun. 30, 2018	Jun. 30, 2017	Jun. 30, 2018	Jun. 30, 2017
Subsequent Event [Line Items]
Quarterly cash dividend declared on common stock (in dollars per share)		$ 0.45	$ 0.45	$ 0.45	$ 0.43	$ 0.90	$ 0.85
Subsequent Event
Subsequent Event [Line Items]
Quarterly cash dividend declared on common stock (in dollars per share)	$ 0.45